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Abstract 
Asthma is a chronic inflammatory disease of the airways characterised by airway hyper-
responsiveness (AHR), inflammation of the airways and reversible airway obstruction. Airway 
remodelling is a feature of asthma, especially in cases of severe and fatal asthma, and includes 
structural changes such as increased airway smooth muscle (ASM) mass, mucous gland 
hyperplasia, subepithelial fibrosis and angiogenesis. TGF-p is a pleiotropic cytokine that has been 
implicated in the development of many of these changes. However, TGF-p is released from cells 
in a latent complex, associated with its pro-peptide the latency associated peptide (LAP). 
Extracellular activation of latent TGF-p is the rate limiting step in TGF-p bioavailability. 
Although TGF -P activation has been investigated in airway epithelial cells, to date, no studies 
have investigated TGF -P activation by airway smooth muscle cells. The hypothesis of this thesis 
is therefore that human airway smooth muscle cells can activate TGF-p in vitro. 
The hypothesis of this thesis has been tested by investigating effects of the serine protease mast 
cell tryptase, mechanical wounding of cell mono layers and the phospholipid lysophosphatidic 
acid (LPA) on TGF-p activation by primary airway smooth muscle cells in vitro. We have 
utilised transformed mink lung epithelial cells, a reporter cell that express a TGF -P responsive 
promoter driving a luciferase gene, and quantitative peR for the TGF-p-inducible gene 
plasminogen activator inhibitor-l (PAIl) to investigate TGF-p activation. Moreover, we show for 
the first time that TGF-p activation can be assessed in vitro by detecting the translocation of 
Smad 2 and 3 from the cytoplasm to the nucleus by western blotting. 
The results presented in this thesis provide evidence that airway smooth muscle cells are capable 
of activating TGF-p in vitro. These data show that the serine protease tryptase, released from 
activated mast cells, can proteolytically activate TGF-p via a mechanism that is independent of 
the tryptase receptor protease activated receptor-2 (PAR2). This effect is not accompanied by 
increased expression of the latent TGF-p complex. Furthermore, these data provide evidence that 
airway smooth muscle cells can activate TGF-f3 via the integrin uVf35 in response to LPA 
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stimulation. We have found that cells from asthmatic patients activate more T G F - ~ ~ in response to 
LP A than cells from non-asthmatic individuals and this is not due to a difference in cell surface 
expression levels of the a . V ~ 5 5 integrin. LPA-induced T G F - ~ ~ activation can be inhibited by the ~ 2 2
adrenoreceptor agonist formoterol, which is a commonly used asthma therapy, and the muscarinic 
receptor agonist methacholine, which causes cell contraction, also causes T G F - ~ ~ activation by 
airway smooth muscle cells. Furthermore, the data presented here show that the cytoplasmic 
domain of the integrin ~ 5 5 subunit interacts with the cytoskeletal protein talin to mediate T G F - ~ ~
activation. 
Together, these data highlight two previously unreported, biologically relevant, mechanisms of 
T G F - ~ ~ activation employed by airway smooth muscle cells in vitro, both of which could 
contribute to the development of airway remodelling in asthma in vivo. Data concerning a . V ~ 5 5
mediated T G F - ~ ~ activation has led us to hypothesise that contraction of airway smooth muscle 
leads to T G F - ~ ~ activation in vivo. If correct, this could be vital to our understanding of how 
airway remodelling is initiated in asthma, and could lead to the development of new therapies 
aimed at inhibiting contraction-induced T G F - ~ ~ activation, for the treatment of asthma. 
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1 Introduction 
1.1 Asthma 
Asthma is a chronic inflammatory condition characterised by reversible airway obstruction, 
airway hyper-responsiveness (AHR) and infiltration of the airway mucosa with inflammatory 
cells, notably eosinophils. Its clinical symptoms include intermittent episodes of coughing, 
dyspnoea, wheezing and a sensation of chest tightness. It is a very common disorder affecting 5.2 
million people in the UK alone (Census 2001), of which 1.1 million are children (Asthma-UK 
2001b). Worldwide asthma prevalence varies greatly between countries; however, it has a 
tendency to be higher in developed countries such as the UK and Australia (ISAAC 1998). The 
prevalence of both adult and childhood asthma in the UK appears to be still increasing (Asthma-
UK 2001 a; Burr 2006), a trend that is also seen in other allergic conditions such as hayfever 
(allergic rhinitis). 
Asthma can be subdivided in to two broad subtypes; atopic and non-atopic, also known as 
extrinsic or allergic and intrinsic or non-allergic respectively. Atopy refers to the genetic 
susceptibility of an individual to develop immediate hypersensitivity reactions against common 
environmental allergens. Clinical features of atopic asthma include increased levels of 
immunoglobulin E (lgE) antibodies in the serum, positive skin tests when challenged with 
common aeroallergens and AHR. Patients with non-atopic asthma show negative results to skin 
tests, serum 19E levels are within the normal range and there are no detectable IgE antibodies 
present in the serum directed against common aeroallergens. Higher age, a lack of family history 
and female sex are associated with an increased risk of non-atopic asthma, which tends to be 
more severe than atopic asthma (Romanet-Manent et al. 2002). The incidence of non-atopic 
asthma varies between studies but is consistently between 10 and 30% of all asthmatics. 
In spite of the clinical differences, both types of asthma appear to share many common 
immunological mechanisms that contribute to the disease. Both atopic and non-atopic asthma 
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have been shown to be characterised by increased numbers of eosinophils present in the bronchial 
mucosa (Amin et al. 2000). Furthermore, despite patients with non-atopic asthma having serum 
19B levels within the normal range it has been shown that these patients have higher 19B levels 
than non-atopic people that do not suffer from asthma (Beeh et al. 2000), suggesting a role for 
19B in non-atopic asthma as well as atopic asthma. This is supported by the fmding that 
immunoglobulin class switching from IgM and IgG to 19B production occurs in both atopic and 
non-atopic asthma (Ying et al. 2001; Takhar et al. 2007). Moreover, the number of cells 
expressing the high affinity IgE receptor, FcaR!, on their surface, such as mast cells, macrophages 
and eosinophils, is also increased in both types of asthma (Humbert et al. 1 996b ). These findings 
imply that non-atopic asthma is not as distinct from atopic asthma as originally thought. It is 
possible that non-atopic asthma is caused by a very similar mechanism to atopic asthma i.e. 
sensitisation towards an inhaled antigen, but that the antigen involved is yet to be identified. This 
would explain why non-atopic asthma patients show a negative result to skin tests and why they 
appear to lack antigen specific 19B in their serum. Although this hypothesis has yet to be 
confirmed experimentally, one study in which families were counselled on how to avoid allergen 
exposure in the home showed that this can significantly reduce asthma attacks in both atopic and 
non-atopic asthmatic children (Nishioka et al. 2006), implying a role for allergen exposure in 
non-atopic as well as atopic asthma. 
1.1.1 Sensitisation 
One of the prominent characteristics of atopic asthma, and possibly non-atopic asthma, is AHR to 
inhaled antigens also known as asthmatic stimuli or allergens. Such stimuli include air pollutants, 
house dust mites, pollen etc. However, for individuals to respond to inhaled antigens they must 
first become sensitised. The airway epithelium is constantly exposed to antigen from the external 
environment through the inhalation of air. At the epithelial surface antigen presenting cells 
(APC), ·such as macrophages and dendritic cells, phagocytose the antigen and become activated. 
They migrate to the local lymph tissue whilst processing and presenting fragments of the antigen 
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on their cell surface in association with major histocompatibility complex (MHC). In the lymph 
tissue the APC present the antigen-MHC complex to naIve T cells, which recognise the antigen 
via their T cell receptor (TCR). This interaction activates the T cells, which then proliferate and 
differentiate into a form capable of producing effector functions such as cytokine secretion. 
Under the influence of cytokines such as IL-4 activated T cells preferentially differentiate into 
T H2 cells over T HI cells (Seder et al. 1992) driving an antibody mediated immune response. 
Antigen-specific IgE antibodies are produced by activated B lymphocytes (B cells) and bind to 
high affInity FCtRI receptors present on mast cells and basophi]s and low affmity FCtRI! 
receptors present on B cells and eosinophils. This creates antigen specific receptors present on the 
surface of these cells and enables them to become activated following interaction with the 
specific antigen. 
... ... ... 
APC e.g. Ag-MHC 
TH cell 
G) 
B cell 
Figure 1.1: Sensitisation 
Foreign antigens are engulfed by APC such as macrophages and dendritic cells. The antigen is 
processed in to peptide fragments, which are presented on the APC surface in a complex with 
MHC. TH cells recognise this complex via their TCR and become activated. They are then able to 
secrete a variety of cytokines, which aid B cell production of antigen specific 19E antibodies. 
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1.1.2 Early and Late Asthmatic Responses 
The early asthmatic response (EAR) occurs when a sensitised individual comes into contact with 
the antigen to which they are sensitised. It is associated with airway obstruction and an instant fall 
in forced expiratory volume in I second (FEV)). The antigen binds to the 19E antibodies present 
on the surface of mast cells and basophils resulting in cross linking of the FCERI and FcREII 
receptors, which initiates cell activation and signalling. Cell signalling events initiated by the 
cross linking of FCERI receptors cause the release of intracellular granules containing preformed 
mediators such as histamine, tryptases, chymases and heparin, and the de novo synthesis of a 
variety of lipid mediators such as leukotrienes and prostaglandins. These mediators cause 
constriction of the bronchial airways (bronchoconstriction), dilation of pulmonary blood vessels, 
they stimulate mucous secretion and increase the permeability of the blood vessels resulting in the 
common clinical symptoms of an "asthma attack," such as wheeze, dyspnoea and coughing. 
Furthermore, mast cell activation can also result in the secretion of cytokines such as IL-4, 
interleukin 13 (lL-13) and eosinophilic chemokines such as RANTES (Rajakulasingam et al. 
1997; Brightling et al. 2003b). Induction of the EAR occurs rapidly after contact with the antigen, 
usually between a few seconds and 30 minutes but also resolves relatively quickly. 
In many, but not all, asthma exacerbations the EAR is followed by a recurrence of symptoms 
known as the late asthmatic response (LAR). This occurs approximately 4 to 8 hours after the 
initial antigen challenge and is caused by the ongoing airway inflammation instigated during the 
EAR. Many mediators released during the EAR can cause increased migration and activation of a 
variety of inflammatory cells into the airways, where they secrete cytokines, proteases and 
chemokines causing a state of chronic inflammation and a recurrence of AHR and 
bronchoconstriction. Helper T lymphocytes and eosinophils are important in orchestrating the 
LAR. Infiltration of these cells into the asthmatic airway is associated with development of LAR 
(Nabe et al. 2005). Furthermore, the transfer of helper T cells from ovalbumin sensitised mice, a 
common murine model of asthma, into naive mice confers antigen-induced LAR (Ohtomo et al. 
22 
2009). The role of inflammatory cells and the mediators they secrete in the pathogenesis of 
asthma is discussed in more detail in the following section. 
1.1.3 Airway Inflammation 
Inflammation of the bronchial mucosa is a key feature of asthma. This dense inflammatory 
infiltrate consists of eosinophils, mast cells, basophils and T lymphocytes (Macfarlane et al. 
2000). Although the cellular composition of the inflammatory infiltrate is very similar between 
the two types of asthma, it is not identical: the infiltrate of non-atopic asthmatics contains large 
numbers of macrophages and neutrophils whereas the infiltrate of atopic asthmatics is composed 
mostly of eosinophils (Bentley et al. 1992; Amin et al. 2000; Shahana et al. 2005). Inflammatory 
cells are attracted into the airways by chemokines, which are produced by structural and 
inflammatory cells already present. The infiltration of inflammatory cells into the bronchial 
mucosa results in abnormal cytokine and chemokine expression, which contributes to the 
pathogenesis of asthma. This chapter will discuss the types of cell and mediators that are involved 
in asthmatic airway inflammation. 
1.1.3.l T Lymphocytes 
T lymphocytes (T cells) are the key instigators of antigen-dependent cell-mediated immunity. 
They develop from lymphoid stem cells in the bone marrow, mature into naIve T cells in the 
thymus then enter the blood stream and circulate the body. They express TCR on their surface 
through which they recognise foreign antigen. When T cells have recognised correctly presented 
foreign antigen (i.e. in a complex with MHC), they differentiate, proliferate and become 
activated. This enables them to perform effector functions involving the secretion of a diverse 
range of cytokines and inflammatory mediators. 
T cells can be broadly sub-divided into four groups. Cytotoxic T cells (T C), which express the cell 
surface marker CD8 are generally involved in the cell mediated immune response, and are able to 
23 
induce apoptosis in infected or damaged cells. Helper T cells (T H) express the surface marker 
CD4 and have various functions including activation of T c cells, assisting B cells in the 
production of antibodies and regulating immune and inflammatory responses through the release 
of cytokines and mediators. Memory T cells are long lasting antigen specific T cells that rapidly 
differentiate into effector cells upon activation allowing the immune system to respond rapidly to 
antigen it has encountered before. Regulatory T cells (T reg), also known as suppressor T cells, are 
involved in regulating T cell mediated responses and suppressing T cells directed against "self' 
antigens. In 1986 it was shown that TH cells could be further sub-divided on the basis of the panel 
of cytokines and chemokines that they secrete (Mosmann et al. 1986). Although some cytokines 
such as granulocyte macrophage-colony stimulating factor (GM-CSF) and tumour necrosis 
factor-a (TNF -a) are produced by both subsets of T H cells, the predominant cytokines produced 
by T HI cells are interleukin-2 (IL-2), interferon-y (IFN-y) and tumour necrosis f a c t o r - ~ ~ ( T N F - ~ ) . .
In contrast, T H2 cells secrete IL-4, IL-5 and IL-13 (Cherwin.ski et al. 1987). T HI cells are 
generally considered to be involved in cell mediated immune responses and T H2 cells are 
involved in humoural or antibody-mediated immune responses. Moreover, each subset down-
regulates the responses of the other subset, so that only one type of response is used to deal with a 
particular antigen. 
Asthma, like many other allergic diseases, is considered to be driven by T H2 responses, an idea 
that is supported by many observations. It has been shown that TH2 cells but not THI cells are 
capable of inducing AHR in sensitised mice following challenge with antigen (Cohn et al. 1998; 
Iwamura et al. 2007). Another prominent feature of asthma is goblet cell hyperplasia and 
increased mucous secretion, which is promoted by TH2 cells in mice (Cohn et al. 1997; Hoshino 
et al. 2004). Furthermore, the expression of IL-4 and IL-5 by T cells and other inflammatory cells 
is increased in the bronchial mucosa of both atopic and non-atopic asthmatics (Humbert et al. 
1996a; Ying et al. 1997a; Brightling et a/. 2003b). These features imply a T H2 mediated rather 
than T HI mediated response. 
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1.1.3.2 LJ2 Cytokines in Asthma 
IL-4 has a diverse range of functions relevant to asthma and other allergic diseases. As mentioned 
in section 1.1.1, IL-4 facilitates B cells in their production of antigen specific IgE molecules (Del 
Prete et al. 1988; Pene et al. 1988; Yamada et al. 2002). Furthermore, it contributes to the 
recruitment of T cells and other inflammatory cells into the airways by increasing vascular 
permeability and increasing expression of adhesion molecules such as vascular cell adhesion 
molecule-l (VCAM-l) by the endothelium (Ying et al. 1997b; Kotowicz et al. 2004). Studies 
using transgenic mice constitutively expressing IL-4 in the lungs have shown that these mice 
suffer from an intense pulmonary inflammatory response, with increased numbers of 
macrophages, eosinophils, lymphocytes and neutrophils. Furthermore, they show a marked 
increase in baseline airway resistance (Rankin et al. 1996). 
The role of IL-5, another T H2 cytokine, in asthma pathogenesis Ras been confirmed using studies 
with IL-5-deficient transgenic mice, which lack blood and tissue eosinophilia and airway 
hyperreactivity to methacholine, both of which are characteristic of asthma (Foster et al. 1996; 
Kopf et al. 1996). Furthermore, anti-IL-5 monoclonal antibodies have been developed for use as 
an asthma therapy. However, the efficacy of such treatment is still unclear. The first clinical trial 
found that although a monoclonal anti-IL-5 antibody caused a reduction in blood and sputum 
eosinophil numbers, there was no discernible effect on AHR or either the EAR or LAR (Leckie et 
al. 2000). However, a more recent study found that anti-IL5 treatment decreased the frequency of 
asthma exacerbations in severe asthmatics as well as reported decreased eosinophil counts in 
sputum and blood (Haldar et al. 2009). The clinical benefit of such a treatment to asthma patients 
is therefore still uncertain but may depend upon the severity of asthma. 
IL-13, also a T H2 cytokine, is closely related to IL-4 and like IL-4 and IL-5 has been implicated 
in asthma. A study using transgenic mice that over express IL-13 in the lung showed that this T H2 
cytokine is involved in several of the features of asthma including eosinophilia, hyper-secretion 
of mucous and goblet cell hyperplasia, obstruction of the airways and AHR (Zhu et al. 1999; 
25 
Kuperman et at. 2002). Moreover, IL-13 is a potent inducer of eotaxin from airway epithelial 
cells (Li et al. 1999; Matsukura et al. 2001), which may contribute to airway eosinophilia in 
asthma. 
In conclusion, T H2 cells have a fundamental role in the orchestration of the inflammatory 
response in an asthmatic setting. After becoming activated by a specific antigen, they are able to 
interact with many other cells such as B cells, eosinophils and mast cells through the secretion of 
a variety of mediators and cytokines. These cytokines augment the inflammatory response by 
activating other inflammatory cells and by acting back on T H2 cells in a positive feedback 
mechanism. The various interactions of T H2 cells and their cytokines with other inflammatory 
cells are summarised in Figure 1.2. 
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Figure 1.2: Role ofTJ:!2 Cells and Their Cytokines in Asthma 
This figure gives an overview of the role of TH2 cells and the cytokioes they produce io asthma. 
TH2 cytokines, such as IL-4, IL-5 and IL-13, are responsible for the development and/or 
activation of several cell types involved in the pathogenesis of asthma. TH2 cells are therefore 
thought of as orchestrators of asthmatic airway inflammation. 
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1.1.3.3 Eosinophils 
Eosinophils are a type of leukocyte that develop and mature in the bone marrow from a myeloid 
precursor, and are so named due to the fact that they bind to the dye eosin. Eosinophilia is the 
term given to the presence of abnormally high numbers of eosinophils. Immature eosinophil 
precursors differentiate and mature through the influence of the cytokines IL-3, granulocyte 
macrophage-colony stimulating factor (GM-CSF) and IL-S, with IL-S being responsible for 
terminal differentiation and therefore eosinophilia. Transgenic mice that lack IL-S are unable to 
develop eosinophilia (Foster et al. 1996; Kopf et al. 1996) and administration of IL-S causes 
blood eosinophilia (van Rensen et al. 2001). Eosinophilia ofthe peripheral blood and tissues is an 
important and prominent characteristic of asthma. Expression of IL-S is increased in the bronchial 
mucosa in asthma (Humbert et al. 1996a; Ying et al. 1997a), which may contribute to pulmonary 
eosinophilia. Furthermore, eosinophils are attracted to sites of inflammation by several 
chemotactic mediators, including RANTES (CCLS), eotrutin (CCLll) and macrophage 
inflammatory protein-la (MIP-la, CCL3) (Lukacs et al. 1996), the expression of which is 
increased in asthma (Alam et al. 1996; Ying et al. 1997c; Lilly et al. 2001). Eosinophils are 
therefore thought to be important in the pathogenesis of asthma. 
Eosinophils have a diverse range of functions many of which are thought to be involved in 
asthma pathogenesis. They are capable of regulating immune responses through the secretion of 
both THI and TH2 cytokines, transforming growth f a c t o r - ~ ~ ( T G F - ~ ) ) and several chemokines. 
They also contain many secondary granules containing pre-synthesised mediators that are 
secreted upon cell activation. Many of these mediators, including eosinophil cationic protein 
(ECP), major basic protein (MBP) and eosinophil peroxidase (EPO), are extremely cytotoxic and 
kill cells by making pores in their cell membranes, which ultimately leads to cell lysis (Young et 
al. 1986). This effect is augmented by the release of reactive oxygen intermediates from 
eosinophils, such as hydrogen peroxide, which are also very damaging to cells. Release of these 
mediators and compounds in the lungs causes damage to the airway epithelium resulting in 
shedding of cells from the epithelial layer. In addition to their cytotoxic effects, MBP and ECP 
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are able to activate mast cells and cause release of histamine, even following an initial activation 
of the mast cells by allergen challenge (Piliponsky et al. 2001), suggesting a role for these 
mediators in LAR. Furthermore, MBP is capable of inducing AHR (Gundel et al. 1991; Coyle et 
al. 1995; Homma et al. 2005). These studies indicate that pulmonary eosinophilia, which occurs 
in asthma, leads to the release of many mediators from eosinophils that are capable of 
contributing to asthma pathogenesis. 
1.1.3.4 B Lymphocytes 
B lymphocytes (B cells) are the primary cell type involved in antibody-mediated, or humoural, 
immune responses. They are produced in the bone marrow from lymphoid stem cells, but unlike 
T cells they do not migrate to the thymus to develop and instead undergo full development in the 
bone marrow. B cell development involves multiple, random rearrangements of the genes 
encoding the heavy and light chains of antibody molecules, resulting in massive diversity in 
antibody specificity. The specificity of a B cell for a certain antigen is achieved via its B cell 
receptor (BCR), which consists of antigen specific membrane-bound immunoglobulin (mIg) and 
a disulphide-linked heterodimer called I g a l I g ~ . . In addition, B cells also express a wide variety of 
cell surface molecules including MHC class II, the complement receptors CRI and CR2, B220 
which is commonly used as a B cell marker and CD40 which interacts with CD40 ligand 
(CD40L) on TH cells. 
Naive B cells circulate the body in an inactive form and must be activated before they are able to 
produce antibodies. Activation occurs when the BCR becomes cross linked by the binding of 
antigen. For some antigen this is sufficient for B cell activation and antibody production, 
however, the majority of antigens are thymus dependent and are unable to cause full activation of 
B cells by this process alone. B cells specific for such antigen also require a second activation 
signal ftom interaction with T H cells before they are able to produce and secrete antibodies 
directed against the antigen. 
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B cells have an important role in the pathogenesis of asthma. Under the influence of cytokines 
such as IL-4 released from activated TH2 cells B cells switch to preferentially producing class E 
antibodies (lgE) (Del Prete et al. 1988; Pene et al. 1988; Yamada et al. 2002). Once secreted 
these antibodies "coat" the surface of mast cells, basophils and other inflammatory cells rendering 
them able to respond immediately to encounters with that antigen, producing an immediate 
hypersensitivity reaction (see chapter 1.1.1). In order for B cells to express 19E over other 
isoforms of immunoglobulins class switch recombination of the immunoglobulin heavy chain 
locus is needed. The gene is rearranged so that the variable region (VDJ) is linked to the constant 
region of immunoglobulin E (Ce) rather than to the constant region of another immunoglobulin 
class (Ca., Oy or CIl). The resulting mRNA is then translated into IgE proteins. Class switch 
recombination can be induced by the actions of certain TH2 cytokines, such as IL-4 (Yamada et 
al. 2002). There is much evidence to show B cells undergo class .switch recombination to the 19E 
isoform in the bronchial mucosa of both atopic and nonatopic asthmatics (Ying et al. 2001; 
Takhar et al. 2007), suggesting that antigen specific IgE molecules are synthesised and secreted 
locally in both forms of asthma. The finding that antigen specific 19E may be produced locally 
may help to explain how the levels of 19E in the serum of nonatopic asthmatics are within the 
normal range despite the apparent allergic nature ofthis form of asthma. 
1.1.3.5 Mast Cells 
Mast cells (MC) appear to playa fundamental role in the orchestration of airway inflammation. 
They are highly granular, tissue resident, cells that develop from CD34+ progenitors in the bone 
marrow. After leaving the bone marrow they circulate in an immature form, lacking the 
characteristic granules of mature MC, until they reach a mucosal or connective tissue site where 
they undergo final differentiation. They are attracted into tissues by a variety of mediators. 
Supematimts collected from HASM cells stimulated with T H2 cytokines are highly chemotactic 
for MC, an effect found to be mediated in part through the IL-8 receptor, CXCR1, as well as 
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CCR3 the receptor for a variety of chemokines such as CCL2, CCL3, CCL4, CCLS, CCLlI, 
CCL24, CCL26 (Sutcliffe et al. 2006). Moreover, all three isoforms of T G F - ~ ~ can induce MC 
chemotaxis (Olsson et al. 2000). The cytoplasm of mature Me contains large numbers of 
granules containing preformed mediators and enzymes. MC can be subdivided into two groups on 
the basis of some of the proteases that their granules contain; Me containing tryptase are 
designated MCT, and MC containing tryptase and chymase are designated MCTC. Both subtypes 
can be found in the lung but the predominant type is MeT (Brightling et al. 2003a). Me granules 
also contain a wide variety of different preformed mediators and proteases including histamine, 
serine proteases including tryptase and chymase, proteoglycans such as heparin and cytokines 
such as TNF-a, certain interleukins and chemokines. Furthermore, MC activation also results in 
the synthesis and secretion of many lipid mediators and cytokines (summarised in Table 1.1). 
In addition to many other receptors, MC express FcsRI, a type .of high affinity 19B receptor on 
their surface, which binds antigen specific 19E molecules. MC can be activated by cross-linking 
of FcsRI-IgE complexes on their surface by specific antigen. Furthermore, they may also be 
activated through the binding of other ligands to their cell surface receptors, independently of 
FceRI cross-linking. Such ligands include complement component 3a (C3a) and pathogen 
associated molecular patterns (PAMPs) from various bacteria and viruses, however, several other 
ligands are able to influence FceRI-dependant activation either negatively or positively. MC 
activation results in release of their cytoplasmic granules, which contain a vast array of enzymes 
and mediators in a process known as degranulation. This causes a classic type I hypersensitivity 
reaction that in asthma is known as EAR (discussed in Introduction section 1.1.2). 
The secretion of preformed mediators from activated MC induces the EAR and the synthesis and 
release of new mediators contributes to LAR, (see Table 1.1) reSUlting in the characteristic 
symptoms of an asthma exacerbation. Histamine is strongly implicated in type I hypersensitivity 
reactions and therefore the induction of EAR. In addition to increasing the permeability of blood 
vessels leading to increased chemotaxis of inflammatory cells, which could later contribute to 
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LAR, it also causes contraction of HASM through activation of HI histamine receptors causing 
severe shortness of breath and wheezing. Furthermore, the most abundant MC protease, tryptase, 
which is released with histamine, can potentiate histamine induced HASM contraction (Johnson 
et al. 1997a). Leukotrienes are also heavily involved, contributing to LAR by causing 
bronchoconstriction, increased mucous production and chemotaxis of inflammatory cells in to the 
lungs. 
Cytokines - in granules 
and newly synthesised 
Interleukin 3 (IL-3), IL-4 (MCTC only), IL-S (MCT only), I 
interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 9 (IL-9), 
interleukin 10 (IL-I0), IL-13 (MOTC only), TNF-a J 
- i:j CCLS, CCLll, MCP-l, -3 and-4, IL-8 I 
granules and newly I 
synthesised J 
----- ------------ ---- ---------------- -------------------
Chemokines 
Growth factors - in 
granules and newly 
synthesised 
Stem cell factor (SCF), GM-CSF, T G F - ~ , , platelet activating I 
factor (P AF), platelet derived growth factor (PDGF) 
I 
~ w l y y f ~ r m e d d m e d i a t o ~ ~ Prostaglandin D2 (PGD2), leukotriene C4 (LTC4) J 
Table 1.1: Mast Cell Mediators 
This table summarises the different types of mediator released from mast cells. Some mediators, 
such as histamine and tryptase, are stored in cytoplasmic granules and released immediately upon 
cell activation. Other mediators are synthesised following MC activation and are therefore not 
released immediately. 
Adapted from Brightling et aI, 2003 
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A role for MC in asthma has been suggested for many years but their relative importance to 
asthma pathogenesis has been debated. It was observed over 20 years ago that increased numbers 
of MC are evident in the bronchoalveolar fluid (BALF) of asthmatics compared with non-
asthmatics (Tomioka et al. 1984). Recently several studies have confirmed that they have an 
important role to play. Studies using transgenic mice deficient for MC, have shown that MC have 
an important role airway inflammation and hyper-responsiveness (Williams et al. 2000). These 
mice exhibit less airway hyper-reactivity and less airway infiltration by eosinophils than wild-
type mice following ovalbumin challenge. Furthermore, the fundamental difference between 
biopsies from patients with asthma and eosinophilic bronchitis is increased MC infiltration of the 
ASM layer in asthmatics (Brightling et al. 2002). Eosinophilic bronchitis is a chronic 
inflammatory disease of the airways which differs from asthma in that patients do not present 
with AHR or reversible airway obstruction. This suggests that t ~ e e presence of MC contributes to 
AHR. Studies have shown that the numbers of MC present in the airways is increased in 
asthmatics compared with non-asthmatics (Carroll et al. 2002) and within the ASM layer of 
sensitised bronchial tissue sections compared with non-sensitised sections (Ammit et al. 1997). 
The degree of MC degranulation is positively associated with asthma severity with fatal severe 
asthmatics showing the most MC degranulation in their airways (Carroll et al. 2002) supporting 
an important role for MC and their products in asthma severity. Interestingly, infiltration of the 
airways by MC is a feature of non-atopic asthma as well as atopic asthma (Humbert et al. 1996b) 
implying that MC are involved in the pathogenesis of both types of asthma, adding further 
support to the hypothesis that they are not as distinct from one another as initially thought. The 
EAR and LAR can be suppressed by inhibiting the binding of 19E molecules to MC using an anti-
IgE monoclonal antibody (Fahy et al. 1997) confirming the role of MC activation in these 
processes. Furthermore, the magnitude of the LAR can also be reduced by treatment of patients 
with an inhaled inhibitor of mast cell tryptase (Krishna et al. 200 I). 
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In summary, MC numbers are increased within asthmatic airways, they localise mainly within the 
ASM layer and they play an important role in the orchestration of airway inflammation and 
hyper-responsiveness. This makes the MC an attractive candidate when studying asthma 
pathogenesis and disease mechanisms, and for the development of drugs to treat and prevent 
asthma. 
1.1.4 Mild, Moderate and Severe Asthma 
Asthma is a heterogeneous disease with huge variability in both the nature and severity of 
symptoms between patients. Broadly, asthma can be subdivided into 3 groups, mild, moderate 
and severe, depending upon symptom severity and efficacy of treatment methods. The majority of 
asthma patients have either mild or moderate forms of the disease. Mild asthma refers to patients 
who suffer from sporadic symptoms of disease which respond extremely well to treatment. Mild 
asthmatics generally have normal lung function when they are not suffering from an asthma 
exacerbation. Moderate asthmatics suffer from symptoms more regularly than mild asthmatics 
and tend to require treatment of their symptoms on a daily basis. Treatment with a short-acting 
medication is usually effective. Unlike mild asthmatics, these patients may have abnormal lung 
function when not suffering from an exacerbation. Approximately 5-10% of asthmatics suffer 
from severe asthma (Holgate et al. 2006). The clinical features of this subgroup of asthma vary 
greatly between patients (ATS 2000); Some patients have intermittent profound airway 
obstruction whereas in others it may be persistent. Similarly some severe asthma patients, but not 
all, suffer from excessive mucous production resulting in mucous plugs in the airways, which 
could contribute to persistent airway obstruction. Severe asthmatics frequently suffer debilitating 
exacerbations of their symptoms and often exhibit significantly diminished lung function 
compared with patients suffering from milder disease (Mascia et al. 2005). They require 
treatment with high dose corticosteroids and long-acting ~ 2 - a d r e n e r g i c c receptor agonists ( ~ 2 2
agonists) on a daily basis (Holgate et al. 2006). In many cases the disease does not respond well, 
if at all, to treatment resulting in a higher risk of hospital admission, mortality and morbidity than 
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the other subgroups of asthma. For these reasons, patients with severe asthma account for a 
disproportionate use ofNHS resources. 
1.2 Airway Remodelling 
Airway remodelling is the collective term given to the structural and cell phenotypical changes 
seen in the asthmatic airway, especially in cases of severe and fatal asthma. The common features 
of airway remodelling are summarised in Figure 1.3. At present there is still much to learn about 
how airway remodelling contributes to asthma pathogenesis. There is currently a lack of non-
invasive procedures available to accurately measure airway remodelling, which means that it is 
difficult to make associations between remodelling events and changes in airway function. 
However, the rate of decline in lung function associated with increased age is much faster in 
asthmatics than in non-asthmatics and diminished lung function over time is associated with 
asthma severity (Lange et al. 1998; Bai et al. 2000; Mascia et al. 2005). Most studies to date 
suggest that airway remodelling is worse in patients suffering from severe asthma than in those 
suffering from moderate asthma (Benayoun et al. 2003; Pepe et al. 2005). Furthermore, computer 
models have shown that asthmatics have increased airway wall thickness, associated with 
irreversible airway obstruction (Kasahara et al. 2002), which would contribute to decreased lung 
function. These studies suggest that decreased lung function over time in chronic asthma is 
caused by airway remodelling. It is still not clear, however, whether airway remodelling is an 
early event in asthma pathogenesis or whether it occurs in response to chronic inflammatory 
events. This chapter will describe the common features of airway remodelling, the mechanisms 
driving the changes and the implications of these changes for the disease. 
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Figure 1.3: Features of Airway Remodelling 
This figure summarises the key changes to the airways of asthmatics that are collectively termed 
airway remodelling. These changes include mucous gland hyperplasia, damage to the epithelial 
layer, angiogenesis, increased numbers of fibroblasts and myofibroblasts, subepithelial fibrosis 
and increased ASM mass. These changes could contribute to the increased loss of lung function 
over time observed in asthmatics. 
1.2.1 Epithelial Changes 
The airway epithelium of both asthmatics and non-asthmatics is constantly exposed to potentially 
damaging agents from the external environment, such as pollution, allergens and viruses . In 
normal individuals, these are dealt with adequately via the epithelial barrier and cells of the innate 
immune system and therefore do not cause any problems. However, evidence suggests that there 
is a fundamental difference between the epithelium of asthmatics compared with non-asthmatics; 
asthmatic epithelium becomes damaged more easily, resulting in apoptosis and excessive 
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shedding of the epithelial layer (Laitinen et al. 1985; Jeffery et al. 1989; Amin et al. 2000; 
Shahana et al. 2005). Expression of epidermal growth factor receptor (EGFR), a marker of 
epithelial repair, is increased in the bronchial epithelium of asthmatics confirming that damage to 
the epithelium has occurred (Puddicombe et al. 2000). In addition, it is thought that asthmatic 
epithelial cells have aberrant repair responses to injury compared with non-asthmatic epithelial 
cells (Wark et al. 2005), augmenting epithelial damage. Furthermore, the number of mucous 
glands present in the asthmatic epithelium is far higher than in non-asthmatic subjects due to 
mucous gland hyperplasia (Ordonez et al. 2001), which can lead to excessive mucous production. 
This can form mucous plugs within the airways making asthma exacerbations much worse and 
contributing to persistent airway obstruction and decreased lung function. 
1.2.2 Airway Smooth Muscle Hyperplasia and Hypertrophy 
The ASM layer of asthmatic airways is also fundamentally different to normal airways. 
Hyperplasia and hypertrophy result in an overall increase in smooth muscle mass in both the large 
and small airways (Ebina et al. 1993; Woodruff et al. 2004; Bentley et al. 2009). This contributes 
to narrowing of the airways and therefore persistent airway obstruction, increasing the stiffness of 
the airway wall which, in turn, increases the resistance of the airways. Greater muscle mass also 
means that the ASM layer can contract with more force during an exacerbation. Studies 
comparing the degree of ASM hyperplasia and hypertrophy between asthmatics have found that 
the ASM layer of severe asthmatics is significantly larger than both control subjects and subjects 
with mild or moderate forms of the disease (Benayoun et al. 2003) suggesting an important role 
for increased ASM mass in asthma pathogenesis. This is supported by the finding that persistent 
airway obstruction is associated with thickening of the bronchial wall (Bumbacea et al. 2004). 
Hyperplasia and hypertrophy of the ASM layer arises due to several factors. Hypertrophy of 
smoE>th muscle occurs as a normal homeostatic response to increased workload and so the 
bronchoconstriction observed during an asthma exacerbation may cause ASM hypertrophy. 
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Furthermore, the presence of a vast array of inflammatory cells within asthmatic airways causes 
altered expression of cytokines, inflammatory mediators and growth factors many of which can 
contribute to ASM cell hypertrophy, including angiotensin and T G F - ~ ~ (McKay et al. 1998; 
Goldsmith et al. 2006). Several factors and mediators, including T G F - ~ ~ and epidermal growth 
factor (EGF), are capable of stimulating ASM proliferation and therefore contribute to ASM cell 
hyperplasia (Black et al. 1996; Berger et al. 2001; Chen et al. 2006). The rate of ASM cell 
proliferation certainly appears to differ between asthmatic subjects and normal controls with 
ASM cells from asthmatic patients proliferating at a much faster rate than those from normal 
controls (Johnson et al. 2001). Migration of ASM cells is also likely to contribute to ASM 
hyperplasia. It has been shown that myofibroblasts, which themselves have a contractile function 
and can differentiate in to ASM cells, migrate into the bronchial mucosa after allergen challenge 
(Gizycki et al. 1997) where they undergo differentiation. Fibrocytes, a type of circulating 
myofibroblast progenitor cell, have also been shown to migrate in to the bronchial mucosa 
following allergen challenge (Schmidt et al. 2003) where they too may begin expressing 
contractile proteins such as a-smooth muscle actin (a-SMA). These studies highlight that several 
contributing processes, including hypertrophy, proliferation and migration, are responsible for the 
increased mass of the ASM layer observed in asthmatics. 
1.2.3 Subepithelial Fibrosis 
Subepithelial fibrosis refers to the thickening of the lamina reticularis, which lies beneath the 
basement membrane, by the deposition of ECM proteins such as collagens and fibronectin. In 
addition to being observed in human asthmatic subjects (Roche et al. 1989; Boulet et al. 1997; 
Tomkowicz et al. 2008), it has also been documented in murine and rat models of asthma 
(Palmans et al. 2000; Silva et al. 2008). Moreover, myofibroblasts migrate into the bronchial 
mucosa during the LAR following allergen challenge (Gizycki et al. 1997), which may contribute 
to subepithelial fibrosis. Subepithelial fibrosis may contribute to persistent airway obstruction 
and alter airway function by increasing the thickness and . stiffness of the airway wall, which 
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increases the resistance of the airways. Using a murine model of severe asthma it has been found 
that increased airway resistance is associated with deposition of collagen (Silva et al. 2008). The 
relationship between subepithelial fibrosis and asthma symptoms is still not entirely clear, 
however, it has been shown that the degree of subepithelial fibrosis is significantly correlated 
with AHR (Boulet et al. 1997) and a decrease in lung function (Kasahara et al. 2002). 
1.2.4 Angiogenesis 
Airway remodelling also involves the bronchial and pulmonary vasculature. The bronchial 
mucosa of asthmatic patients has many more blood vessels, which are also larger in size, than that 
of non-asthmatics (Li et al. 1997; Vrugt et al. 2000). Angiogenesis occurs in response to many 
inflammatory mediators and growth factors including vascular endothelial growth factor (VEGF), 
angiotensin and plasminogen activator inhibitor-l (PAIl). Many of these mediators are increased 
in the asthmatic airway. A study by Hirst and colleagues' found that BALF from asthmatic 
patients had significantly higher concentrations of many pro-angiogenic mediators, including 
VEGF and MCP-l, compared with BALF from non-asthmatics (Simcock et al. 2007). 
Furthermore, levels of VEGF and angiotensin are increased in the sputum of asthmatics (Kristan 
et al. 2009). These findings are supported by data which show that human ASM cells from 
asthmatic patients are able to promote angiogenesis in vitro via increased release of VEGF in to 
culture media (Simcock et al. 2008). 
In summary, airway remodelling is a collective term used to describe the many, diverse structural 
changes that occur within the airways of asthmatics. It involves most types of structural cell 
present in the airways. At present, it is not known whether airway remodelling results from the 
chronic inflammation that characterises asthma, or whether it occurs prior to disease onset and 
actually contributes to the development of an asthma phenotype. However, airway remodelling is 
detrimental to both baseline lung function and asthma symptoms, especially in patients suffering 
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from severe asthma. It is therefore an important process to study and develop new treatment 
strategies for. 
1.2.5 Epithelial-Mesenchymal Trophic Unit (EMTU) 
The airway wall contains many different cell types. Below the airway epithelium and its 
associated basement membrane lies a layer of mesenchymal cells, mainly fibroblasts and 
myofibroblasts, which has been termed the attenuated fibroblast sheath. This layer is in very close 
proximity to the epithelial layer above it and the ASM layer below it. The epithelial-
mesenchymal trophic unit (EMTU) refers to communication between the airway epithelium and 
the underlying mesenchymal layer via cell-cell and cell-ECM interactions and also the paracrine 
and autocrine secretion of mediators involved in cell proliferation and fibrosis. This allows 
metabolic changes in one cell to directly influence the response of other cell types present within 
the airway wall. EMTU has a fundamental role in promoting branch formation during foetal lung 
development and is thought to play a role in epithelial repair responses to injury since the 
attenuated fibroblast sheath is able to respond quickly to signals and stimuli received from the 
epithelial layer above. 
Recently it has been proposed that the EMTU is reactivated in the asthmatic airway (Holgate et 
al. 2004). It is thought that damage to the epithelium and epithelial shedding, which occurs in 
asthma, causes the epithelium to release a vast array of mediators and growth factors as part of its 
repair response. These mediators act in a paracrine manner on the attenuated fibroblast sheath 
regulating processes such as cell proliferation, ECM protein deposition and chemotaxis of 
inflammatory cells. This form of communication between the airway epithelium and underlying 
fibroblasts has been observed in an in vitro model. Airway epithelial cells were cultured in air-
liquid interface (ALI) with normal lung fibroblasts cultured on the basal side of the ALI insert. 
The ALI insert only, and therefore only the epithelial cells, was subjected to mechanical stress by 
increasing atmospheric pressure. Soluble signals released from the stressed epithelial cells caused 
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increased expression of collagens by the unstressed fibroblasts and increased production of 
fibronectin by the epithelial cells, confmning communication between the two cell types (Swartz 
et al. 200 I). Another study using a similar model found that epithelial cell injury caused 
fibroblast proliferation and secretion of mediators and growth factors such as T G F - ~ 2 , , bFGF, 
PDGF and endothelin-l in to culture medium (Zhang et al. 1999). 
Although reactivation of the EMTU is a normal epithelial response to injury, the epithelium of 
asthmatics is more prone to injury than the epithelium of non-asthmatics (Bucchieri et al. 2002) 
and shows increased expression of markers of cell injury and stress such as epidermal growth 
factor receptor (EGFR) (Puddicombe et al. 2000). Moreover, there is evidence of increased 
apoptosis of the epithelial layer of asthmatics (Benayoun et al. 2001). This leads to increased 
reactivation of EMTU and aberrant repair responses, which contribute to chronic inflammation 
and airway remodelling. For many years it was thought that reactivation of the EMTU occurs 
mainly as a response to the chronic inflammation observed in asthmatics. However, it has 
recently been described that there is evidence of epithelial damage and airway remodelling within 
the airways of asthmatic children without any associated increase in eosinophil numbers (Fedorov 
et al. 2005). This suggests a role for epithelial abnormalities and reactivation of the EMTU very 
early on in the pathogenesis of asthma. 
1.3 Airway Smooth Muscle 
ASM cells, like all smooth muscle, are structural cells derived from the mesenchyme. 
Individually, the cells are spindle shaped with a centrally located, oval nucleus but collectively 
they form large sheets or bundles. In culture, confluent ASM cells have a "hill and valley" 
appearance (Pang et al. 1997). ASM cells have a fundamental role in the pathogenesis of asthma 
since- it is the ASM layer that contracts in response to asthmatic stimuli, resulting in 
bronchoconstriction. In addition to this fairly obvious role for ASM cells in asthma pathogenesis, 
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they are also capable of synthesising and secreting a vast array of inflammatory mediators, 
cytokines and growth factors. ASM cells, like vascular smooth muscle cells, are capable of 
switching from a contractile phenotype to a synthetic phenotype and vice versa via a process 
known as phenotypic plasticity (Chamley-Campbell et al. 1979; Halayko et al. 1996; Johnson et 
al. 1997b). 
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Figure 1.4: Synthetic Functions of Airway Smooth Muscle Cells in Asthma 
This diagram illustrates the diverse synthetic functions of ASM cells in asthma. Airway smooth 
muscle cells are capable of synthesising and releasing a vast array of cytokines, chemokines, 
inflammatory mediators, adhesion molecules, growth factors and mediators involved in regulation 
of wound repairs. A) Mediators released from inflammatory cells present in the asthmatic airway 
regulate the production of cytokines and chemokines from ASM cells. For example IFN-y and 
TNF-a upregulate the chemokine RANTES but lL-4 , lL-13 and IL-IO downregulate it. TNF-a 
and IL-l P increase the cytokines IL-6 and IL-8, wh ich contribute to increased migration and 
activation of other inflammatory cells. B) PGE2, which relaxes smooth muscle cells, is produced 
by ASM cells in response to inflammatory mediators such as bradykinin and IL-lP, and 
acetylcholine re leased from cholinergic nerves. C) The pro-inflammatory mediator TNF-a 
upregulates expression of the adhesion molecules ICAM, VCAM and CD44 by ASM cells, which 
contributes to migration and adhesion of inflammatory cells and lymphocytes. D) IL-l P 
stimulates the production ofPDGF, a mitogen for ASM cells. ASM cells produce IGF. Following 
stimulation of ASM cells with LTD4, IGF activity is increased due to increased production of 
MMP-l. 
(Adapted from Johnson et al. 1997b) 
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The secretory function of ASM has implications for both asthmatic inflammation and airway 
remodelling. Many of the mediators secreted are chemoattractive for a wide range of 
inflammatory cells, which contributes to airway wall infiltration by inflammatory cells. For 
example ASM cells are capable of secreting transforming growth f a c t o r - ~ ~ ( T G F - ~ ) ) and stem cell 
factor (SCF), which are chemoattractive for mast cells (Berger et al. 2003), interleukin-8 (IL-8), 
which recruits neutrophils (Mullan et al. 2007) and Regulated Upon Activation Normal T cell 
Expressed and Secreted (RANTES) and eotaxin, which recruit eosinophils (Pang et al. 2006). 
Many ofthese mediators are released from ASM cells in asthma, which are likely to contribute to 
the increased numbers of inflammatory cells seen in the ASM layer of asthmatics compared with 
non-asthmatics (Brightling et al. 2002; Begueret et al. 2007). Furthermore, ASM cells express 
various adhesion molecules, both constitutively and in response to several pro-inflammatory 
mediators (Oliver et al. 2006), which facilitates airway infiltration by inflammatory cells. Such 
molecules include V-CAM-I, I-CAM-I and CD44. 
Several ASM derived mediators are also involved in processes of airway remodelling, most 
notably T G F ~ . . As will be discussed in the following chapters, T G F - ~ , , which can be secreted by 
ASM cells (Berger et al. 2003), has been implicated in several different remodelling events 
including ASM cell hypertrophy and hyperplasia. Moreover, ASM cells are capable of secreting a 
vast array of ECM proteins (Johnson et al. 2000; Coutts et al. 2001; Moir et al. 2008), which 
contribute to subepithelial fibrosis. 
1.4 Transforming Growth Factor-ft 
The TGF - ~ ~ superfamily of genes, of which TGF - ~ ~1 is the prototype, includes a diverse group of 
45 different proteins including T G F - ~ , , inhibins, activins and bone-morphogenetic proteins 
(BMPs) (all members of the superfamily are shown in Figure 1.5). Members of this superfamily 
regulate fundamental developmental and physiological processes such as cell proliferation, 
survival and differentiation. The carboxyl terminal domain of all T G F - ~ ~ superfamily members 
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contains seven highly conserved cysteine residues. Six of these cysteine residues form a 
characteristic fold known as a cysteine knot in the tertiary structure of TGF-p superfamily 
members. Some members, including the TGF-p isoforms and certain inhibins, also contain a 
further two cysteine residues within this domain. Members of TGF-p superfamily can be sub-
divided into smaller families based upon sequence homology outside of the cysteine knot region. 
The TGF-p isoforms form one such family. 
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Figure 1.5: TGF-Q Superfamily 
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This figure described all members of the T G F - ~ ~ superfamily of proteins, which includes TGF-p, 
activins and BMPs. Members of this superfamily are subdivided into smaller families. The three 
isoforms ofTGF-p form the TGF-p family. 
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1.4.1 Structure and Expression of TGF - ~ ~
At present three mammalian isoforms of TGF - ~ ~ have been identified, designated TGF - ~ ~1, TGF-
~ 2 , , T G F - ~ 3 , , following the discovery and isolation o f T G F - ~ 1 1 in the 1980s (Assoian et al. 1983; 
Derynck et al. 1985; Cheifetz et al. 1987). All three of these isoforms ( T G F - ~ I , , T G F - ~ 2 2 and 
T G F - ~ 3 ) ) are expressed in humans, sharing 64-85% sequence homology between one another 
(Frank et al. 1996). All three isoforms are expressed by most cell types in the body, however, 
T G F - ~ l l is the most abundant isoform found in humans. The genes for these 3 isoforms are 
located on separate chromosomes: T G F - ~ 1 1 is found on chromosome 19q13 (Fujii et al. 1986), 
T G F - ~ 2 2 on chromosome Iq41 (Nishimura et al. 1993) and T G F - ~ 3 3 is located on chromosome 
14q23-24 (ten Dijke et al. 1988). The protein products of these genes are large precursors of the 
mature proteins containing an amino terminal signal peptide, a pro-domain and the mature protein 
located at the carboxyl terminal. 
TGF-Ws are subject to considerable post-transcriptional modifications. The endopeptidase, furin 
initially cleaves the precursor protein in two leaving a mature T G F - ~ ~ domain that is 390 amino 
acids in length and the N terminal propeptide (Dubois et al. 1995). Mature T G F - ~ ~ domains then 
associate with one another to form homodimers, resulting in biologically active T G F - ~ ~ molecules 
of 25kD. The remaining N terminal propeptide domains form disulphide-bonded homodimers 
known as latency associated proteins (LAP). These associate non-covalently with mature T G F - ~ ~
homodimers forming a functionally inactive complex called latent- T G F - ~ ~ (L- T G F - ~ ) , , which is 
secreted. This form is also known as the small latent complex (SLC) (see Figure 1.6). 
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Figure 1.6: Processing ofTGF-6 by Furin 
Schematic diagram showing the post-transcriptional processing of TGF-p precursors by the 
endopeptidase furin. The TGF-p precursor contains an N-terminal propeptide and TGF-p. This 
precursor protein is cleaved by furin within the Golgi complex. Both the pro peptide and TGF-p 
form homodimers resulting in mature TGF-p molecules of 25kDa. Homodimers of the propeptide 
are known as lantency associated protein (LAP). LAP proteins non-covalently associate with 
mature TGF-p homodimers forming an inactive complex known as the small latent complex 
(SLC). 
It is thought that SLC is secreted from cells very slowly and that for efficient and proper secretion 
of L-TGF-p it must be bound to the protein product of a separate gene called latent TGF-p 
binding protein (LTBP) (Miyazono et al. 1991). LTBP is covalently bound to the SLC via a 
disulphide bond between cysteine residues within the amino terminal of TGF-p and cysteine 
residues in LTBP (Gleizes et al. 1996). There are 4 different isoforms ofLTBP and despite being 
structurally similar they bind to LAP with varying affmities; LTBP-2 is not capable of binding 
LAP at all and LTBP-4 binds LAP relatively poorly, whereas the remaining two isoforms (LTBP-
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1 and LTBP-3) readily bind to LAP (Saharinen et al. 2000). A key function of LTBP appears to 
be in the tethering ofL-TGF-p to the ECM via a covalent interaction between amino acids within 
the N-terminal of LTBP and proteins of the ECM (Saharinen et al. 1996). This allows cells to 
accumulate stores of L-TGF-p in their ECM, which require activation before it can bind to cell 
surface TGF-p receptors. 
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Figure 1.7: Structure of Lateot TGF-I} 
This schematic diagram, adapted from (Annes et al. 2003), illustrates the structure of both the 
small latent complex and large complex of TGF-p. The LAP contains an RGD integrin binding 
domain. The active TGF-p molecule is secreted non-covalently associated with latency associated 
peptide (LAP). This complex is called the small latent complex (SLC). However, LAP can also 
bind to latent TGF-p binding proteins (LTBP) forming the large latent complex (LLC). LTBP 
serves to tether the latent TGF -P complex to proteins of the ECM. 
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1.4.2 Transforming Growth Factor-p Activation 
Secretion o f T G F - ~ ~ in a latent form allows cells and tissues to build up large stores in their ECM 
and activation of this T G F - ~ ~ is the main rate-limiting step in T G F - ~ ~ bioavailability (Annes et al. 
2003). Various physical mechanisms of activation have been described in vitro including 
acidification, alkalization, high temperature and reactive oxygen species (ROS) (Jullien et al. 
1989; Brown et al. 1990; Barcellos-Hoff et al. 1994). In addition, many biological mechanisms of 
activation have been described in vitro but considerably fewer mechanisms have been shown to 
function in vivo. The various biological mechanisms of T G F - ~ ~ activation and their relevance in 
vivo are described here in further detail. 
1.4.2.1 Proteolytic Activation 
Activation of T G F - ~ ~ can occur through the actions of a variety of proteases. Proteolytic cleavage 
results in liberation of the mature T G F - ~ ~ homodimer from the non-covalently attached LAP 
leaving it free to interact with T G F - ~ ~ receptors on the cell surface. Such proteases act by 
degrading the LAP at specific cleavage sites that vary depending upon the protease involved. To 
date, all mechanisms of TGF - ~ ~ activation that are mediated by proteolysis result in liberation of 
soluble active T G F - ~ ~ from cells (Lyons et al. 1988; Lyons et al. 1990; Taipale et al. 1992; Yu et 
al. 2000; Mu et al. 2002; Tatler et al. 2008). Several proteases have been shown to activate TGF-
~ ~ in this manner in vitro including the serine protease plasmin (Lyons et al. 1990), urokinase-type 
(uPA) and tissue-type plasminogen activators (tPA) (Chu et al. 1998), the ECM proteases matrix 
metalloproteinase-2 (MMP-2), MMP-9 (Yu et al. 2000) and MMP-13 (D'Angelo et al. 2001). 
Many of these proteases are normally involved in processes of ECM degradation and so could 
provide an important link in vivo between ECM degradation events and the release of a mediator 
involved in the production of ECM components. This would allow homeostatic replacement of 
ECM when it has been degraded. However, at present none of the above proteases capable of 
activating T G F - ~ ~ in vitro have been shown to be in vivo T G F - ~ ~ activators. 
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1.4.2.2 Activation by Thrombospondin-l (TSPl) 
The thrombospondin (TSP) family consists of 5 members, termed TSP1, TSP2, TSP3, TSP4 and 
TSP5. The thrombospondins are large, multifunctional, glycoproteins involved in processes such 
as cell adhesion, platelet aggregation, angiogenesis and cell proliferation. They can be divided 
into two groups: TSP-l and TSP-2 are homotrimers and make up group A, and TSP-3, TSP-4 are 
homopentamers and make up group B. Thrombospondin-l is a large (420 kDa) disulphide bonded 
homotrimer (see Figure 1.8), in which each of the three subunits contains 6 domains; the amino-
terminal domain, a procollagen homology domain, type 1 repeats, type 2 repeats, type 3 repeats 
and the carboxyl-terminal domain (Esemuede et al. 2004). TSP-l has a limited expression profile 
in the healthy adult. In addition to being a major secretory product of the alpha granules (a-
granules) of platelets, TSP 1 can be found in the ECM of a variety of tissues. TSP-l is also up-
regulated in many tissues in response to injury. It has been located in the peritubular connective 
tissue of kidneys, along the luminal surface of the aorta, in the interstitial area between skeletal 
muscle bundles, at the dermal-epidermal junction in the skin, and beneath epithelial cells in both 
the dermis and the lung (Wight et al. 1985). 
T G F - ~ , , like TSP1, is released from a-granules of activated platelets mainly in the form ofLLC. It 
has been shown, however, that T G F - ~ ~ can be released in its active form in a complex with TSPI 
(Murphy-Ullrich et al. 1992). Further work by the same group showed that TSPI is capable of 
activating latent T G F - ~ ~ secreted from endothelial cells (Schultz-Cherry et al. 1993) and in cell 
free systems (Schultz-Cherry et al. 1994b) and this occurs independently of proteases. The TSP 1 
domain involved in T G F - ~ ~ activation has been identified as the K412RFK415 sequence located 
between the first and second type 1 repeats (Schultz-Cherry et al. 1994a; Schultz-Cherry et al. 
1995). This sequence interacts with the sequence L54SKL57 found at the amino terminus of LAP 
causing a rearrangement in the conformation of LAP, which leaves the active domain of T G F - ~ ~
free to interact with its cell surface receptors despite the ongoing association of LAP (Ribeiro et 
al. 1999). Activation of TGF - ~ ~ by TSP 1 could represent a positive feedback loop in certain cells 
since treatment of endothelial cells with T G F - ~ ~ results in increased expression of TSPI 
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(RayChaudhury el al. 1994). TSP-l-mediated TGF-p activation appears to be relevant in vivo 
because mice null for either TGF-p or TSPI share similar phenotypes (Crawford el al. 1998), 
including hyperplasia of vascular smooth muscle, airway epithelium and pancreatic islet cells, 
and hypoplasia of exocrine pancreas. TSP-1 null mice did not completely recapitulate the 
phenotype of TGF-pi null mice; inflammation was not as extensive in the TSP-I null mice and 
they urvived past week four, unlike T G F - ~ ~ I null mice. TSP-I-mediated TGF-p 1 activation is 
thought to contribute to several inflammatory and/or fibrotic diseases including fibrotic renal 
disease (Daniel et al. 2004). However TSPI is not solely responsible for TGF-p activation in 
vivo. Residual taining for active TGF-p was still ob erved in TSPl null mice (Crawford el al. 
1998) and not all available latent TGF-p was activated by TSPI in vitro (Schultz-Cherry et af. 
1993). This means that additional mechanisms ofTGF-p activation mu t be employed in vivo. 
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Figure 1.8: Structure of Thrombospondin-l 
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This schematic diagram shows the structure of TSP-l. It is a large homotrimeric, glycoprotein of 
approximately 420kDa. The amino terminal domain contains a heparin binding site and is 
involved in platelet aggregation, and cell adhesion. The procollagen homology domain has a role 
in angiogenesis. The type 1 repeats contribute to cell adhesion, chemotaxis and angiogenesis. The 
type 2 repeats contain epidermal growth factor-like domains. The type 3 repeats contain RGD 
integrin binding sites and have a role in cell adhesion. The carboxyl terminal domain contains 
binding site for integrin associated protein (lAP) and functions in cell adhesion and chemotaxis. 
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1.4.2.3 Integrin Mediated Activation 
Integrins are a group of transmembrane, heterodimeric, cell surface receptors that are involved in 
cell-cell interactions and in anchoring cells to components of the ECM. Moreover, integrins are 
able to transduce signals from the ECM to the cell, allowing cells to respond to changes in the 
extracellular environment. They consist of two distinct subunits, named a and ~ . . There are 
currently 18 a and 8 ~ ~ subunits identified creating 24 distinct integrin molecules (Takada et aZ. 
2007). The different combinations of a and ~ ~ subunits are illustrated in Figure 1.9. Both integrin 
subunits are type I transmembrane proteins, consisting of a short carboxy terminal cytoplasmic 
domain, a single-spanning transmembrane domain and a large amino terminal extracellular 
domain. In the intact molecule the extracellular domains of the two subunits form two "legs" 
extending out from the membrane on top of which is a large globular head, which is responsible 
for binding of ligands. 
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Figure 1.9: Pairing of Integrin Subunits 
There are 18 a and 8 P integrin subunits in vertebrate . Thi figure shows the 24 possible pairings 
of integrin a (blue) and p (pink) subunits. Integrin subunits are inactive alone and must form 
heterodimers with each other for functionality . lntegrin heterodimers have diverse ligand binding 
specificities and are differentially expressed . Integrins containing P2 and p7 subunits are 
exclusively expressed upon leukocytes. Integrins containing the PI subunit are generally widely 
expressed on many cell types. The aIIbp3 integrin is exclusively expressed on platelets and is 
rapidly activated during platelet aggregation. Half of integrin a subunits contain an I-domain, 
which is involved in ligand binding. This subunits are aL, aM, aX, aD, aE, aI , alO, all and a2. 
All of the aV containing integrins have been shown to activate TGF-p. 
The integrin family of receptors can be grouped into 2 smaller families based upon the presence 
or absence of the aA domain (aka insertion domain or I-domain) within the extracellular domain 
of the a subunit of the integrin. There are 9 integrin a subunits that have an I-domain. This 
domain contains a region essential for ligand binding that is able to bind divalent metal cations 
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(Michishita et al. 1993), called the metal ion-dependant adhesion site (MIDAS). Furthermore, all 
integrin ~ ~ subunits have a region that is very similar to the aA and contains a MIDAS site. This 
region is termed the ~ A A domain and is involved in ligand binding. In integrins that do not contain 
an aA domain in their a subunit the ~ A A domain is solely responsible for ligand binding (Xiong et 
al. 2002). In aA containing integrins it is thought that the ~ A A domain indirectly influences ligand 
binding by interacting with the aA domain at the ligand binding interface (Alonso et al. 2002). 
Several integrins, including all those containing the aV subunit, have been shown to bind to L-
T O F - ~ ~ via an ROD motif located within the amino terminal of LAP. Some of these integrins are 
also able to activate the latent T O F - ~ ~ complex including a V ~ 3 3 (Asano et al. 2005a), a V ~ 5 5
(Asano et al. 2005b; Asano et al. 2006; Wipff et al. 2007), a V ~ 6 6 (Munger et al. 1999; Jenkins et 
al. 2006), a V ~ 8 8 (Mu et al. 2002) and possibly integrins containing the ~ I I subunit (Wipff et al. 
2007). The LAP o f T O F - ~ 2 2 does not contain a ROD integrin b ~ n d i n g g domain and so, unlike TOF-
~ I I and T O F - ~ 3 , , cannot be activated by integrins. At present, two main mechanisms of integrin-
mediated T O F - ~ ~ activation have been described. These are illustrated in Figure 1.10. Some 
integrins, such as a V ~ 8 8 (Mu et al. 2002), appear to activate T O F - ~ ~ by utilising a protease and it 
has been suggested that these integrins facilitate proteolytic activation by localising L-TOF - ~ ~ to 
specific areas of the cell surface allowing efficient interaction with the protease. Other integrins 
appear to mediate T O F - ~ ~ activation independently of proteolytic activity, such as a V ~ 6 , , a V ~ 3 3
and a V ~ 5 . . The mechanism employed by integrin a V ~ 6 6 to activate T O F - ~ ~ has been well 
elucidated, however, the mechanism employed by a V ~ 3 3 and a V ~ 5 5 is still not completely clear. 
Binding of a V ~ 6 6 to LAP is not sufficient for T O F - ~ ~ activation (Munger et al. 1999) suggesting 
that binding to LAP and T O F - ~ ~ activation are distinct processes in a V ~ 6 - m e d i a t e d d T O F - ~ ~
activation. Whether this applies to the other integrins remains to be determined. 
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Figure 1.10: Two Mechanisms ofIntegrin -Mediated TGF-8 Activation 
These are two main mechanisms ofTGF-p activation employed by integrins. One mechanism 
requires proteolytic activity and the second acts independently of proteolytic activity. (Goodwin 
et al. 2009) 
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A recurring theme between integrins that do not require proteolysis to activate T G F - ~ ~ is the 
involvement of the cytoskeleton. For example, activation o f T G F - ~ ~ by the integrin a V ~ 5 5 and the 
~ 3 3 and ~ l l subunits occurs in response to contraction of myofibroblasts or myofibroblast 
cytoskeleton preparations (Wipff et al. 2007). Furthermore, the cytoskeleton was found to be 
involved in a V ~ 6 6 mediated T G F - ~ ~ activation since inhibitors of RhoA, a protein involved in 
reorganisation of the actin cytoskeleton, and cytochalasin D, an inhibitor of cytoskeletal 
reorganisation, are able to inhibit activation of T G F - ~ ~ mediated via this integrin (Munger et al. 
1999; Jenkins et al. 2006). These fmdings suggest that reorganisation of the cytoskeleton is a 
requirement for T G F - ~ ~ activation by these integrins. The ECM is also thought to be important for 
integrin-mediated T G F - ~ ~ activation. Activation of T G F - ~ ~ by a V ~ 5 5 can be increased by 
increasing the stiffness or tension of the ECM matrix (Wipff et al. 2007) and a V ~ 6 6 mediated 
T G F - ~ ~ activation is dependent upon the LLC being bound to the ECM (Annes et al. 2004). These 
findings have led to the proposal that cytoskeletal c h a n g e ~ ~ are transferred via integrins into 
conformational changes within the LLC due to the fact that the LLC is tethered to the ECM. 
These conformational changes result in exposure of the active T G F - ~ ~ molecule to its cell surface 
receptors despite continuing association with LAP and LTBP. However, this proposed 
mechanism has not been investigated and at present no direct evidence exists to confirm this 
hypothesis. 
Integrin-mediated T G F - ~ ~ has been shown to be extremely important in vivo by several studies 
using transgenic mice. One such study developed transgenic mice that express RGE instead of 
RGD in the LAP o f T G F - ~ , , rendering their integrins unable to bind and activate L - T G F - ~ . . These 
mice display many of the fundamental characteristics of T G F - ~ ~ null mice, including extensive 
inflammation of the lungs, heart and liver and defective vasculogenesis, despite being able to 
produce and secrete L - T G F - ~ ~ normally (Yang et al. 2007). In support of these observations, the 
lungs of integrin ~ 6 6 knockout mice develop normally but after approximately 21 days show signs 
" 
of inflammation reminiscent of T G F - ~ ~ null mice (Huang et al. 1996). These mice also develop 
emphysema of the lungs as they age (Morris et al. 2003). Deletion of the aV integrin subunit 
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results in mice that lack many of the TGF-p activating integrins. A very large percentage of these 
mice die during gestation despite appearing to have normal organ development. Those that 
survive develop extensive haemorrhaging and cleft palates (Bader et al. 1998), similar to T G F - ~ 3 3
and T G F - ~ 2 2 null mice (Proetzel et al. 1995; Sanford et al. 1997). A role for aVp8-mediated TGF-
~ ~ activation in vivo has been identified since loss of this integrin on leukocytes causes 
autoimmunity in mice (Travis et al. 2007). Furthermore, a recent study has highlighted the 
fundamental role of a V ~ 6 6 and a V ~ 8 8 in activation of T G F - ~ 1 1 and T G F - ~ 3 , , since mice lacking 
these integrins develop cleft palates and autoimmunity similar to T G F - ~ 1 1 and T G F ~ 3 3 knockout 
mice (Aluwihare et al. 2009). Taken together, these studies show that integrin-mediated T G F - ~ ~
activation is essential in vivo. 
1.4.3 Receptors and Signal Transduction 
Members of the T G F - ~ ~ superfamily signal to cells through interaction with two types of specific 
cell surface receptors, termed type I and type II, both of which have intracellular serine/threonine 
kinase domains. There are seven different type I receptors, which are also known as Activin-
receptor-like kinases (ALKs), and five different type II receptors. Each member of the T G F - ~ ~
super family binds to a certain combination of the two types. The 3 TGF -P isoforms bind to type 
II TGF-p receptor ( T G F - ~ R I I ) ) and several type I receptors, including type I T G F - ~ ~ receptor 
( T G F - ~ R I ) , , ALK-5 and ALKI, but most commonly to ALK5. Both type I and type II receptors 
form homodimers on the cell surface. There is also a third type of T G F - ~ ~ receptor ( T G F - ~ R I I I ) )
called betaglycan. This is a transmembrane proteoglycan with a molecular mass of 250-350 kDa. 
It has a role in presentation of T G F - ~ ~ to TGF-PRII, rather than being directly involved in 
signalling. Although both T G F - ~ l l and T G F - ~ 3 3 bind TGF-PRII receptors with high affinity, TGF-
~ 2 2 only binds with low affinity. Betaglycan interacts with T G F - ~ 2 2 and increases its affinity for 
T G F - ~ R I I , , therefore aiding T G F - ~ 2 2 signalling (Esparza-Lopez et at. 2001). 
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The first step in initiation of TGF - ~ ~ signalling is the binding of active TGF - ~ ~ to TGF - ~ R I I . . This 
interaction causes recruitment of a type I receptor forming a large hetero-tetrameric complex. The 
serine/threonine kinase domain of T G F - ~ R I I I phosphorylates T G F - ~ R I I causing activation of its 
kinase domain. A specific family of transcription factors called Smads are involved in 
propagating T G F - ~ ~ signals from the activated receptor to the cell nucleus. There are three subsets 
of Smads within the family; receptor-regulated Smads (R-Smads), common partner Smads (Co-
Smads) and inhibitory Smads (I-Smads). Following phosphorylation o f T G F - ~ R I , , its cytoplasmic 
serine/threonine kinase domain phosphorylates two of the R-Smads, Smad2 and Smad3. This is 
aided by interaction of the Smad Anchor for Receptor Activation (SARA) with T G F - ~ R I , , Smad2 
and Smad3. The R-Smads then form heterotrimeric or heterodimeric complexes with Smad4, a 
Co-Smad, which then migrates to the nucleus to regulate gene transcription. There are several 
other R-Smads (Smads-l, -5 and -8) but these are involved in the signalling of other members of 
the T G F - ~ ~ super family, such as BMPs. The I-Smads (e.g. Sm.ad 7), as the name implies, have an 
inhibitory effect on T G F - ~ ~ signalling and serve to regulate and terminate signalling. Smad7 
recruits Smurfl and Smurf'2 and moves to the plasma membrane where it is able to inhibit 
phosphorylation of Smad2 and Smad3 by competing for the receptor binding site (Hayashi et a/. 
1997). Furthermore, the Smad7/Smurfl and 2 complex can target the T G F - ~ ~ receptor for 
degradation (Kavsak et a/. 2000). An overview of the T G F - ~ ~ Smad signalling pathway is 
illustrated in Figure 1.11. 
57 
,." ,..-
,." 
lGF-IlRll 
.... -... -
.. ---
SARA 
..... ------------
Gene Transcription 
Figure 1.11: Overview of Smad Signalling Pathway 
The Smad signalling pathway is initiated following the binding of active T G F - ~ ~ to its cell surface 
receptors . Activation of the TGF - ~ ~ receptor leads to phosphorylation, and therefore activation of 
Smad2/3, which then associate with Smad4. This complex then trans locates to the nucleus to 
initiate gene transcription. 
1.4.4 Biological Functions of TGF -6 
The T G F - ~ ~ isoforms are widely distributed multifunctional proteins that are able to induce 
multiple effects in the same cell and have different effects on different cell types. They are able to 
influence and regulate many processes that are fundamental to development, homeostasis and 
repair including cell proliferation, differentiation, wound repair and fibrosis , angiogenesis and 
inflammation. T G F - ~ ~ I is the most abundant of the 3 human isoforms followed by TGF - ~ 2 2 then 
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T G F - ~ 3 . . Studies using transgenic mice have confIrmed the distinct roles and importance of these 
molecules in development, organogenesis and regulation of inflammation and tissue remodelling. 
Disruption of the T G F - ~ 1 1 gene in mice causes early lethality, commonly mid-gestation, which 
suggests a very important role for this isoform in development (Kulkarni et al. 1993; Dickson et 
al. 1995). Those mice that survived gestation suffer from a progressive wasting condition and 
widespread, massive inflammation of many organs including the heart, lungs, pancreas and colon 
which caused death by four weeks (Kulkarni et al. 1993). Shull et al (1992) also reported 
widespread organ inflammation and a progressive wasting phenotype in T G F - ~ 1 1 null mice; 
however, they did not find that disruption of the T G F - ~ 1 1 gene caused early lethality. Another 
study identified an essential role for T G F - ~ 1 1 in vasculogenesis during development (Dickson et 
al. 1995). These mice showed aberrant differentiation of endothelial cells and signifIcantly lower 
numbers of circulating erythrocytes. However, no difference in the number of circulating 
erythrocytes was found by a separate study (Shull et al. 1992). Together, these studies highlight 
the fundamental role of T G F - ~ 1 1 in development, especially of the vascular system, and in 
regulating immune responses. 
Development of TGF - ~ 2 2 knockout out mice has suggested that this isoform has a very important 
role in development and organogenesis, however, the phenotype of these mice shared no 
similarities with T G F - ~ 1 1 null mice (Sanford et al. 1997). Two thirds of mice homozygous for the 
T G F - ~ 2 2 null allele die before or during birth and the survivors have widespread developmental 
defects of multiple organs including the heart and kidney, and skeletal abnormalities (Sanford et 
al. 1997). The heart of T G F - ~ 2 2 null mice had many structural abnormalities including a 
hypoplastic aorta wall and abnormal pulmonary valves. Although the development of the lungs 
did not appear to be affected, widespread collapse of the conducting airways occurred in some 
cases following birth. 
Disruption of the T G F - ~ 3 3 gene in mice causes early but not prenatal lethality, with death 
occurring within 24 hours of birth. Unlike the T G F - ~ 2 2 mice, these mice have severe 
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developmental defects of the lungs, which results in respiratory failure (Kaartinen et al. 1995). 
These mice also have a cleft palate suggesting disruption of normal epithelial-mesenchymal 
interactions during development (Kaartinen et al. 1995; Proetzel et al. 1995). The findings 
described here highlight the differences in function between the three isoforms of T G F - ~ . . TGF-
~ 1 1 is primarily involved in regulation of inflammatory and immune responses. The role of TGF-
~ 2 2 appears to be primarily in development of multiple organs, notably the heart. T G F - ~ 3 3 seems to 
have an important role in development, especially in the lungs. 
1.4.5 TGF -p in Asthma and Airway Remodelling 
TGF - ~ ~ isoforms are implicated in asthma and airway remodelling due to the wide variety of 
effects they produce, including their roles in fibrosis, angiogenesis and cell proliferation. It has 
been reported that the levels of all three isoforms are increased in the airways of asthmatics 
(Redington et al. 1997; Batra et al. 2004; Torrego et al. 2007) and the level of phosphorylated 
Smad2, a marker o f T G F - ~ ~ signalling, is also increased in asthmatic airways (Sagara et al. 2002). 
Increased levels of T G F - ~ ~ have been detected in BALF taken from asthmatics after allergen 
challenge (Batra et al. 2004). Furthermore, several inflammatory mediators that are implicated in 
asthma pathogenesis have been shown to increase expression of T G F - ~ , , including I L - l ~ , , IL-4 
and IL-13 (Offner et al. 1996; Wen et al. 2002; Lee et al. 2006). ECP released from activated 
eosinophils present in the asthmatic airway is able to stimulate T G F - ~ ~ release from lung 
fibroblasts (Zagai et al. 2007). Furthermore, studies concentrating on the identification of gene 
polymorphisms in disease have also found that a polymorphism in the T G F - ~ ~ gene is associated 
with asthma, which may result in increased T G F - ~ ~ transcription in asthmatics (Silverman et al. 
2004). 
Most studies to date have focused on the role o f T G F - ~ 1 1 in asthma. Such studies have shown that 
T G F - ~ l l has a very important role in asthma pathogenesis. It is chemoattractive for mast cells 
(Olsson et al. 2000; Berger et al. 2003) and induces expression of various genes involved in 
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asthma pathogenesis and airway remodelling, including PAIl, fibronectin, VEGF and collagen 
(Laiho et al. 1987; Kucich et al. 2000; Kenyon et at. 2003; Kobayashi et al. 2005; Moir el al. 
2008). However, recently more attention has been paid to the role of T G F - ~ 2 2 in asthma. 
Following allergen challenge large increases in the number of eosinophils expressing T G F - ~ 2 2 but 
not T G F - ~ ~1 have been described (Torrego et al. 2007). Increased expression of T G F - ~ 2 2 but not 
T G F - ~ ~ I has been described in the bronchial mucosa of asthmatics (Chu et al. 2004) and IL-4 and 
IL-13, T H2 cytokines abundant in asthma, increase expression of T G F - ~ 2 2 but not T G F - ~ ~1 (Wen 
et al. 2002). Furthermore, T G F - ~ 2 , , but not T G F - ~ I , , can induce mucin expression, a component 
of mucous (Chu et al. 2004). These data suggest that both T G F - ~ 1 1 and T G F - ~ 2 2 could be 
important for asthma pathogenesis. There is very little data showing a role for T G F - ~ 3 3 in asthma 
and airway remodelling. 
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Figure 1.12: Role ofTGF-8 in Airway Remodelling 
This figure summarises the effects that T G F - ~ ~ has on various cell types m the lung. The e 
responses contribute to airway remodelling. 
(Makinde et al. 2007) 
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As discussed in Introduction section 1.2, the term airway remodelling refers to the structural 
changes that occur in asthmatic airways and includes changes such as subepithelial fibrosis, 
hyperplasia and hypertrophy of ASM cells and angiogenesis. T G F - ~ ~ has been implicated in many 
of these changes (for summary see Figure 1.12). Arguably the most important function o f T G F - ~ ~
in the context of airway remodelling and asthma is its effects on ECM production. T G F - ~ ~
potently induces the expression of many matrix proteins, which can contribute to subepithelial 
fibrosis. Administration of T G F - ~ l l into the lungs of experimental mice results in increased 
deposition of collagen in the ECM and increased expression of collagen I and III mRNA (Kenyon 
et al. 2003). Furthermore, proteolytic activation o f T G F - ~ ~ from ASM cells stimulates ASM cells 
to synthesise collagen I (Coutts et al. 2001). Stimulating ASM cells with exogenous T G F - ~ ~
causes increased production of glycosaminoglycans (Black et al. 1996), from which ECM 
proteoglycans can be produced, and fibronectin (Moir et al. 2008). It has also been shown that 
exposing vascular smooth muscle to cyclical mechanical strain results in T G F - ~ ~ production and 
increased expression of ECM proteins (O'Callaghan et al. 2000). It is very possible that a similar 
mechanism exists in ASM cells since there are many similarities between these two types of 
smooth muscle. In addition to its direct effects on production ofECM proteins, T G F - ~ ~ has effects 
on fibroblasts and myofibroblasts, which could contribute to the development of airway 
remodelling. It promotes fibroblast proliferation (Zhao et al. 1996; Meran et al. 2008) and 
promotes their differentiation into myofibroblasts (Evans et al. 2003; Asano et al. 2006). 
Increased ASM mass is an important feature of airway remodelling (see Introduction section 1.2) 
and is thought to be caused by hypertrophy, hyperplasia and increased migration of ASM cell 
precursors. T G F - ~ l l is thought to be involved in these processes. It is able to induce both 
hypertrophy and hyperplasia of ASM cells (Black et al. 1996; Chen et al. 2006; Goldsmith et al. 
2006; Xie et al. 2007) and inhibition of T G F - ~ ~ in a rat allergen-challenge model of asthma 
decreases both airway inflammation and remodelling events such as cell proliferation (Leung et 
al. 2006). In addition to its effects on ASM hyperplasia and hypertrophy, T G F - ~ l l can stimulate 
migration of ASM cells (Howat et al. 2002), which may also contribute to increased ASM mass. 
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T G F - ~ ~ is thought to contribute to epithelial shedding, which occurs in asthma. It promotes 
apoptosis of epithelial cells and potentiates the effects of apoptosis inducing stimuli (Solovyan et 
al. 2006; Cheng et al. 2007). Furthermore, T G F - ~ ~ inhibits the proliferation of epithelial cells 
(Bogdanowicz et al. 2000), which could affect repair of the epithelium in response to injury. 
Indeed, T G F - ~ ~ delays epithelial wound closure in a wounding model of cellular injury (Neurohr 
et al. 2006). In addition, it is very likely that T G F - ~ ~ is involved in the angiogenesis observed in 
asthmatic airway remodelling. T G F - ~ ~ up-regulates expression of the potent pro-angiogenic 
mediator VEGF (Stocks et al. 2005; Clifford et al. 2008) and PAIl (Laiho et al. 1987; Kutz et al. 
2001). 
In conclusion, T G F - ~ ~ is released from various cells in the asthmatic airway as part of the chronic 
inflammatory response. Once released and activated it can exhibit both pro-inflammatory and 
anti-inflammatory functions depending upon the cell type it is stimulating. Although it may be 
involved in both amplifying and inhibiting the inflammatory response, T G F - ~ ~ has a fundamental 
role in the structural changes collectively known as airway remodelling, causing cell proliferation 
and differentiation, fibrosis and angiogenesis. 
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1.5 Summary 
Asthma is an extremely common inflammatory disease of the airways, in which airway 
remodelling is an important feature, especially in cases of severe asthma. Airway remodelling 
includes structural changes such as ASM cell hyperplasia and hypertrophy, subepithelial fibrosis, 
shedding of the epithelial layer, angiogenesis and goblet cell hyperplasia, which contribute to 
decreased lung function. The mechanisms responsible for the development of airway remodelling 
in asthma are not well understood. However, the widely distributed, pluripotent cytokine T G F - ~ ~
has been implicated. 
T G F - ~ ~ is secreted by most cell types present in the asthmatic airways including inflammatory 
cells such as eosinophils and structural cells such as fibroblasts and ASM cells. T G F - ~ ~ is potently 
pro-fibrotic and mitogenic and could contribute to many of the changes associated with airway 
remodelling. However, T G F - ~ ~ is released from cells and sequestered in the ECM as a latent 
complex. Activation of latent T G F - ~ ~ is therefore a fundamental step in T G F - ~ ~ bioavailability. 
Various methods of T G F - ~ ~ activation have been described in vitro, however, the mechanism of 
T G F - ~ ~ activation employed in vitro has still not been confirmed. It is possible that the mechanism 
differs between cell types and during different processes. Whether HASM cells can activate TGF-
~ ~ in vitro is not known, and the mechanism by which this might be done has not been 
investigated. Furthermore, whether HASM cell activation of T G F - ~ ~ is involved in asthma 
pathogenesis has not been studied. 
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1.6 Aims 
The overall aim of this thesis was to test the hypothesis that HASM cells can activate T G F - ~ ~ in 
vitro. This was achieved by addressing three more specific aims 
1) Investigate the effect of mast cell tryptase on T G F - ~ ~ activation by HASM cells. 
2) Investigate the effect of mechanical wounding of HASM cell monolayers on T G F - ~ ~
activation. 
3) Investigate the effect of lysophosphatidic acid on TGF - ~ ~ activation by HASM cells. 
If HASM cells can activate T G F - ~ ~ in response to any of these stimuli the mechanism of 
activation will be further investigated. 
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2 Methods and Materials 
2.1 Introduction 
This chapter outlines the general methods employed in this thesis. The source of human tissue 
and cells is described. All primer sequences, buffer and media recipes and reagents are listed in 
the Appendix. 
2.2 Cell Culture 
2.2.1 Human Airway Smooth Muscle Cells 
Human airway smooth muscle (HASM) cells from non-asthmatic donors were supplied by either, 
Professor Chris Brightling, Institute for Lung Health, University of Leicester, UK or Professor 
Maria Belvisi, Imperial College London, UK. HASM cells from asthmatic patients were supplied 
by Professor Chris Brightling, Institute for Lung Health, University of Leicester. They were 
cultured in serum plus Dulbecco's modified Eagles medium (DMEM) (see Appendix) at 37°C, 
5% C02 in a humidified atmosphere. The medium was changed every 2 to 3 days. Experiments 
were performed on 100% confluent cells. The cells were growth arrested for 24 hours prior to all 
experiments in serum free DMEM (see Appendix) and experiments were performed in this 
medium. All cells were classified as being free from mycoplasma infection prior to experiments. 
2.2.2 Normal Human Bronchial Epithelial Cells 
Normal human bronchial epithelial (NHBE) cells were purchased from Cambrex Biosciences, 
Walkersville Inc at passage number 2. These cells had been certified as free from HIV -I, 
mycoplasma, hepatitis-B, hepatitis-C, bacteria, yeast and fungi by the supplier prior to shipping. 
The cells were delivered to the lab packed in dry ice and transferred to liquid nitrogen on arrival. 
The cells were cultured in the supplier's own Bronchial Epithelial Cell Medium containing the 
supplied supplements (hydrocortisone, epinephrine, transferrin, insulin, retinoic acid, 
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triiodothyronine, human epidermal growth factor) at 37°C, 5% C02 in a humidified atmosphere. 
NHBE cells were used in experiments at passage 4-5 when 100% confluent. The cells were 
growth arrested for 24 hours prior to experiments in the suppliers Bronchial Epithelial Cell 
Medium without the addition of the supplements. Cells were classified as being free from 
mycoplasma infection prior to experiments. 
2.2.3 Transfonned Mink Lung Epithelial Cells 
Transformed mink lung epithelial cells (TMLC) were a kind gift from Professor Dan Rifkin, 
University of New York, USA. TMLC were used as a reporter cell to detect T G F - ~ ~ activity (Xu 
et al. 2009). They stably express a T G F - ~ ~ responsive element of the PAIl promoter driving a 
luciferase gene and a neomycin resistance gene. TMLC were cultured in specific growth media 
containing the antibiotic G418 (see Appendix) at 37°C, 5% C02 in a humidified atmosphere. 
Experiments were performed in serum free DMEM. Cells were certified as free from mycoplasma 
infection prior to experiments. 
2.2.4 CS-I Cells 
CS-l cells are a hamster melanoma suspension cell line and were kindly supplied by Professor 
Dean Sheppard, University of California, San Francisco. Prior to transfection they were cultured 
in Roswell Park Memorial Institute (RPMI) medium containing 10% serum (see Appendix) at 
37°C, 5% C02 in a humidified atmosphere. Following transfection with plasmids containing the 
neomycin resistance gene CS-l cells were cultured as before with the addition of 500Ilg/ml of the 
antibiotic G418 to the culture medium. Cells were growth arrested prior to experiments for 24 
hours in serum free RPMI (see Appendix). Cells were certified as being free from mycoplasma 
infection prior to experiments. 
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2.2.5 A549 Cells 
A549 cells are a lung cancer derived human alveolar epithelial cell line. These cells were used as 
a positive control for protease-activated receptor (PAR) expression in Results section 3.3.9. They 
were cultured in serum plus RPMI (see Appendix). Cells were growth arrested for 24 hours in 
serum free RPMI and experiments were performed in this medium. Cells were certified as being 
free from mycoplasma infection prior to experiments. 
2.2.6 Freezing Cells 
Cells were cultured in 150cm3 flasks until fully confluent and trypsinised. After centrifugation 
(1500 rpm, 5 minutes) the pellet Was resuspended in l5m190% foetal calf serum (FCS) plus 10% 
dimethyl sulfoxide (DMSO). The suspension was ali quoted in Iml cryovials and placed in a Nunc 
Cryo 1°C Freezing Container. This contains 100% isopropan-2-01, which allows the cells to be 
frozen at a rate of I°C/min. This was placed in -80°C freezer overnight. The following day the 
cells were transferred to liquid nitrogen and stored until required. 
2.2.7 Cell Counting 
The number of cells in a cell suspension was determined using an Improved Neubauer 
haemocytometer and a light microscope. Cells were diluted 1: 10 with Trypan blue to distinguish 
between live and dead cells. 10lll of cells was pipetted under the cover slip on the 
haemocytometer. The cells were observed under the microscope using the x40 magnification lens 
and the number of cells in each of the large squares in the comers of the grid was counted. Cells 
lying on the margins of the grid were counted. The total number of cells was divided by 4, 
multiplied by 10 (dilution factor) then multiplied by 104 to give the number of cells per ml. To 
determine the total number of cells, this number was multiplied by the total volume of the 
suspensio,n. 
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2.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
2.3.1 Principles 
RT-PCR is a semi-quantitative technique used to assess gene expression within a cell or tissue by 
measuring messenger RNA (mRNA) levels. mRNA makes up approximately 1-5% of the total 
RNA present in mammalian cells and is the product of gene transcription, which is translated into 
protein. The first step of RT-PCR is the isolation of RNA from cells or tissues. Due to the 
unstable nature of RNA and its susceptibility to digestion by RNase enzymes, experimental work 
with RNA is always performed on ice. RNA is commonly isolated using the phenol-chloroform 
extraction method originally described by Chromczyski and Sacchi (Chomczynski et al. 1987). 
Cells are digested in a solution containing guanidinium thiocyanate, which disrupts the cell 
membranes, denatures intracellular proteins including endogenous RNases, and solubilises the 
cell contents. Phenol and chloroform are then added. Centrifugation of the mixture results in 
phase separation of its components, with proteins in the bottom phase, RNA in the top aqueous 
phase and DNA at the interface of the two. The top phase containing RNA is collected and 
isopropanol added to precipitate the RNA, which can then be collected by centrifugation. 
The second step of RT-PCR is reverse transcription of the collected RNA into complementary 
DNA (cDNA). Most mRNAs have a polyA tail at their 3' end composed of multiple adenosine 
residues. Primers composed of multiple tyrosine residues, known as Oligo dT primers, are used as 
templates from which reverse transcriptase polymerises DNA. The Oligo dT primers associate 
with the 3' polyA tails of the mRNA strands and reverse transcriptase polymerises a DNA strand 
complementary to the mRNA strand. 
The final step of RT-PCR is the polymerase chain reaction (PCR) itself. PCR involves the 
amplification of DNA using the enzyme DNA polymerase. PCR reaction mixtures contain several 
essential elements: themostable DNA polymerase, commonly from Thermus aquaticus (l'aq), a 
pair of synthetic oligonucleotide primers complementary to sequences located at the two ends of 
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the DNA to be amplified, deoxynucleoside triphosphates (dNTPs) from which the polymerase 
amplifies the DNA and template DNA i.e. cDNA produced by reverse transcription. Furthermore, 
thermostable DNA polymerases require free divalent cations to catalyse DNA polymerisation. 
This is generally supplied as Mg2+. The PCR reaction consists of three steps performed at 
different temperatures. The first step is denaturation of the DNA. Denaturation serves to separate 
the two template DNA strands to allow the primers and DNA polymerase to bind to a single 
template DNA strand. This is performed at around 90-95°C. The second step involved allowing 
the sequence specific primers to anneal to the single stranded template DNA. The temperature 
required for annealing is dependent upon many factors, including the length of the primers and 
the percentage of guanine and cytosine residues present. Usually the annealing temperature used 
is around 3-5°C below the melting temperature of the primers. Because of this primer pairs with 
similar melting temperatures are generally used. The final step of PCR is DNA elongation, in 
which the thermostable DNA polymerase polymerises DNA f r o ~ ~ the primers and template DNA. 
This step is performed at the temperature at which the DNA polymerase optimally synthesises 
DNA, which is usually around noc. These three steps are performed sequentially over a number 
of cycles, with production of the target DNA occurring at an exponential rate until one or more of 
the reagents becomes limiting. The DNA products can then be separated by gel electrophoresis 
and visualised by staining the gel with a fluorescent DNA intercalating agent such as ethidium 
bromide. 
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Denaturation 
'" 30 cycles Annealing 
? ·C for 1 minute 
Extension 
7rc for 1 minute 
Figure 2.1: Typical peR Thermal Profile 
This figure gives an example of the typical thermal profile used for a PCR reaction including the 
three steps denaturation, annealing and DNA extension. Individual PCR thermal profiles for 
specific primer sets are described in the Appendix. 
2.3.2 Isolation of RNA 
To increase the speed of RNA isolation and to make isolation of mUltiple amples easier the 
Nuc\eoSpin RNA II kit (Macherey Nagel, Germany), which uses silica membrane technology, 
was used. All columns and buffers used were supplied with the kit. Following treatment, cells 
were lysed in 350111 of RAI lysis buffer supplemented with 1 o Ill/m I ~ - m e r c a p t o e t h a n o l l and 
stored at -80°C until required. RNA was thawed at room temperature then added to the 
homogenisation column (pink) and centrifuged at 11 ,000 rpm for 30 seconds. The column was 
discarded and 350111 70% ethanol added to each tube and mixed thoroughly. The RNA was then 
added to the NucleoSpin Filter column (blue) and centrifuged at 11 ,000 rpm for 30 seconds to 
collect the RNA on the membrane inside the column. The waste in the tube was discarded and the 
membrane washed in 500111 Membrane Desalting buffer (MDB), to remove contaminating salts, 
and centrifuged at 11 ,000 rpm for 30 seconds. The DNase I Reaction Mixture was prepared by 
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adding IOll1 reconstituted DNase I to 90111 of DNase I Reaction Buffer per sample. Any 
contaminating DNA on the membrane was then digested by adding 90111 of the DNase I Reaction 
Mixture to each column and leaving at room temperature for 15 minutes. The membrane was 
washed in 200lli RA2 buffer (supplied with kit) and centrifuged at 11,000 rpm for 30 seconds. 
The flow-through was discarded and 600lli RA3 buffer added to each column. After centrifuging 
at 11,000 rpm for 30 seconds and discarding the flow-through, a further 250111 RA3 buffer was 
added and the columns centrifuged at 13,000 rpm for 2 minutes to completely dry the membrane. 
The RNA was then eluted from the membrane by adding 30111 nuclease-free water to each column 
and centrifuging at 13,000 rpm for 1 minute. 
2.3.3 Determination of RNA Concentration 
RNA concentrations were determined using a spectrophotometer. Absorbance was measured at 
260 and 280nm. The spectrophotometer was calibrated against a distilled water zero. The RNA 
concentration of the eluate was calculated using the following equation: 
[RNA] Ilg/ml = OD @ 260nm x 38 (extinction coefficient of RNA) x dilution factor 
Purity of the preparation was assessed using the ratio of OD at 260nm: OD at 280nm. Purity 
ratios of 1.8-2 were deemed to be acceptable for use in PCR reactions. 
2.3.4 Reverse Transcription 
All reagents and RNA were kept on ice for the duration of the experiment. After determining the 
RNA concentration Illg of RNA was added to 0.51lg of oligo (DT) primers, 2mM of each dNTP, 
200 units Moloney murine leukaemia virus (MMLV) reverse transcriptase, 25 units RNAsin, 5111 
RT buffer (Promega, supplied with MMLV reverse transcriptase). The volume of the reaction 
mixture was made up to 25111 with nuclease-free water. The reaction mixtures were mixed 
thoroughly and placed in a BioRad PCR cycler on the following cycle: 72°C for 5 minutes, 42°C 
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for 90 minutes followed by 90°C for 5 minutes. The resulting cDNA was stored at -20°C until 
required. 
2.3.5 Polymerase Chain Reaction 
All reagents, samples and enzymes were kept on ice throughout the experiment. A 25 J.lI reaction 
mixture was prepared by adding 1 J.lI of cDNA to 5 J.lI of 5x GoTaq® buffer, 200J1M DNTPs, 1 J1M 
sense primer, IJ1M anti-sense primer, 1.5mM MgCI, 0.125J.lI GoTaq® DNA polymerase and 
nuclease-free water. PCR was performed using a Bio-Rad PTC-IOO thermal cycler on the 
appropriate program for the primers being used (see Appendix). DNA products were subjected to 
electrophoresis on a 2% agarose gel stained with O.5J.lglml ethidium bromide in 0.5 x TBE buffer. 
PCR products were visualised by illuminating the gel with ultraviolet (UV) light and 
photographed using GeneGenius gel documentation and analysis system (Syngene). 
2.4 Quantitative Polymerase Chain Reaction 
2.4.1 Principles 
Quantitative polymerase chain reaction (Q-PCR), also known as real-time polymerase chain 
reaction, is used to amplify and quantify DNA within a tissue or cell sample using a fluorescence-
detecting thermocycler. Fluorescent DNA binding dyes, such as ethidium bromide or SYBR 
Green I, are added to the PCR reaction mixture. These intercalate into the double stranded DNA 
PCR product. These dyes do not bind to the primer DNA as primers are only single stranded. The 
intensity of the fluorescent signal is directly proportional to the mass of DNA present and is 
determined after each cycle of amplification. This allows the accumulation of PCR product to be 
determined in real time throughout the course of the reaction. To minimise variability between 
samples an endogenous standard is used. These are DNA sequences (often referred to as a 
housekeeping gene) whose expression level is expected to be constant between samples. These 
sequences are amplified in addition to the target DNA sequence. Quantification of the expression 
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of target DNA is calculated by comparing the amount of housekeeping gene DNA to the target 
DNA. 
At the end of the reaction, the PCR products are subjected to dissociation curve analysis to ensure 
that a single amplification product has been produced and no primer dimers have formed. The 
thermocycler is used to generate a thermal denaturation curve (dissociation curve) of the PCR 
product. Presence of a single peak, and therefore single melting temperature, indicates the 
presence of a single DNA product. The melting temperature gives an indication that the correct 
product has been amplified. Presence of multiple peaks in the dissociation curve indicates that 
multiple products are present. This may be the result of non-specific binding of the primer pairs 
to DNA or by the primers binding to one another to form primer dimers. The presence of primer 
dimers in the product is confirmed by peaks in the dissociation curve at relatively low melting 
temperatures. 
2.4.2 Q-peR Method 
QPCR analysis of cDNA was performed using primers and thermal cycling conditions described 
in the Appendix 9.7. 2 ~ 1 1 cDNA was subjected to QPCR using Takara SYBR Premix Ex Taq 
mastermix containing SYBR green and an Mx3000P® QPCR system (Stratagene). Amplification 
was performed in 1 O ~ 1 1 Takara SYBR Premix Ex Taq in the presence of200nM of both sense and 
antisense primers and nuclease-free water to achieve a final volume of 2 0 ~ 1 . . A no-template 
control containing no cDNA was performed for every experiment. All samples and controls were 
assayed in duplicate. Integration of SYBR green into the product was recorded after each 
annealing step. The cycle threshold (Ct), which is the point at which PCR product is detectable 
above a fixed threshold, was determined for both the target gene and the housekeeping gene. 
Expression of target gene was determined as previously described (Weglarz et al. 2006). Data 
was normalised to the housekeeping gene p2-microglobulin (P2-M) by subtracting the Ct for P2-
M from the Ct for the target gene. Data for control samples (0 hour time point) was then 
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subtracted from all data sets resulting in values for ddCt. The relative expression of the target 
gene compared with control was then calculated using the following equation: 
Relative expression = 2-ddCt 
(Fold increase) 
Confirmation that amplification of a single product had occurred was obtained by dissociation 
curve analysis. Presence of a single dissociation peak confirmed the presence of a single PCR 
product. 
2.5 TGF -p 1 ELISA 
Levels of total T G F - ~ 1 1 in cell culture supernatants were determined by ELISA assay as 
previously described (Tatler et al. 2008) according to the manufacturer's instructions. Cell culture 
supernatants were collected following stimulation of cells and stored at -20°C. Prior to loading of 
samples on to ELISA plate each sample was acid treated with 20% v/v IN HCI acid for 10 
minutes to activate all T G F - ~ ~ present. The samples were neutralised by adding 20% v/v 1.2N 
NaCl. They were loaded on to an ELISA plate coated the previous day with a n t i - T G F - ~ 1 1 with a 
standard curve of known T G F - ~ 1 1 concentrations. Following addition of a secondary antibody 
conjugated to horseradish peroxidase (HRP) a colorimetric HRP substrate was added and the 
optical density at 450nm was determined. 
2.6 Reporter Cell Assay 
2.6.1 Principles of Assay 
The reporter cell assay utilises transformed mink lung epithelial cells (TMLC), which stably 
express a T G F - ~ - s e n s i t i v e e portion of the PAIl promoter driving luciferase (Abe et al. 1994) and 
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can measure T G F - ~ ~ activity in cell supernatants (Tatler et al. 2008). The production of luciferase 
by these cells increases concentration-dependently upon stimulation with T G F - ~ . . This is a very 
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sensitive assay to detect all three isoforms of T G F - ~ , , and is also relatively specific for T G F - ~ ~
since other inducers of PAIl have a negligible effect on these cells (Abe et al. 1994). Addition of 
a pan- T G F - ~ ~ blocking antibody allows any T G F - ~ - i n d e p e n d e n t t luciferase activity to be 
determined. Cell supernatants are removed from stimulated cells and used to stimulate TMLCs. 
After 16 hours the cells are lysed and the luciferase activity of the cell lysates is measured using a 
luminometer (Berthold Technologies, UK). The raw luciferase data can be converted into T G F - ~ ~
activity using a T G F - ~ 1 1 standard curve of known T G F - ~ ~ concentrations against luciferase 
activity. The TMLCs can only detect active T G F - ~ . . This gives the opportunity to investigate the 
levels of active and active plus latent T G F - ~ ~ in cell supernatants by utilising the property of latent 
T G F - ~ ~ to become activated in extremes of heat; heating samples to 80°C for 10 minutes prior to 
stimulation of TMLCs activates all T G F - ~ ~ present (Brown et al. 1990). TMLCs are therefore a 
powerful tool for investigating T G F - ~ ~ activation in vitro. 
2.6.2 Method 
TMLCs were cultured as described in Methods section 2.2.3. TMLC were counted and 
resuspended at a density of 0.5xl 06 cells/ml in serum free DMEM (see Appendix). To an aliquot 
ofTMLC a pan T G F - ~ ~ neutralising antibody (clone IDll) at 20J.lg/ml was added (achieving final 
concentration of 10J.lg/ml following stimulation). The cells were plated at 100J.lllwell in a 96 well 
plate and left to adhere to the plate for 1 hour. Cell supernatants from HASM cells were used to 
stimulate the TMLC (1 OOJ.lllwell). All stimulations were performed in duplicate, ensuring that 
each sample was used to stimulate both TMLC alone and TMLC plus a n t i - T G F - ~ ~ antibody. To 
measure the levels of total TGF - ~ ~ an aliquot of the cell supernatants were heated to 80°C for 10 
minutes and allowed to cool prior to stimulation of TMLCs (Brown et al. 1990). After 16 hours, 
the medium was removed and 50J.ll luciferase lysis buffer (supplied with Luciferase reporter 
assay kit) was added to each well to lyse the TMLCs. The plate was frozen at -20°C for at least 1 
hour to aid cell lysis. After thawing the luminescence was measured using a luminometer 
(Berthold Technologies). Each well was exposed to the light detector in the luminometer for 10 
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seconds and the relative light units (RLU) were recorded. Mean data from wells containing the 
pan T G F - ~ ~ blocking antibody was subtracted from the data obtained from the wells treated in the 
same manner but without the antibody. This removes any T G F - ~ - i n d e p e n d e n t t luciferase activity 
from all data. 
2.7 Co-culture Assay 
2.7.1 Principles of Assay 
The TMLC reporter cells described in Methods section 2.6.1 can also be used in a co-culture 
assay to detect T G F - ~ ~ activation that requires direct cell-cell contact, for example integrin-
mediated T G F - ~ ~ activation (Xu et al. 2009). TMLC are seeded directly on top of the 
experimental cells, in this case HASM cells. The co-culture is then stimulated according to the 
experimental requirements and incubated for 16 hours. The cells are lysed and the luminescence 
measured as described in Methods section 2.6.1. The raw luciferase data can be converted into 
T G F - ~ ~ activity using a T G F - ~ l l standard curve of known T G F - ~ ~ concentrations against luciferase 
activity. TMLCs can be influenced directly by agonists used in experiments and so the effect of 
agonists on the response of TMLCs must be investigated. 
2.7.2 Method 
Following growth arrest of HASM cells, TMLC were plated directly on top of HASM cells at 
0.5xl06 cells/ml, IOOIll/well in a 96 well plate. To an aliquot of TMLC, a pan T G F - ~ ~ blocking 
antibody was added at 20Ilg/ml (to achieve final concentration of IOIlg/ml following stimulation), 
before the cells were seeded on to the HASM cells. The co-culture was stimulated in duplicate as 
required for each individual experiment, ensuring that each stimulation was performed on TMLC 
and TMLC plus a n t i - T G F - ~ . . Certain wells of the co-culture were stimulated with 0,250,500 and 
1000 pg/nil recombinant T G F - ~ l l to obtain a T G F - ~ 1 1 standard curve. The cells were incubated for 
16 hours and the cells were lysed as in Methods section 2.6.2. The luminescence was measured 
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using a luminometer (Berthold Technologies) as in Methods section 2.6.2. Mean data from wells 
containing the pan TGF - ~ ~ blocking antibody was subtracted from the data obtained from the 
wells treated in the same manner but without the antibody. This removes any T G F - ~ - i n d e p e n d e n t t
luciferase activity from all data. This data was then converted into concentrations of T G F - ~ ~
activity using the T G F - ~ 1 1 standard curve. The co-culture assay was also used to measure levels 
of total T G F - ~ ~ sequestered in the ECM by unstimulated HASM cells. Unstimulated, growth 
arrested HASM cells were treated with 20% v/v IN HCL acid directly in to the culture medium 
for 10 minutes. The acid was neutralised by addition of an equal volume of 1.2N NaCl. TMLCs 
were seeded directly on top of these HASM as described above and culture for 16 hours. A TGF-
~ 1 1 standard curve using 0, 250, 500 and 1000 pg/ml T G F - ~ ~ was obtained as described above to 
allow the raw luciferase data to be converted into concentrations of T G F - ~ ~ activity. The cells 
were lysed and the luminescence measured as in section Methods 2.6.2. 
2.8 Cell Titer Glow Assay 
2.8.1 Principles of Assay 
Due to reported differences in cell size of HASM cells isolated from asthmatics and non-
asthmatics (Ebina et al. 1993), it was necessary to normalise all data from asthmatic vs non-
asthmatic co-culture experiments to cell number. Cell Titer-Glow® luminescent cell viability 
assay (Promega, UK) determines the number of viable cells by quantifying the amount of ATP 
present. Its 96 well plate format makes it ideal for quantifying the number of cells in the co-
culture assay, which is also performed in a 96 well plate. Both the co-culture assay and the Cell 
Titer-Glow® assay require cell lysis to obtain the data. Therefore, when calculation of cell 
number was required additional wells of the co-culture were treated exactly the same as the 
experimental wells. The experimental wells were lysed according to Methods section 2.6.2 and 
the additional wells were used to quantify cell number according to the protocol below. 
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2.8.2 Method 
Wells to be used for quantifying cell number were treated in exactly the same manner as the 
experimental wells. Additional HASM cells were trypsinised and counted then seeded in 
duplicate at 0,3.38,6.75, 12.5, 25 and 50 xl04 cells/ml, 100J.11/well to produce a standard curve 
of known cell densities against luminescence. After the 16 hour co-culture assay incubation 
period the experimental co-culture wells were lysed according to Methods section 2.6.2. The plate 
containing the wells for cell number quantification was removed from the incubator and the 
temperature allowed to adjust to room temperature for approximately 10 minutes. 100J.11 Cell 
Titer-Glow® reagent was added directly to the culture medium of each well. The plate was 
placed on a rocker for 30 minutes at room temperature to allow efficient cell lysis and 
stabilisation of the luminescent signal. The signal remains stable for up to 6 hours. The 
luminescence was then measured using a luminometer (Berthold Technologies, UK), exposing 
each well to the light detector for 0.1 seconds. The luminescence data was converted into actual 
cell numbers using the standard curve of known cell numbers against luminescence. 
2.9 Isolation of Nuclear and Cytoplasmic Protein Fractions 
2.9.1 Principles of Assay 
Once activated, many transcription factors trans locate from the cytoplasm into the nucleus to 
interact with DNA promoter regions and initiate gene transcription. By isolating cytoplasmic and 
nuclear fractions of cell protein separately it is possible to detect this translocation by western 
blotting (see Methods section 2.11). This has been shown for numerous transcription factors 
(Clarke et al. 2008; Clifford et al. 2008; John et al. 2009). Since Smad2 and Smad3 are 
transcription factors that trans locate to the nucleus it is possible to detect this translocation as an 
additional method of measuring T G F - ~ ~ activity. 
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Isolation of nuclear and cytoplasmic fractions of cell protein is achieved by manipulating the 
difference in osmotic pressure between the cytoplasmic and nuclear compartments of cells. Since 
proteins are very susceptible to damage from heat and proteases, nuclear and cytoplasmic protein 
isolations are performed on ice in the presence of several protease inhibitors. Cells are collected 
and lysed in a hypotonic lysis buffer, which causes the cells to swell and lyse leaving the nuclei 
intact. The nuclei are collected by centrifugation, storing the supernatant which contains the 
cytoplasmic proteins, and then lysed in a high-salt lysis buffer (hypertonic) to collect the nuclear 
proteins. Insoluble proteins are removed by centrifugation and the two fractions of cell protein 
stored at -80°C to minimise degradation of the proteins. 
2.9.2 Method 
Isolation of nuclear and cytoplasmic proteins was performed using a NXtract CellLytic nuclear 
extraction kit as previously described (Clifford et al. 2008) according to the manufacturer's 
instructions. Following stimulation cells were washed with ice cold PBS, scraped into sterile 
eppendorfs and centrifuged for 5 minutes at 450xg at 4°C. After discarding the supernatant the 
cell pellet was lysed in 250111 Ix lysis buffer plus ImM OTT and 1% protease inhibitor cocktail 
on ice for 15 minutes. 0.06% v/v IGEPAL CA-360 detergent was added and the samples vortexed 
for 10 seconds, avoiding foaming of the sample. Samples were centrifuged at 11000xg for 30 
seconds at 4°C. The supernatant containing the cytoplasmic fraction of cell proteins was collected 
and stored at -80°C. The remaining pellet was washed in lysis buffer plus ImM OTT and 1% 
protease inhibitor cocktail and centrifuged to minimise contamination of the nuclear fraction with 
cytoplasmic proteins. The cell pellet was lysed in 50111 Extraction buffer plus 1 % protease 
inhibitor cocktail and 1 mM OTT by vortexing for 15 minutes. The samples were centrifuged at 
20000xg for 5 minutes at 4°C. The supernatant containing the nuclear fraction was collected and 
stored at -80°C. 
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2.10 Bicinchoninic Acid (BeA) Protein Assay 
The BCA assay is a colorimetric assay for determining protein concentrations in experimental 
samples. The BCA protein assay kit was supplied by Pierce, UK. A standard curve of known 
BSA concentrations was added in duplicate to a 96 well flat bottomed plate. Samples were diluted 
I: 10 and 1 :25 and also added in duplicate to the plate. Reagent B (contains 4% cupric sulphate, 
supplied with kit) was diluted I :50 with reagent A (contains sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in O.IM sodium hydroxide, supplied with kit) 
and mixed. Then 200/l1 of this solution was added to each well containing standards or samples. 
The plate was incubated at 37°C for 30 minutes. After cooling the plate to room temperature the 
absorbance at 590nm was determined using a plate reader. A best-fit standard curve was 
constructed by the plate reader and protein concentrations of the experimental samples were 
calculated. Protein concentrations were determined immediately prior to separation by western 
blotting to avoid freeze thawing the samples, which can promote protein degradation. 
2.11 Western Blotting 
2.11.1 Principles of Assay 
Western blotting is a commonly used semi-quantitative technique to detect specific proteins 
within a sample of cells or homogenised tissue. It was originally based upon the techniques 
Northern and Southern blotting. It utilises gel electrophoresis to separate proteins within a sample 
of mixed proteins according to their molecular weight. Cells or tissue are lysed on ice and in the 
presence of various protease inhibitors to inhibit protein degradation. The protein is then 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Following separation the proteins are transferred via an electric current onto a membrane of either 
nitrocellulose or polyvinylidene fluoride (P.V.D.F) membrane. It is then possible to probe this 
membrane ,with an antibody directed against a protein of choice to detect expression of that 
protein. 
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2.11.2 Cell Lysis 
Following removal of culture medium the cells were washed with ice-cold sPBS. Cells were 
lysed on ice in 1001l1lysis buffer (see Appendix 9.5.2.). The celllysates were collected into pre-
chilled eppendorfs and centrifuged (10,000 rpm, 3 minutes at 4°C) to remove any insoluble 
protein. The protein concentration was determined by BCA assay (Methods section 2.10). 
2.11.3 SDS-PAGE 
The gel casting apparatus was set up according to the manufacturer's instructions (BioRad). A 
10% resolving gel was prepared and poured into the gel casting apparatus. Once set the stacking 
gel was prepared and poured on top of the resolving gel. The comb was inserted and the gel left at 
room temperature to set. After removal of the comb the apparatus was carefully loaded into the 
tank. The middle compartment was filled with Ix running buffer (see Appendix) and the tank was 
filled to about 1/3 full with Ix running buffer. Rainbow™ protein marker was added to the first 
lane (71l1 for small gels and 20111 for large gels) and the samples loaded into the subsequent wells. 
Gels were then ran on ice at 90mA for approximately 45 minutes. 
2.11.4 Transfer 
Two pieces of filter paper, two sponges and a piece of pure P.V.D.F membrane were soaked in 
methanol for 30 seconds. They were washed in tap water then left to soak with the sponges for 
the transfer apparatus in Ix transfer buffer (see Appendix 9.5.2) on a rocker for 3 minutes. The 
gel was removed from the running apparatus and soaked for 3 minutes in Ix transfer buffer. A 
piece of sponge was laid on to the cassette, followed by filter paper and then the P.V.D.F 
membrane. The gel was carefully placed on top of the membrane. A piece of filter paper then a 
piece of sponge was laid on top of the gel and any bubbles expelled by rolling a pipette across the 
top. The transfer cassette placed in the transfer tank with the gel closest to the negative (black) 
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electrode and the membrane closest to the positive electrode. After addition of transfer buffer (see 
Appendix), voltage was applied through the system at 100m V for I hour standing in ice. Once the 
transfer was completed the membrane was removed and stained with Ponceau's stain to ensure 
that protein had transferred to the membrane. The membrane was then washed for 2 x 5 minutes 
in Tris buffered saline plus Tween (TBST) (see Appendix 9.5.2) 
2.11.5 Protein Detection 
The membrane was blocked in 5% non-fat milk at room temperature for I hour to reduce the non-
specific binding of antibodies. The membrane was washed three times in TBST. The primary 
antibody was applied in 5% non-fat milk at the correct dilution for the antibody and the 
membrane was left on a rocker at 4°C overnight. The following day the membrane was washed in 
TBST for 3 x 5 minutes on a rocker. The secondary antibody was then applied in 5% non-fat milk 
at the correct dilution for the antibody and the membrane was left on a rocker for I hour at room 
temperature. After I hour the membrane was washed for 3 x 5 minutes as before. Equal volumes 
of the two ECLTM detection reagents were mixed together and poured over the membrane 
ensuring the whole surface of the membrane was covered and the membrane was left for 2 
minutes. It was blotted dry with tissue paper to remove excess ECLTM detection reagent and 
placed in a plastic wallet. The membrane was then developed in a dark room using Hyperfilm 
ECLTM. The position of the bands was checked against the Rainbow™ protein marker to 
determine the molecular weight. In order to ensure equal loading of protein samples, the 
membranes were also probed with a monoclonal antibody against GAPDH. GAPDH is an 
example of a housekeeping gene that is constitutively expressed in all cells and whose expression 
should not vary between cell types or with stimulation. 
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2.12 Stable Transfections 
2.12.1 Principles of Assay 
Transfection involves the delivery of nucleic acids, commonly DNA, in to eukaryotic cells, which 
consequently translate the nucleic acids into protein. This can be achieved by biochemical or 
physical means. Physical means of transfection generally involve physically perforating the cell 
membrane using electrical pulses, which allows the delivery of nucleic acids across the cell 
membrane. Biochemical transfection uses a chemical agent that forms a complex with the nucleic 
acids and aids its transfer across the cell membrane. Several different biochemical agents can be 
used for transfection of nucleic acids into eukaryotic cells including calcium phosphate and 
cationic lipids. Calcium phosphate complexes with DNA and forms an insoluble precipitate 
which is taken up by the cell by endocytosis. Cationic lipids form liposomes that bind to the 
nucleic acids. These fuse to the phospholipid cell membrane and ~ e l i v e r r the nucleic acid in to the 
cell. 
Transfections of nucleic acids into eukaryotic cells can be either transient or stable. Transient 
transfection involves the temporary introduction of nucleic acids into a cell. The expression level 
of the nucleic acid will be high but will only remain for a short period of time because the 
introduced nucleic acids are not incorporated into the host cell genome. Stable transfection 
involves the generation of clonal transfected cell lines by selective cell culture. The cell lines 
often have the nucleic acids inserted into their genome. The vector containing the nucleic acids to 
be transfected carries an antibiotic resistance gene. This means that successfully transfected cells 
survive culture in the presence of the antibiotic allowing clonal expansion of the transfected cells. 
Such stable transfectants can be maintained in culture for long periods of time providing that the 
selection agent is present. 
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2.12.2 Method 
DNA plasmid constructs corresponding to the common full length integrin ~ 5 5 subunit and a 
polymorphic integrin ~ 5 5 subunit in the vector pc.DNA3.1 were kindly provided by Professor 
Kawahara (Kanazawa University, Japan). The transfection reagent Transfast (Promega, UK), 
which uses cationic lipids for nucleic acid delivery, was used to stably transfect CS-l hamster 
melanoma cells. Four different concentrations of DNA (1, 2, 3 and 4tJ.g) were used to separately 
transfect CS-l cells with a ratio of DNA: Transfast of 1 :2. This was the recommended ratio 
outlined in the manufacturer's instructions. Cells were transfected in 75cm2 tissue culture flasks 
in a total volume of 6ml. The appropriate amount of DNA and Transfast reagent was added to 
transfection media to make a final volume of 6ml. After vortexing the mixture, it was left for 15 
minutes at room temperature to allow the DNA to complex with the Transfast. The DNA: 
Transfast complex was then added to cells cultured in transfection medium (see Appendix 9.6). 
The cells were incubated overnight at 37°C in a humidified atmosphere. The following day, the 
media was removed and fresh transfection medium applied. Expression of ~ 5 5 was evident after 2 
days when CS-l cells began to adhere to the plastic. At this point the cells were cultured in CS-l 
media containing 500tJ.g/ml 0418 to select for transfected cells. 
2.13 Co-Immunoprecipitation 
2.13.1 Principles of Assay 
Immunoprecipitation refers to the precipitation of proteins out of a mixture of proteins using 
specific antibodies directed against the protein of choice. Co-Immunoprecipitation (Co-Ip) is used 
in molecular biology to investigate protein interactions within the cell. Cells are lysed on ice in 
the presence of protease, phosphatase and deacetylase inhibitors, to prevent dissociation of any 
protein complexes within the cell. The cell protein is incubated with an antibody directed against 
a target prot,ein. Magnetic beads that bind to antibodies are used to immunoprecipitate the target 
protein. Any proteins that are associated with the target protein are "captured" simultaneously. 
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Proteins that are suspected to be associated with the target protein can then be detected by 
western blot. Co-Ip is a powerful experimental tool for measuring protein-protein interactions. 
2.13.2 Method 
The interaction of the integrin pS subunit with the cytoskeletal protein talin was investigated 
using a Universal Magnetic Co-IP kit (Active Motif, USA) as previously shown for different 
proteins (Clifford et al. 2008). A rabbit polyclonal antibody directed against integrin pS and a 
mouse monoclonal directed against both tal in 1 and 2 (clone 804) were used (both from Abeam, 
UK). SOOllg protein was incubated with Sllg antibody for 4 hours. 20111 magnetic beads coated 
with protein G, which binds with high affinity to IgG antibodies, were added and the tubes 
incubated at 4°C on a rocker for 1 hour. Using a magnet the beads were washed in Iml Co-Ip 
wash buffer (supplied with kit) S times then resuspended in 20111 2x reducing loading buffer 
(130mM Tris pH 6.8, 4% SOS, 0.02% bromophenol blue, 20% glycerol, 100mM OTT) and 
stored at -20°C. Protein was separated by SOS-PAGE (see Methods section 2.11.3). IOllg of 
protein prior to immunoprecipitation was also loaded on to the gel as a loading control. The 
resulting membrane was probed with the second antibody (IOIlg/ml) and developed as previously 
described (Methods section 2.11.S). 
2.14 Flow Cytometry 
2.14.1 Principles of Assay 
Flow cytometry is a powerful technique used to accurately quantify and examine cells or other 
particles within a suspension. A flow cytometer can provide information about individual cell 
size, the internal complexity or granularity of a cell and the relative fluorescence intensity of a 
cell using a combination of fluid mechanics and optics. Cell suspensions are hydrodynamically 
focused within a sheath fluid through a laserbeam, and optical detectors detect the scatter of light. 
Forward scatter (FSc) is detected directly in front of the passing cells and laser beam. FSc refers 
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to light defracted from the cell surface as it passes the laser beam. Forward scatter gives 
information about the cell size. Side scatter (SSc) is detected at a 90° angle to the laser beam and 
refers to light reflected and refracted from the cell surface. SSc provides information about the 
internal complexity of the cells. 
Flow cytometry can also be used to assess expression of proteins by cells. The target protein, 
either intracellular or cell surface, is labelled with a specific antibody conjugated to a 
fluorochrome. The flow cytometer is set up so that the laser beam excites the fluorochrome at its 
specific excitation wavelength and the emitted light is detected. The emitted fluorescence 
intensity is directly proportional to the number of binding sites for the antibody allowing accurate 
determination of protein expression levels. Many different fluorochromes exist allowing the 
simultaneous detection of more than one protein on a cell. 
2.14.2 Method 
Cell surface expression of aVp5 by HASM cells was assessed by flow cytometry using a method 
previously used to assess expression of a V ~ 6 6 by epithelial cells. Cells were trypsinised using 
0.25% trypsinlEOTA solution and counted (see Methods section 2.2.7). 0.5xl06 cells were added 
to F ACs tubes. The cells were centrifuged and the media discarded. They were then washed in 
PBS, centrifuged and the PBS discarded. The cells were blocked in 200,.d goat serum for 20 
minutes at 4°C to inhibit non-specific binding of the antibodies. The goat serum was removed by 
centrifugation and the cells washed in PBS. After removing the PBS the primary antibody was 
added at 25).1g/ml for 20 minutes at 4°C. After removal of the primary antibody by centrifugation 
the cells were washed and the PBS removed. The cells were incubated with the secondary 
phycoerythrin (PE) labelled antibody 1 :200 dilution for 20 minutes at 4°C in the dark to prevent 
light bleaching of PE. The antibody was removed, the cells washed in PBS the resuspended in 
500).11 PBS. The cells were analysed using a BO F ACSCalibur flow cytometer. 
88 
2.15 Statistics 
Data is expressed as mean ± SEM for all experiments unless otherwise stated. Statistical analysis 
was performed using GraphPad Prism 4. When a comparison of only two data sets was needed an 
unpaired Student's t test was performed. When comparing more than 2 data sets a one-way 
analysis of variance (ANOVA) was performed, with either a Bonferroni's post test to compare 2 
specific data sets, or a Dunnet post test to compare all data sets with a control data set. When 
comparing two treatment groups, each with multiple data sets, a two-way ANOV A was 
performed. This determines if means were significantly different for a) data sets within a 
treatment group, or b) between the treatment groups. P values less than 0.05 were accepted as 
significant. 
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3 Proteolytic Activation of TGF - ~ ~ from HASM Cells by Mast Cell 
Tryptase 
3.1 Rationale 
Mast cells (MC) play a fundamental role in orchestration of airway inflammation in asthma 
(discussed in Introduction section 1.1.3 .5). The EAR, and therefore brochoconstriction, is 
instigated when FceRI receptors on the surface of MC become cross-linked by antigen, causing 
MC degranulation and the release of a vast array of inflammatory mediators. The number of MC 
present in the airways is much higher in asthmatics compared with non-asthmatics (Carroll et al. 
2002) and infiltration of the ASM layer by MC is an important characteristic of asthma 
(Brightling et al. 2002). Furthermore, the degree of MC degranulation correlates positively with 
asthma severity (Carroll et al. 2002). 
Tryptase is the most abundant protease released from activated MC. It is a serine protease with 
trypsin-like activity, which is unique to the secretory granules ofMC. Several isoforms have been 
identified and can be divided in to four groups designated a-tryptases, ~ - t r y p t a s e s , , 'Y-tryptases and 
e-tryptases. ~ ~ tryptases is one of the most abundant proteases present in MC. a tryptases, 
however, are predominantly found in the secretory granules of basophils. 'Y tryptases are 
expressed in a variety of tissues but, unlike a and ~ ~ tryptases, they have a hydrophobic region at 
their carboxyl terminal, which is important for tethering the protease to the cell membrane. e 
tryptases are widely expressed in the lungs, especially in the epithelium but are not expressed by 
mast cells. For the purposes of this thesis I will concentrate upon ~ - t r y p t a s e e since this is the 
predominant form released from MC. ~ - t r y p t a s e e will now be referred to as tryptase. 
Tryptase is stored as proteolytically active tetramers in MC granules. The monomers form a 
square ring with the catalytic domains of each subunit pointing towards a central pore, which 
forms the active site (Pereira et al. 1998). The tetramers are complexed with a proteoglycan, 
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usually heparin, which stabilises the tetramer complexes and is essential for tryptase activity 
(Schwartz et al. 1986). Our group has shown that tryptase can cleave and inactivate the 
chemokines CCLS and CCLlI in vitro (Pang et al. 2006). However, in vivo a substrate for 
tryptase still needs to be identified. It is commonly thought that tryptase mediates many of its 
effects via cleavage and activation of proteinase-activated receptor-2 (PAR2). Members of this 
family of receptors are activated by a novel proteolytic mechanism. The receptor is recognised by 
its activating protease, which cleaves the receptor at a specific site within the amino terminal 
domain. This exposes a tethered ligand which interacts with the second extracellular loop of the 
receptor to initiate cell signalling in a similar manner to other G protein coupled receptors (see 
Figure 3.1). 
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Figure 3.1: Mechanism of Activation of PARs 
Proteolytic activators of PARs cleave the extracellular domain of the receptor at a specific site 
(2). This liberates a tethered ligand, which is now able to interact with the second extracellular 
loop of the receptor causing activation of G proteins and cell signalling (3). Synthetic peptides 
corresponding to the tethered ligand domain are able to activate the receptor in a proteolysis 
independent mechanism by interacting directly with the second extracellular loop of the receptor. 
Adapted from (Macfarlane et a\. 2001). 
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Tryptase has been implicated in asthma pathogenesis. The level of tryptase in BALF from atopic 
asthmatic is increased (Wenzel et al. 1988), and increases following allergen challenge have been 
reported (Flint et al. 1985). The immediate effects of tryptase following its release are associated 
with EAR (see Introduction section l.l.2). It can potentiate histamine-induced 
bronchoconstriction (Johnson et al. 1997), activate MC causing degranulation (Molinari et al. 
1996) and has been implicated in AHR (Schmidlin et al. 2002; Ebeling et al. 2005). A role for 
tryptase in the LAR has also been suggested since inhalation of the tryptase inhibitor APC366 can 
diminish allergen-induced LAR (Krishna et al. 2001). It also contributes to infiltration of the 
airways by inflammatory cells. It increases microvascular permeability (He et al. 1997) and can 
stimulate migration of eosinophils and neutrophils (Walls et al. 1995; He et al. 1997). Moreover, 
it can cause increased expression of intercellular adhesion molecule 1 (ICAM-1) and the 
chemokine CXCL8 (IL-8) by epithelial cells (Cairns et al. 1996) aiding inflammatory cell 
migration. Our group has shown tryptase can cause increased expression of CXCL8 in ASM cells 
(Mullan et al. 2007). 
A role for tryptase in airway remodelling has been suggested. It is a potent mitogen for fibroblasts 
(Hartmann et al. 1992), ASM cells (Brown et al. 1995; Brown et al. 2002) and bronchial 
epithelial cells (Cairns et al. 1996), which could contribute to subepithelial fibrosis and ASM 
hyperplasia. Furthermore, conditioned media from tryptase stimulated HASM cells has increased 
T G F - ~ ~ activity (Berger et al. 2003). Since T G F - ~ ~ is secreted as a latent complex (see Introduction 
section l.4.2) there are two possible ways in which tryptase could cause increased T G F - ~ ~
activity. It may activate T G F - ~ ~ from ECM stores by either direct proteolysis or via activation of 
its receptor PAR2. Alternatively it may cause increase expression of L - T G F - ~ ~ which is then 
activated, either by tryptase or by a separate mechanism (see Introduction section 1.4.2). 
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3.2 Aims 
The aims of this chapter were to investigate whether tryptase causes increased T G F - ~ ~ activity in 
HASM cell supernatants by increasing total T G F - ~ ~ expression or by activating existing stores of 
L-TGF - ~ , , or by a combination of both mechanisms. The effects of tryptase' s proteolytic activity 
on T G F - ~ ~ activity will be investigated. The role of the tryptase receptor PAR2 in tryptase-
mediated effects on T G F - ~ ~ expression and activity will be determined using a synthetic peptide 
that has the same amino acid sequence as the tethered ligand of P AR2. 
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3.3 Results 
3.3.1 Concentration-Response of Tryptase on Levels of Active and Total T G F - ~ ~ in Cell 
Supernatants 
HASM cells were treated in duplicate with 0, 3.75, 15 and 60 mU/ml tryptase. Cell culture 
supernatants were collected after 4 or 24 hours and the amount of active and total T G F - ~ ~
determined by reporter cell assay (see Methods section 2.6). The T G F - ~ - i n d e p e n d e n t t luciferase 
activity was subtracted from all data sets as described in Methods section 2.6 and the data 
expressed as fold increase in T G F - ~ ~ activity. Stimulation of HASM cells with tryptase caused a 
concentration-dependent increase in active T G F - ~ ~ released in to cell supernatants after 4 hours 
(Figure 3.2). The lowest concentration tested was 3.75mU/ml which caused a 2.2 fold increase in 
T G F - ~ ~ activity (p<0.05) rising to a 4.84 fold increase when stimulated with 60mU/ml tryptase 
(p<O.OI). The levels of total T G F - ~ ~ released in to cell supernatants after 4 hours did not change 
with increasing tryptase concentration. 
The tryptase-induced increase in active T G F - ~ ~ observed after 4 hours of stimulation was not seen 
when cell supernatants were collected after 24 hours of stimulation. None of the tryptase 
concentrations tested caused an increase in active TGF - ~ ~ in cell supernatants as shown in Figure 
3.3. The highest concentration of tryptase tested (60mU/ml) only caused a 1.28 ± 0.25 fold 
increase in active T G F - ~ ~ over basal. Furthermore, none of the concentrations tested had any 
effect on levels of total TGF - ~ ~ present in the supernatants after 24 hours of stimulation. 
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Figure 3.2: Concentration-Response of Tryptase on Levels of Active and Total TGF-8 in 
Cell Supernatants After 4 Hours· 
HASM cells were stimulated with 0, 3.75, 15 or 60m D/ml tryptase. The cell supernatants were 
collected after four hours and used in a reporter cell activity to detect active and total T G F - ~ . .
Tryptase induced a concentration-dependent increase in active T G F - ~ ~ present in cell supernatants 
after 4 hours. Levels of total T G F - ~ ~ remained unchanged at all concentrations tested. This figure 
shows the amalgamation of data from 3 separate experiments expressed as the mean fold increase 
over basal ± SEM. 
* P<0.05 ** P<O.OI 
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Figure 3.3: Concentration-Response of Tryptase on Levels of Active and Total TGF-6 in 
Cell Supernatants After 24 Hours 
HASM cells were stimulated in duplicate with 0, 3.7S, IS and 60mU/ml tryptase. Cell 
supernatants were collected after 24 hours and assayed for active and total T G F - ~ ~ using a reporter 
cell assay. Tryptase had no effect on levels of active of total T G F - ~ ~ present in cell supernatants 
collected after 24 hours of stimulation. This figure represents data from 3 separate experiments 
expressed as the mean fold increase over basal ± SEM. 
3.3.2 Effect of Tryptase Stimulation Time on Levels of Active and Total T G F - ~ ~ in 
Conditioned Media 
Results from the previous experiment showed that stimulation of HASM cells with lSmU/ml 
tryptase causes a statistically significant increase in active T G F - ~ ~ pre ent in cell supernatants 
after four hours of stimulation (see Figure 3.2). The response appeared to plateaux at this 
concentration as stimulation with 60mU/mi tryptase did not induce a much greater increase in 
active T G F - ~ . . All future experiments were therefore performed using ISmU/ml tryptase. HASM 
cells were treated in duplicate with ISmU/ml purified human lung tryptase. Cell culture 
supernatants were collected after 0, 4, 8, 16 and 24 hours and assayed for active and total T G F - ~ ~
using the reporter cell assay (Methods ection 2.6). As Figure 3.4 shows, trypta e caused a 3.61 ± 
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0.36 fold increase in active T G F - ~ ~ present in the cell supernatants at 4 hours (P<O.OS). By 8 hours 
levels of active T G F - ~ ~ had declined. Levels of active T G F - ~ ~ had returned to basal after 16 hours 
and remained at basal levels at 24 hours. Tryptase had no significant effect on levels of total 
T G F - ~ ~ in cell supernatants at any time point tested. 
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Figure 3.4: Effect of Tryptase Stimulation Time on Levels of Active and Total TGF-B in 
Cell Supernatants 
HASM cells were stimulated in duplicate with lSmU/ml tryptase and cell supernatants assayed 
for active and total T G F - ~ ~ after 0, 4, 8, 16 and 24 hours. Stimulation of HASM cells with 
lSmU/ml tryptase caused an increase in active T G F - ~ ~ present in cell supernatants after 4 hours, 
after which time levels declined returning to basal at 16 hours. Levels of total T G F - ~ ~ were 
unaffected. Data was expressed as fold increase in TGF - ~ ~ activity. This figure represents an 
amalgamation of data from 3 separate experiments. 
* P<O.OS 
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3.3.3 Effect of Tryptase on Expression of TGF-B-Inducible Gene Plasminogen 
Activator Inhibitor-l (PAIl) by HASM Cells 
To confinn that stimulation of HASM cells with tryptase results in T G F - ~ ~ activation, expression 
of the T G F - ~ - r e s p o n s i v e e gene PAIl was assessed by Q-PCR. HASM cells were stimulated with 
15mUlmi purified human lung tryptase in duplicate and total cell RNA was collected after 0, 1,2, 
4 and 8 hours. HASM cells were also stimulated with 2ng/ml T G F - ~ I I and RNA collected after 4 
hours as a positive control. After reverse transcription (see Methods section 2.3.4) the resulting 
cDNA was subjected to Q-PCR analysis for PAIl and the housekeeping gene ~ 2 - m i c r o g l o b u l i n n
( ~ 2 m ) ) mRNA. Figure 3.5 shows that tryptase caused a time dependant increase in PAIl mRNA 
expression. There was no significant increase in PAl I after 2 hours of tryptase stimulation but 
after 4 hours tryptase induced an 8.56 ± 3.15 fold increase in PAil mRNA. Expression of PAIl 
mRNA had increased further after 8 hours where a 17.33 ± 4.76 fold increase was recorded. 
Stimulation of HASM cells with 2ng/ml T G F - ~ ~ caused a 24.71 ± 14.39 fold increase in PAIl 
mRNA. Tryptase-induced expression of PAIl mRNA was statistically significant at both 4 and 8 
hours (P<0.05). 
99 
50 
40 
JQ 
CD CD > 30 CD UJ 
....I as 
« ~ ~ * ZO 
n:..!:: 20 E:y 
"1"-0 
-LL ~ ~ 10 
0 
0 2 4 8 TGF-p 
lime 
(Hours) 
Figure 3.5: Effect of Tryptase on Expression of PAIl mRNA 
HASM cells were stimulated with lSmU/ml tryptase and total cell RNA was collected after 0,2, 
4 and 8 hours. After reverse transcription expression of PAIl And ~ 2 M M was determined by Q-
PCR. Stimulation ofHASM cells with tryptase caused a time dependant increase in PAIl mRNA 
expression. This figure shows the data from 3 separate experiments. Data is expressed as fold 
increase over basal. 
* P<O.OS 
3.3.4 Effect of Tryptase on Total T G F - ~ ~ Present in Cell Supernatants 
To confmn that tryptase had no effect on levels of total T G F - ~ ~ present in cell supernatants an 
ELISA was used. HASM cells were stimulated with lSmU/ml tryptase in duplicate and cell 
supernatants collected after 24 hours. The amount of total T G F - ~ ~ present in the supernatants was 
measured by ELISA (Methods section 2.5) and T G F - ~ ~ concentrations were calculated from a 
standard curve of recombinant active T G F - ~ . . As shown by Figure 3.6, tryptase had no effect on 
the amount of total T G F - ~ ~ present in cell supernatants. Cell supernatants from unstimulated cells 
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contained 160.9 ± 12.Spg/ml T G F - ~ ~ following activation of all T G F - ~ ~ present (see Figure 3.6). 
Supernatants from tryptase stimulated cells contained ISO.8 ± 17.1 pg/ml T G F - ~ . .
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Figure 3.6: Effect of Tryptase on Total TGF-8 Present in Cell Supernatants 
HASM cells were stimulated in duplicate with ISmU/ml tryptase and cell supernatants assayed 
after 24 hours by ELISA for the amount of total T G F - ~ . . Stimulation of HASM cells with 
lSmU/ml tryptase did not affect the amount of total T G F - ~ ~ present in cell supernatants after 24 
hours of stimulation. This figure represents data from 3 separate experiments expressed as mean 
± SEM. 
3.3.5 Effect of Leupeptin on Tryptase-Induced Activation ofTGF-B 
To determine if tryptase-induced T G F - ~ ~ activation occurred due to proteolysis leupeptin, a 000-
selective protease inhibitor was used in a reporter cell assay. HASM cells were either left 
untreated, treated with lSmU/ml tryptase or ISmU/ml tryptase plus 2.SIlg/ml leupeptio . Cells to 
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be treated with leupeptin were pre-incubated for 30 minutes with leupeptin prior to addition of 
tryptase. All stimulations were performed in duplicate. Cell supernatants were collected after 0, 4, 
8, 16 and 24 hours and were used in a reporter cell assay (see Methods section 2.6) to assay levels 
of active and total T G F - ~ . . As Figure 3.7 illustrates, treatment of HASM cells with 2.Sf.lg/ml 
leupeptin completely abrogated tryptase-induced T G F - ~ ~ activation. At 4 hours tryptase induced a 
2.23 ± 0.12 fold increase in active T G F - ~ . . However, in the presence of leupeptin tryptase did not 
increase levels of active T G F - ~ ~ (P<O.OOS). 
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Figure 3.7: Effect of Leupeptin on Tryptase-Induced TGF-8 Activation 
HASM cells were either left untreated, treated with ISmU/ml tryptase or treated with ISmU/ml 
tryptase plus 2.Sf.lg/ml leupeptin. Addition of leupeptin completely abolished tryptase-induced 
T G F - ~ ~ activation. This figure shows data from 3 separate experiments expressed as mean fold 
increase over basal ± SEM. 
** P<O.OI *** P<O.OOS 
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3.3.6 Effect of Selective Tryptase Inhibitor on Tryptase-Induced TGF-B Activation 
To confinn that activation of T G F - ~ ~ is due to the proteolytic activity of tryptase and not of a 
contaminating protease in the purified tryptase preparation, the selective tryptase inhibitor 
nafamostat mesilate (FUT175) was used. HASM cells were either left untreated, treated with 
15mU/mi tryptase or 15mU/mi tryptase plus O.2nM selective tryptase inhibitor FUT175. Cells to 
be treated with FUT175 were pre-incubated for 30 minutes with the inhibitor. All stimulations 
were perfonned in duplicate. Cell supernatants were collected after 0, 4, 8, 16 and 24 hours and 
were used in a reporter cell assay (see Methods section 2.6). FUT175 completely abolished 
tryptase-induced T G F - ~ ~ activation (Figure 3.8). After 4 hours of stimulation tryptase induced a 
5.53 ± 0.53 fold increase in active T G F - ~ ~ present in cell supernatants. After 8 hours, levels of 
active T G F - ~ ~ had returned to basal. In the presence of FUT175 tryptase-induced T G F - ~ ~
activation was inhibited (P<0.005). 
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Figure 3.8: Effect of Selective Tryptase Inhibitor on Tryptase-Induced TGF -8 Activation 
HASM cells were either left untreated, treated with ISmU/ml tryptase or treated with ISmU/ml 
tryptase plus O.2nM FUT17S. Cell supernatants were assayed for active TGF-p using a reporter 
cell assay after 0, 4, 8, 16 and 24 hours. All treatments were performed in duplicate. Addition of 
FUT17S completely abolished tryptase-induced activation of TGF-p. This figure shows the data 
from 3 separate experiments expressed as mean fold increase over basal ± SEM. 
*** P<O.OOS 
3.3.7 Effect ofPAR2 Activating Peptide (PAR2-AP) on TGF-p Activation 
Tryptase-induced TGF-p activation occurs via proteolysis as shown by Figure 3.7 and Figure 3.8. 
As mentioned in Results section 3.1 tryptase mediates many of its effects through proteolytic 
cleavage and therefore activation of P AR2 on the cell surface. The involvement of P AR2 in 
tryptase-induced TGF-p activation was assessed using a synthetic peptide (PAR2-AP) 
corresponding to the tethered ligand of P AR2 (SLIGKV -NH2)' HASM cells were either left 
unstimulated, stimulated with tryptase (ISmU/ml) or with a synthetic PAR2 activating peptide, 
SLIGKV-NH2 (SOOIJ-M). All stimulations were performed in duplicate. Cell supernatants were 
collected after 0, 4, 8, 16 and 24 hours and assayed for active TGF-p and total TGF-p using a 
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reporter cell assay (Methods section 2.6). Figure 3.9 illustrates that tryptase caused a 3.36 ± 0.28 
fold increase in active TGF-p present in cell supernatants after 4 hours, after which levels 
returned to basal. However, stimulation of HASM cells with the PAR2-AP (SLIGKV -NH2) did 
not result in an increase in active TGF -p present in cell supernatants at any time point tested. 
Furthermore, neither SLIGKV-NH2 nor tryptase had any effect on levels of total TGF-p present 
in cell supernatants at any time point tested (Figure 3.10). 
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Figure 3.9: Effect of P ARl-AP on Levels of Active TGF -8 in Cell Supernatants 
HASM cells were treated in duplicate with either media alone, ISmU/ml tryptase or SOOf.1M 
SLIGKV-NH2. Cell supernatants were assayed for active TGF-p using a reporter cell assay after 
0,4,8, 16 and 24 hours. Tryptase caused an increase in active TGF-p at 4 hours after which levels 
returned to basal. SLIGKV -NH2 had no effect on levels of active TGF-p at any time point tested. 
This figure shows the amalgamation of data from 3 separate experiments and is expressed as 
mean fold increase over basal ± SEM. 
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Figure 3.10: Effect ofPARl-AP on Levels of Total TGF-B in Cell Supernatants 
HASM cells were treated in duplicate with either media alone, 15mU/mi tryptase or 500JlM 
SLIGKV-NH2• Cell supernatants were assayed for total TGF-p using a reporter cell assay after 0, 
4, 8, 16 and 24 hours. Neither tryptase nor the PAR2-AP SLIGKV-NH2 altered the level of total 
TGF -p present in cell supernatants at any time point tested. This figure shows data from 3 
separate experiments expressed as fold increase over basal ± SEM. 
3.3.8 Expression ofPAR2 Protein by HASM Cells 
Data presented in Figure 3.9 show that the PAR2-AP SLIGKV-NH2 had no effect on TGF-p 
activation at any time point tested, despite tryptase inducing an increase in active TGF-p after 4 
hours. This may be because tryptase-induced TGF-p activation occurs independently of PAR2, 
because the cells used did not express P AR2, or because P AR2 is expressed but not functional. 
The expression of P AR2 protein by HASM cells was therefore assessed using western blotting 
(Methods section 2.11). 30Jlg of total protein from unstimulated HASM and NHBE cells was 
separated by SDS-PAGE and transferred onto a PVDF membrane. The membrane was probed 
with a 1:1000 dilution ofanti-PAR2 monoclonal antibody (clone SAM11) and a 1:10,000 dilution 
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of anti-GAPDH monoclonal antibody as a loading control. NHBE cells constitutively express 
P AR2 protein and were used as a positive control. Figure 3.11 shows that NHBE cells express 
PAR2 protein illustrated by a band at 50kD. However, no band corresponding to PAR2 was 
observed in total cell protein collected from HASM cells. GAPDH was used as a loading control 
and bands representing GAPDH can be seen in both NHBE and HASM cells at 35kD. 
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Figure 3.11: Expression ofPARl Protein by HASM Cells 
Western blotting was used to assess expression of PAR2 protein in unstimulated HASM cells 
using NHBE cells as a positive control. 30llg of total cell protein was loaded per lane. This is a 
representative blot from 3 separate experiments. 
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3.3.9 Expression of PAR mRNA by HASM Cells 
As Figure 3.11 shows, PAR2 protein was not expressed by HASM cells. In order to determine 
whether PAR2, and the other three members of the PAR family, were expressed at the mRNA 
level, their expression was assessed using RT-PCR (chapter 2.3.5). Total cell RNA was collected 
from unstimulated, growth arrested HASM cells. RNA from NHBE and A549 cells was used as 
positive controls. NHBE cells were used as a positive control for P AR2 and A549 cells were used 
as a positive control for PARI, PAR3 and PAR4. The primers used are outlined in Appendix 9.7. 
As shown by Figure 3.12, A549 cells expressed mRNA for PARI, PAR3 and PAR4. NHBE cells 
expressed PAR2 mRNA. However, HASM cells only expressed mRNA for PARI and PAR3. No 
mRNA for PAR2 and PAR4 was detected in HASM cells. Expression of PARI and PAR3 by 
HASM was at a much lower level than that observed for A549 cells. 
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Figure 3.12: Expression of PAR mRNA by HASM cells 
RNA from unstimulated HASM, A549 and NHBE cells was reverse transcribed and subjected to 
peR analysis for PARI , PAR2, PAR3 and PAR4 to determine expression of these four receptors 
at the mRNA level. HASM cells were shown to express both PARI and PAR3 at a very low 
level , as shown by faint bands in these lanes. However, P AR2 and P AR4 were not expressed by 
HASM cells. DNA bands were present in the positive control lane for each receptor confirming 
that the primers were functional. This is a representative figure from 3 separate experiments. 
3.3.10 Effect ofPAR2-AP on NHBE Cells 
These data show that tryptase can activate T G F - ~ ~ independently of PAR2 as the HASM cells 
used did not express P AR2. However, it has previously been shown that activation of PAR2 by 
tryptase causes increased expression of T G F - ~ ~ (Berger et al. 2003). In order to investigate the 
effect of PAR2 activation on levels of T G F - ~ ~ released NHBE cells, which express PAR2 (see 
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Figure 3.11), were used. NHBE cells were stimulated in duplicate with either 15mU/mi tryptase 
or 5 0 0 ~ M M PAR2-AP (SLIGKV-NH2). Cell supernatants were collected after 0, 4, 8, 16 and 24 
hours and used in a reporter cell assay to determine levels of total T G F - ~ . . Neither tryptase nor 
PAR2-AP had an effect on levels of total T G F - ~ ~ in cell supernatants at any time point tested (see 
Figure 3.13). 
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Figure 3.13: Effect of Tnptase and P ARl-AP on NHBE Cells 
NHBE cells were stimulated in duplicate with either 15mU/mi or 5 0 0 ~ M M PAR2-AP. Cells 
supernatants were collected after 0, 4, 8, 16 and 24 hours and assayed for T G F - ~ ~ using reporter 
cell assay. Neither tryptase nor PAR2-AP had any effect on levels of total T G F - ~ ~ released in to 
the cell supernatants. This figure is representative of 3 independent experiments. Data is 
expressed as mean fold increase ± SEM. 
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3.4 Discussion 
The aim of this thesis was to determine the mechanisms ofTGF-p activation employed by HASM 
cells in vitro. It has previously been shown that stimulation of HASM cells with tryptase can 
affect TGF-p function (Berger et al. 2003), as shown by increased migration of mast cells towards 
conditioned media from tryptase-stimulated HASM cells. I found that mast cell tryptase released 
active TGF-p from HASM cells without affecting the overall levels ofTGF-p. Tryptase increased 
active TGF-p via proteolysis, however, this effect was not mediated through PAR2 because the 
HASM cells used did not express P AR2 at either the protein or mRNA level. 
These data are consistent with a mechanism of proteolytic cleavage of latent TGF-p by tryptase 
because overall levels of TGF-p (latent plus active) remained unchanged. Tissues generally 
contain large stores of latent TGF-p awaiting activation. These stores are sequestered in the ECM 
by interaction between L TBP and proteins in the ECM (Annes et al. 2003). A similar mechanism 
of TGF-p activation has been described for the serine proteases plasmin and thrombin (Lyons et 
al. 1990; Taipale et al. 1992), which proteolytically cleave latent TGF-p sequestered in the 
extracellular matrix without affecting overall expression of the latent complex. 
Addition of leupeptin to the reporter cell assay completely abrogated tryptase-induced TGF-p 
activation confirming that the mechanism of TGF-p activation was proteolytic. Since tryptase, 
like plasmin, is a serine protease we performed experiments to determine if activation of TGF-p 
was due to the proteolytic activity of tryptase and not any contaminating proteases within the 
human lung tryptase preparation. We used the serine protease inhibitor FUT175 which is a potent 
competitive inhibitor of tryptase (Ki=0.095nM) (Mori et al. 2003). FUT175 also inhibits other 
serine proteases such as plasmin and trypsin but the Ki for inhibition of these proteases is much 
higher than the Ki for inhibition oftryptase. For example, the Ki of FUT175 for human thrombin 
is 840nM, human factor B is 60JiM, plasmin is 31 OnM and human factor Xa is 4.1 JiM (Matsuoka 
et al. 1989; Mori et al. 2003). We found that FUT175, when used at a concentration that 
specifically inhibits tryptase, completely abrogated TGF -P activation confirming that tryptase-
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induced T G F - ~ ~ activation is mediated by the proteolytic effect of tryptase rather than any 
contaminating proteases that may be present. 
The tryptase-induced increase in active T G F - ~ ~ present in cell supernatants was transient, peaking 
at 4 hours. It is unlikely that the amount of latent T G F - ~ ~ available is the limiting factor in this 
system since large stores of latent T G F - ~ ~ are sequestered in the ECM and subsequent 
experiments showed that tryptase had no effect on levels of total T G F - ~ ~ (see Results section 
3.3.4). The transient increase in active T G F - ~ ~ observed was probably due to the half-life of 
tryptase, which is approximately 2.5 hours (Schwartz et al. 1986). After 2.5 hours the levels of 
tryptase would begin to decrease resulting in a slower rate of T G F - ~ ~ activation. Decreased 
tryptase activity over time has been previously reported (Berger et al. 2003). It is likely that after 
8 hours of stimulation only negligible amounts oftryptase remained and so very little or no TGF-
~ ~ activation occurred, despite there being large amounts sf latent T G F - ~ ~ still sequestered in the 
ECM. 
It is possible that tryptase activates PAR2 (Akers et al. 2000; Berger et al. 2001), a G protein 
coupled receptor. P AR2 is up-regulated in the respiratory epithelium of asthmatics (Knight et al. 
2001) implying that PAR2 may be involved in asthma pathogenesis. In an ovalbumin mouse 
model of asthma, activation of PAR2 using a P AR2-AP enhances inflammation and AHR 
(Ebeling et al. 2005). Furthermore, activation of PAR2 on eosinophils can cause release of 
cysteinylleukotrienes which may contribute to asthma (Bolton et al. 2003). In the present study, 
however, it was found that PAR2-AP did not mimic the effects of tryptase on HASM T G F - ~ ~
activation suggesting the PAR2 is not involved in tryptase-induced T G F - ~ ~ activation. The peptide 
was functional as we have shown previously that it can cause increased release of IL-8 from 
NHBE cells (Mullan et al. 2007). Furthermore, neither tryptase nor P AR2-AP activated TGF - ~ ~ in 
NHBE cells. These data contradict the findings of Berger et al (2003) who found that stimulation 
of HASM cells with P AR2-AP caused the cell supernatants to have increased chemotactic 
activity for mast cells, which the authors attributed to increased T G F - ~ ~ due to the ability of a 
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T G F - ~ ~ neutralising antibody to inhibit the chemotaxis. However, the authors did not directly 
measure T G F - ~ ~ activity in the cell supernatants. In contrast, I have used two direct bioassays to 
measure T G F - ~ ~ activity in response to both tryptase and PAR2-AP. This may suggest that PAR2 
mediated effects lead to downstream T G F - ~ ~ synthesis and activation in cells that express this 
receptor. 
As the PAR2-AP had no effect on T G F - ~ ~ activation in HASM cells, we decided to assess the 
expression ofPAR2 by HASM cells. We applied western blotting and RT-PCR to determine the 
expression level of PAR2 protein and mRNA respectively and found that neither was expressed 
in HASM cells. The antibodies and primer sets were functional as expression was detected in 
NHBE cells. There are several published reports demonstrating expression ofPAR2 in ASM cells 
(Chow et af. 2000; Schmidlin et af. 2001; Ebeling et af. 2005; Freund-Michel et af. 2006; Mullan 
et af. 2007), which the findings presented here contradict. . It is possible that the cells used in this 
study have lost their expression of P AR2 as an artefact of cell culture, as all HASM cells were 
used at passage 6. Variability in expression of PAR2 by HASM cells is evident. Some studies 
have reported high expression in HASM (Schmidlin et af. 2001) whereas other have described 
very low level expression (Mullan et af. 2007). However, this confirms that tryptase-induced 
activation o f T G F - ~ ~ can occur independently ofPAR2 cleavage and activation. 
Although it is commonly thought that tryptase mediates many of its effects via cleavage and 
activation of P AR2 it is also known to have several P AR2 independent effects. It is able to 
activate human eosinophils causing the release of eosinophil peroxidise (EPO) from the secretory 
granules (Vliagoftis et al. 2004) and induce proliferation of dog airway smooth muscle cells 
(Brown et al. 2006), all of which are PAR2-independent effects. It has also been shown to 
stimulate proliferation of HASM cells via a completely non-proteolytic mechanism (Brown et al. 
2 ~ 0 2 ) . . Furthermore, tryptase can cleave and inactivate eotaxin and RANTES in a PAR2 
independent manner (Pang et al. 2006). 
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These data show that tryptase can activate T G F - ~ ~ without affecting levels of total T G F - ~ ~ present 
in cell supernatants. This contradicts data from a separate group who found that both tryptase and 
the PAR2-AP (SLIGKV-NH2) cause increased expression o f T G F - ~ ~ mRNA and protein (Berger 
et al. 2003). NHBE cells, which I have shown express P AR2, were used to investigate the effect 
oftryptase and the PAR2-AP on T G F - ~ ~ released from cells that express PAR2. However, release 
of T G F - ~ ~ from NHBE cell was unaffected by either tryptase or PAR2-AP, suggesting that 
activation ofPAR2 does not lead to increased release of latent T G F - ~ ~ in this cell type. However, 
NHBE cells are not very contractile thus it is possible that in HASM cells that express P AR2, 
agonists ofPAR2 cause downstream expression and activation o f T G F - ~ , , as in the case of Berger 
et al (2003). 
In conclusion we have shown that tryptase activates latent T G F - ~ ~ from HASM cells in vitro via a 
proteolytic but P AR2 independent manner. It is possible that tryptase is released from activated 
mast cells, which infiltrate the smooth muscle layer of asthmatics (Brightling et al. 2002), during 
an asthma exacerbation. Released tryptase could activate T G F - ~ ~ sequestered in the ECM of the 
surrounding cells, which could contribute to the development of airway remodelling (discussed in 
Introduction section 1.4.5) 
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4 Activation of TGF - ~ ~ by HASM Cells In Response to Mechanical 
Wounding 
4.1 Rationale 
As discussed in Introduction section 1.1.1, the airways are constantly challenged with agents from 
the external environment such as pollution, viruses etc, which can cause damage or injury to the 
airways. In non-asthmatic individuals this causes no problems and the insults from the external 
environment are dealt with adequately by the epithelial barrier and the innate immune system. 
However, there is evidence to suggest that the epithelial layer of asthmatics is abnormal 
compared with non-asthmatics and becomes damaged more easily resulting in shedding of 
epithelial cells (Laitinen et al. 1985; Jeffery et al. 1989). In vitro mechanical wounding of cell 
mono layers can be used to simulate the cell injury that ~ c u r s s in vivo (Puddicombe et al. 2000; 
Howat et al. 2002), a method that has been extensively used to study the effects of epithelial 
damage. It has been shown previously that wounding epithelial cells causes activation of both 
T G F - ~ l l and T G F - ~ 2 2 (Howat et al. 2002) and increased expression o f T G F - ~ 2 2 (Puddicombe et al. 
2000). 
The effects of in vitro wounding on the ASM layer are less well studied. The location of the ASM 
layer within the airway wall, below the epithelium and basement membrane, means that it is 
unlikely to become damaged to any significant degree in asthma despite extensive damage to the 
epithelium. However, one study has shown that conditioned media from wounded bovine ASM 
cells has increased TGF-p activity (Coutts et al. 2001), and a further study found that expression 
of type I and type II TGF-p receptors by bovine ASM cells is increased following mechanical 
wounding (Chen et a/. 2002). 
In addition to its use as a model of cell injury, mechanical wounding of cells can also stimulate 
cell migration (Savani et al. 1995; Li et al. 2003; Wadsworth et al. 2006). Migration of ASM 
116 
cells is thought to contribute to the increased ASM mass evident in the remodelled airways of 
asthmatic patients. It is possible that stimulating ASM cells to migrate results in endogenous 
activation of T G F - ~ ~ since cell supernatants from wounded ASM cells has increased T G F - ~ ~
activity (Coutts et al. 2001), however, the mechanism of activation has not been investigated. 
4.2 Aims 
The effects of mechanical wounding on T G F - ~ ~ activation by HASM cells have not been 
investigated so it is the aim of this work to establish if HASM cells are capable of activating 
T G F - ~ ~ in response to wounding using an in vitro wound model. If activation occurs neutral ising 
antibodies will be used to determine which of the three T G F - ~ ~ isoforms are activated. The 
mechanism o f T G F - ~ ~ activation (see chapter 1.4.2) will also be investigated. 
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4.3 Results 
4.3.1 Basal Expression of Active and Total T G F - ~ ~ by HASM Cells 
The basal expression of both active and latent T G F - ~ ~ by HASM cells was determined using 
TMLC reporter cells and the ability to activate L - T G F - ~ ~ by acid treatment (see Methods section 
2.7). Following acidification and neutralisation of unstimulated HASM cells, which activates all 
available latent T G F - ~ ~ in the ECM and culture media (Brown et al. 1990), TMLC reporter cells 
were added to the HASM cells and the luciferase activity measured after 16 hours. TMLC were 
also added to HASM cells that had not been acidified to measure basal levels of active T G F - ~ . .
Under basal conditions HASM cells activate latent T G F - ~ ~ as shown by 33.1 ± 32.1 pglml T G F - ~ ~
activity in cells that were not acid treated (see Figure 4.1). However, following acidification, and 
therefore activation of all latent T G F - ~ , , 1478 ± 891 pglml T G F - ~ ~ activity was detected. This 
means that under basal conditions HASM cells activate ~ m l y y around 2% of the available latent 
T G F - ~ ~ stored intracellularly and in their ECM. 
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Figure 4.1: Basal Expression of Active and T6tal TGF-6 by HASM Cells 
The expression of both active and total TGF-p by HASM cells was determined using TMLC 
reporter cells. TMLC were added to HASM cells or HASM cells following acidification. The 
figure shows the means ± SEM from 2 separate experiments each for 3 HASM cell lines. 
4.3.2 Optimising Wound Model 
Several different methods of wounding cell monolayers have been described using both pipette 
tips and rubber policemen (Savani et al. 1995; Chen et al. 2002; Howat et al. 2002). In order to 
optimise the wound model for the purposes of this study HASM cells were wounded by a variety 
of pipette tips and to varying degrees. The types of wound used are illustrated in Table 4.1. 
Following wounding, the cells were washed twice in PBS to remove any cell debris. RNA was 
collected after 8 hours in order to allow any TGF-p activated to bind to its receptor and initiate 
gen.e transcription . Following reverse transcription (Methods section 2.3.4) the cDNA was 
subjected to QPCR analysis (see Methods section 2.4) to assess expression of the TGF-p-
inducible gene PAIl . The primer are outlined in Appendix 9.7 . 
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Sample Number Type of Wound Pipette Tip Size 
1-2 No Wound N/A 
3-4 CD 1 O ~ 1 1
5-6 EB 1 O ~ 1 1
7-8 EB 1 0 0 0 ~ 1 1
9-10 ~ ~ 1 O ~ 1 1
11-12 CD 1 0 0 0 ~ 1 1
Table 4.1: Overview of Types of Wound 
This table outlines the different types of wound used to optimise the wounding model. Each line 
represents a single scratch with a pipette tip. 
As shown by Figure 4.2, the type of wound that produced the largest increase in PAil expression 
after 8 hours was a single scratch across diameter of well with a 1 O ~ l l pipette tip, which gave a 
71.99 ± 17.33 fold increase in PAil expression. Scratching a criss-cross in the well using a 1 O ~ 1 1
pipette tip was the second most effective technique resulting in an 11.04 ± 3.7 fold increase in 
" 
PAil mRNA. However, a criss-cross scratch with a 1 0 0 0 ~ 1 1 pipette tip resulted in no increase in 
PAil mRNA. Scratching a grid of 3 vertical and 3 horizontal lines in the wells caused T G F - ~ ~
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activation but the magnitude was less than previously described, resulting in only a 4.07 ± 2.93 
fold increase in PAil mRNA. The final type of wound tested was a single scratch across diameter 
of well using a I O O O ~ I I pipette tip. This resulted in a 6.29 ± 0.69 fold increase in PAIl mRNA. 
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Figure 4.2: Optimising Wound Model 
The wound model was optimised using different techniques of wounding and measuring PAll 
expression in response. HASM cells were wounded by various methods using either a I O ~ I I or a 
I O O O ~ I I pipette tip (see Table 4.1). Cells were washed with sterile PBS to remove any cell debris 
and RNA was collected after eight hours. Data was normalised to the housekeeping gene ~ - 2 M M
and relative PAIl expression calculated using the delta CT equation. This figure shows data from 
2 separate experiments expressed as mean fold increase ± SEM. 
** P<O.Ol 
4.3.3 Effect of Wounding on Expression of the T G F - ~ - I n d u c i b l e e Gene PAIl 
The data presented in Figure 4.2 shows that wounding HASM cells with a single scratch using a 
1 O ~ 1 1 pipette tip produced the largest increase in PAll gene expres ion . This method of wounding 
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was therefore used for all future experiments. HASM cells were wounded and RNA collected 
after 0, 4, 8 and 24 hours. After reverse transcription (see Methods section 2.3.4) the resulting 
cDNA was subjected to QPCR analysis (see chapter 2.4) for the TGF-p-inducible gene PAIl and 
the housekeeping gene p-2M. Figure 4.3 shows that expression of PAIl mRNA increased 
following wounding by 6.9 ± 3.7 fold after 4 hours implying activation of TGF-p. PAIl mRNA 
increased further after 8 hours (21.9 ± 18.5 fold increase). The increase observed did not reach 
statistical significance (P value at 4 hours was 0.198 and at 8 hours it was 0.279). 
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Figure 4.3: Effect of Wounding on PAil Expression 
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HASM cells were wounded as previously described and RNA collected after 0, 4 and 8 hours. 
cDNA was subjected to QPCR analysis for the TGF-p inducible gene PAIl. Wounding caused a 
time-dependent increase in PAil gene expression. The figure shows the means ± SEM from 8 
separate experiments. 
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4.3.4 Effect of Wounding on Levels of Active T G F - ~ ~ Present in Cell Supernatants 
Proteolytic activation of T G F - ~ ~ results in the release of active T G F - ~ ~ into cells supernatants 
(Lyons et al. 1988; Lyons et al. 1990; Taipale et al. 1992; Yu et al. 2000; Mu et al. 2002; Tatler 
et al. 2008). Presence of active T G F - ~ ~ in cell supernatants following wounding would suggest 
that a proteolytic mechanism of T G F - ~ ~ activation. To investigate whether active T G F - ~ ~ is 
released into cell supernatants following wounding levels of active T G F - ~ ~ in cell supernatants 
was determined using a reporter cell assay (see Methods section 2.6). Cells were either wounded 
or left unwounded and cell supernatants collected after 0, 4, 8, 16 and 24 hours. The supernatants 
were used to stimulate TMLC reporter cells (see Methods section 2.6). T G F - ~ ~ activity present in 
cell supernatants from unwounded HASM cells, as shown by luciferase activity in Figure 4.4, 
increased steadily with increasing time. There was no difference in levels of active T G F - ~ ~ present 
in cell supernatants between wounded and unwounded HASM cells. 
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Figure 4.4: Effect of Wounding on Levels of Active TGF-8 Present in Cell Supernatants 
HASM cells were either wounded or left unwounded and cell supernatants collected after 0, 4, 8, 
16 and 24 hours. Levels of active T G F - ~ ~ present in the cell supernatants were determined by 
reporter cell assay. Wounding had no effect on the release of active T G F - ~ ~ into cell supernatants 
at any time point tested over 24 hours. This figure shows the amalgamation of data from 2 
separate experiments expressed as mean relative light units (RLU) ± SEM. 
4.3.5 Effect of Anti-TGF-pl and Anti-TGF-p2 Antibodies on Wound-Induced PAIl 
Expression 
Data presented in Figure 4.3 suggests that wounding results in activation of T G F - ~ ~ by HASM 
cells, as expression of the T G F - ~ - i n d u c i b l e e gene PAIl increased in response to wounding. To 
investigate which isoform of T G F - ~ ~ is activated in response to wounding neutral ising antibodies 
directed against T G F - ~ l l and T G F - ~ 2 2 were used. HASM cells were pre-treated for 30 minutes 
with a n t i - T G F - ~ l l (200ng/ml), a n t i - T G F - ~ 2 2 (20Ong/ml) or an anti-IgGl isotype control 
(200nglml) antibodies then wounded in the presence of antibody. RNA was collected after 0, 4 
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and 8 hours, reverse transcribed and analysed by QPCR. Figure 4.5 shows that addition of an 
anti-TGF-Bl neutralising antibody to the wound model appeared to abrogate wound-induced 
increases in PAIl mRNA. Wounding caused an increase in PAIl mRNA after 4 hours, which was 
blocked by an anti-TGF-BI antibody. There was a minimal increase in PAIl expression at 8 hours 
but it was again blocked by the anti-TGF-Bl antibody. The anti-TGF-BI had no effect on basal 
PAIl expression by HASM cells. The large error bars illustrated by Figure 4.5 show that there 
was large variability between experiments resulting in large values for SEM and statistical 
significance was not reached. 
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Figure 4.5: Effect of Anti-TGF-61 on Wound-Induced PAIl Expression 
HASM cells were wounded in the presence of either 10)!g/ml anti-TGF-BI (dark bars) or an 
equivalent amount of an IgG isotype control antibody(light bars). PAIl gene expression was 
assessed after 0, 4 and 8 hours by QPCR using the primers described in the Appendix. Addition 
of a TGF-BI blocking antibody appeared to abrogate wound-induced increases in PAIl 
expression. This figure shows data from 6 separate experiments amalgamated and expressed as 
mean fold increase in PAIl expression ± SEM. P values less than 0.05 were accepted as 
significant. 
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Addition of an anti-TGF-p2 neutral ising antibody also appeared to inhibit wound-induced 
increases in PAIl mRNA (Figure 4.6). A 2.51 ± 0.73 fold increase in PAll mRNA was recorded 
4 hours after wounding. This was partially inhibited by addition of an anti-TGF-p2 antibody. This 
was also observed 8 hours after wounding. Inhibition of wound-induced increases in PAIl mRNA 
by anti-TGF-p2 did not reach statistical significance. However, the anti-TGF-p2 antibody 
appeared to increase ba eline PAL 1 expression. 
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Figure 4.6: Effect of Anti-TGF-82 on Wound-Induced PAIl Expression 
JlA M cell weI' wounded ill the presence or either IOIlg/ml anti -TGF-p2 (dark bars) or an 
equivalent amount of an Ig isotype control antibody (light bar ). PAIl gene expre ion wa 
as es ed after 0, 4 and 8 hours by QPCR using the primers described in the Appendix. Addition 
orTGF-p2 blocking antib dy appeared to inhibit wound-induced PAll expres ion at both 4 and 8 
hour. This figure how the amalgamation of data from 4 eparate experiment expre sed as 
mean fold increase in PAll mRNA ± SEM. P values Ie s than 0.05 were accepted a significant. 
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4.3.6 Effect of Integrin aVB5 Neutralising Antibody on Wound-Induced PAIl 
Expression 
Wound-induced activation o f T G F - ~ ~ by HASM cells does not result in the release of active TGF-
~ ~ in to cell supernatants, suggesting that the mechanism is not mediated by proteolysis. Integrin-
mediated T G F - ~ ~ activation is another possible mechanism. The integrin a V ~ 5 5 has been shown to 
activate T G F - ~ ~ in other mesenchymal cell types such as myofibroblasts and fibroblasts (Asano et 
al. 2005b; Wipff et al. 2007; Scotton et al. 2009). The role of this integrin in wound-induced 
T G F - ~ ~ activation was investigated. HASM cells were pre-treated with an a n t i - a V ~ 5 5 blocking 
antibody (lOJ,lg/ml) or an IgG1 isotype control (10J,lg/ml) for 30 minutes. Cells were wounded 
and PAIl gene expression assessed after 0, 4 and 8 hours. As shown by Figure 4.7, the a V ~ 5 5
neutral ising antibody appeared to cause an increase in baseline PAIl mRNA. At 4 hours 
wounding caused an increase in PAIl expression (6.93 ± 3.01 fold increase), which returned to 
basal at 8 hours. The antibody completed inhibited the increase in PAIl mRNA observed after 4 
hours (P<0.05). 
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Figure 4.7: Effect ofIntegrin aVOS Neutralising Antibody on Wound-Induced PAIl 
Expression 
HASM cells were wounded in the presence of either anti-aVpS or an isotype control. PAIl gene 
expression was assessed after 0, 4 and 8 hours. Addition of a neutral ising antibody directed 
against aVpS appeared to inhibit wound-induced PAIl expression. Figure shows the 
amalgamation of data from 4 separate experiments expressed as mean fold increase in PAIl 
mRNA ± SEM. 
4.3.7 ExpressIon ofIntegrin Subunits 65 and aV mRNA following Wounding 
QPCR analysis wa applied to mRNA collected from wounded HASM c lis to d l rminc Ih ' 
effect wounding has on the expres ion of the integrin subunits aV and pS using the primers 
described in Appendix 9.7. Figure 4.8 demonstrates that wounding HASM cells causes a time 
dependent increase in expression of mRNA for the aV integrin ubunit. he increase in aV 
mRNA was observed after 4 hours of wounding and is increased further after 8 hours. By 24 
hours levels of aV mRNA had returned almost to basal. 
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Figure 4.8: Effect of Wounding on Expression of aV Integrin Subunit 
I 
HASM cells were wounded and expression of aV integrin subunit mRNA was assessed by QPCR 
after 0, 4, 8 and 24 hours. Wounding HASM cells causes increased expression of the aV integrin 
subunit at mRNA level. This figure shows the amalgamated data from 3 separate experiments 
expressed as fold increase over basal ± SEM. Statistical analysis was perfonned using ANOV A 
comparing all data sets to the 0 hour data set. 
** p<O.OI 
Similar levels of increased expression of mRNA for the ~ S S integrin ubunit were observed 
foil wing wounding (Figure 4.9). Like aV, ~ S S mRNA was increa ed after 4 hour of wounding 
and increased further after 8 hours (24 .09 ± 18.49). However, unlike the expression of aV 
mRNA, levels of ~ 5 5 mRNA remained elevated at 24 hour although reduced from 8 hours. 
However, none of these data were statistically significant. 
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Figure 4.9: Effect of Wounding on Expression of 65 Integrin Subunit 
HASM cells were wounded and expression of ~ 5 5 integrin subunit mRNA was assessed by QPCR 
after 0, 4, 8 and 24 hours. Wounding HASM increases expression of the ~ 5 5 integrin subunit at 
mRNA level. This figure shows amalgamated data from 3 separate experiments expressed as fold 
increase over basal ± SEM. 
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4.4 Discussion 
The effects of wounding airway epithelial cells have been extensively studied. Work by other 
authors has shown that wounding epithelial cells causes activation of both T G F - ~ 1 1 and T G F - ~ 2 2
(Howat et al. 2002) and increased expression of T G F - ~ 2 2 (Puddicombe et al. 2000). The aims of 
this chapter were to determine whether in vitro wounding of HASM cells could activate T G F - ~ . .
Data from these experiments were extremely variable resulting in little or no statistical 
significance in most experiments. Experimental variability occurred both between separate 
experiments and between replicates in a single experiment. The wound model was optimised 
using various different types of wound and the wound that produced the largest and most 
consistent response was used in subsequent experiments. However, large variability remained a 
problem. Due to this variability, conclusions based on the data are difficult to make. The results 
described here suggest that HASM cells can activate T G F - ~ ~ in response to wounding since 
expression of the T G F - ~ - i n d u c i b l e e gene PAil did increase inconsistently following wounding. 
Experiments were performed using neutralising antibodies against T G F - ~ l l and T G F - ~ 2 2 to 
confirm that the increase in PAIl expression was caused by T G F - ~ ~ activation and to determine 
which isoform o f T G F - ~ ~ is activated. Addition o f a n t i - T G F - ~ 2 2 appeared to affect wound-induced 
PAIl expression by HASM cells. However, the data also suggests that T G F - ~ l l might be involved 
in the response to wounding. The data also suggests that the mechanism could be mediated by the 
widely expressed integrin a V ~ 5 . .
Release of active T G F - ~ ~ into cell supernatants was not increased following wounding implying 
that if T G F - ~ ~ is activated by HASM cells in response to wounding then the activated T G F - ~ ~
remains bound to the cell surface. This observation excludes the possibility that proteolysis is 
involved in wound-induced T G F - ~ ~ activation by HASM. All previous mechanisms of T G F - ~ ~
activation that involve proteolysis result in the liberation of active T G F - ~ ~ into cell supernatants 
( L y o ~ s s et al. 1988; Lyons et al. 1990; Taipale et al. 1992; Yu et al. 2000; Mu et al. 2002; Tatler 
et al. 2008), due to the proteolytic cleavage or degradation of LAP. 
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As discussed in Introduction section 1.4.2.3 , several integrins have been shown to activate TGF-
~ ~ in vitro (Munger et al. 1999; Mu et al. 2002; Asano et al. 2005b; Jenkins et al. 2006; Wipff et 
al. 2007). A fundamental role for integrin mediated activation has been suggested since mutation 
of the integrin binding domain in the LAP of TGF - ~ ~1 in mice causes a phenotype that 
recapitulates the phenotype o f T G F - ~ 1 1 knockout mice (Yang et al. 2007). Furthermore, mice null 
for both a V ~ 6 6 and a V ~ 8 8 share many developmental defects with T G F - ~ 1 1 null mice (Aluwihare et 
al. 2009). However, it is likely that other T G F - ~ - a c t i v a t i n g g integrins are involved in the 
pathogenesis of disease. It has previously been shown that the integrin a V ~ 5 5 can mediate T G F - ~ ~
activation in myofibroblasts (Wipff et al. 2007) and fibroblasts (Asano et al. 2005a; Scotton et al. 
2009). Furthermore, wounding of HASM cells is likely to cause changes in cell shape. Therefore 
it was interesting to investigate the role of this integrin in this model. Addition of a neutralising 
antibody directed against the integrin a V ~ 5 5 appeared to abrogate wound-induced T G F - ~ ~
activation. Contraction of myofibroblasts, which like HASM cells are mesenchymal in origin and 
have many similarities to HASM cells, causes T G F - ~ ~ activation via a V ~ 5 5 (Wipff et al. 2007). 
Changes in cells shape and cell migration leads to reorganisation of the actin cytoskeleton, the 
formation of stress fibers and the presence of traction forces from the ECM. Reorganisation of the 
cytoskeleton has been implicated in integrin-mediated T G F - ~ ~ activation (Munger et al. 1999; 
Wipff et al. 2007; Xu et al. 2009). It is therefore plausible that HASM cells are capable of 
activating T G F - ~ ~ via the a V ~ 5 5 integrin in response to wounding. 
The precise mechanism of a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation has not yet been fully elucidated, 
however, it has been shown that a V ~ 5 5 interacts with both T G F - ~ R I I and T G F - ~ R I I I receptors 
within clathrin-coated vesicles (Asano et al. 2006). This suggests that once activated, active TGF-
~ ~ is internalised with a V ~ 5 5 and both types of T G F - ~ ~ receptor. It has been proposed that such 
internalisation of active T G F - ~ ~ would potentiate T G F - ~ ~ signalling by sequestering T G F - ~ ~ away 
from inhibitors of T G F - ~ ~ signalling such as Smad7 and Smurf2 (Di Guglielmo et al. 2003). It is 
therefore possible that the effects of a V ~ 5 5 on T G F - ~ ~ signalling are twofold; it may cause T G F - ~ ~
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activation and help potentiate T G F - ~ ~ signalling once it is activated by interacting with T G F - ~ ~
receptors. 
The results presented here also show that mechanical wounding of HASM cells causes increased 
expression of both aV and ~ 5 5 integrin subunits at the mRNA level. This may be via autocrine 
induction following T G F - ~ ~ activation because T G F - ~ ~ causes increased expression of ~ 5 5 mRNA 
(Sheppard et al. 1992; Lai et al. 2000; Kintscher et al. 2002) and the promoter of the ~ 5 5 gene 
contains a T G F - ~ - r e s p o n s i v e e element (Lai et al. 2000). However, existing data concerning the 
effects of T G F - ~ ~ on aV mRNA are contradictory. Expression of aV is increased in response to 
T G F - ~ ~ in human cells (Chin et al. 2003) but not in guinea pig cells (Sheppard et al. 1992). In 
light of these studies, it is not surprising that mechanical wounding of HASM cells, which 
probably causes T G F - ~ ~ activation, results in increased expression of aV and ~ 5 5 mRNA. This 
could provide a positive feedback loop for the cells, where a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation 
causes increased cell surface expression of a V ~ 5 5 integrin which in turn enhances the ability of the 
cells to activate T G F - ~ ~ via the a V ~ 5 5 integrin. It is widely believed that expression of the aV 
subunit is less important with regards to cell surface expression of a V containing integrins than 
expression of the ~ ~ subunit. It is thought that the a V subunit is synthesised in excess, while 
expression of the ~ ~ subunits is tightly regulated, resulting in a limited number of complete 
integrin heterodimers being expressed on the cell surface (Sheppard et al. 1992). The effects of 
activated T G F - ~ ~ on expression of the ~ 5 5 subunit in this model are likely to influence cell surface 
expression of a V ~ 5 5 more profoundly than the effects of TGF - ~ ~ on expression of the a V subunit. 
The continued irregularities and variability in the data were likely to be due to the nature of the 
wound model used. It was impossible to completely control the size of the wound both between 
replicates and between experiments. Even taking utmost care, mechanically wounding a 
monolayer of HASM cells sometimes resulted in lifting a large section of the monolayer from the 
plate causing a very large wound area. Occasionally some of these cells would re-adhere to the 
plate but oftentimes they would become completely detached and die. Cell death results in the 
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release of a variety of mediators which may influence the response of the remaining cells to 
wounding. Due to the number of problems using the wound model and the inconsistency of the 
data it was concluded that the wound assay was not a suitable model of studying the mechanism 
o f T G F - ~ ~ activation in HASM cells and further experiments were not performed. However, these 
data raised the interesting possibility that HASM contraction could lead to T G F - ~ ~ activation via 
the C l V ~ 5 5 integrin, which could be studied using different experimental methods. 
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5 LPA-Induced T G F - ~ ~ Activation is via a V ~ 5 5 Integrin 
5.1 Rationale 
The results presented in the previous chapter raised the possibility that HASM cells could activate 
T G F - ~ ~ in response to mechanical wounding via the cell surface integrin a V ~ 5 . . Activation of 
T G F - ~ ~ by a V ~ 5 5 has been described in various other cell types including myofibroblasts in 
response to cellular contraction (Wipff et al. 2007). In addition to its use as a model of cellular 
injury, wounding can also be used as a stimulus of cell migration (Savani et al. 1995; Wadsworth 
et al. 2006). There are many similarities between the cellular processes of migration and 
contraction, both of which require reorganisation of the actin cytoskeleton and traction forces 
from the ECM. 
Airway hyper-responsiveness (AHR) to asthmatic stimuli and enhanced bronchoconstriction are 
significant features of asthma and ASM cells are the main cell type responsible. Contraction of 
airway smooth muscle cells occurs due to increased levels of phosphorylated myosin light chain 
(MLC), which interacts with the actin filaments of the cytoskeleton to cause cell contraction. 
Levels of phosphorylated MLC increase due to either an increase in intracellular calcium levels, 
which activates myosin light chain kinase to phosphorylate MLC, or by inactivation of myosin 
light chain phosphatase (MLCP) by the cytoplasmic proteins RhoAlRho kinase (Kimura et al. 
1996), resulting in accumulation of levels of phosphorylated MLC. 
There is evidence to suggest that the ASM cells themselves are fundamentally altered in asthma, 
contributing to enhanced bronchoconstriction and AHR. Primary cells isolated from asthmatic 
patients are more contractile than cells from non-asthmatic individuals in a cell culture model 
(Ma et al. 2002; Matsumoto et al. 2007), suggesting that it is the ASM cells that are different 
rather than the influence of any factors present in the environment of the asthmatic airway. Wipff 
and colleagues (Wipff et al. 2007) have shown that inducing contraction of myofibroblast results 
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in T G F - ~ ~ activation. However, the effects of ASM cell contraction on T G F - ~ ~ activation, 
especially in the context of asthma and airway remodelling, have not been investigated. 
Lysophosphatidic acid is a soluble, bioactive phospholipid released from activated platelets and is 
present in serum (Eichholtz et al. 1993). It is a contraction agonist for smooth muscle 
(Chrzanowska-Wodnicka et al. 1996; Ainslie et al. 2004) and many other cell types. Furthermore, 
it has been shown to enhance contraction of HASM cells in response to several contraction 
agonists and leads to the formation of actin stress fibers in ASM cells and airway epithelial cells 
(Toews et al. 2002; Hirakawa et al. 2007; Xu et al. 2009). LPA induces cell contraction via 
activation of one of 4 LPA receptors (named LPA receptor I(LPARI), LPA receptor 2 (LPAR2) 
LPA receptor 3 (LPAR3) and LPA receptor 4 (LPAR4», all of which are G protein coupled 
receptors (GPCRs). Following receptor activation by LPA, the G12/13 proteins coupled to the 
receptor dissociate and bind to a Rho-specific guanine nucleotide exchange factor (GEF). The 
GTPase Rho, which is part of the Ras superfamily of proteins, is subsequently activated and in 
tum activates Rho kinase. Rho kinase is then able to phosphorylate both MLCK and MLC 
resulting in cytoskeletal changes and cell contraction. For a summary of this pathway see Figure 
5.1. 
In addition to its effects on cell contraction LPA has been implicated in wound repair and in 
asthma pathogenesis. Concentrations of LPA are increased in bronchoalveolar lavage fluid 
(BALF) following allergen challenge (Georas et al. 2007). It may contribute to airway 
inflammation by increasing infiltration of eosinophils and neutrophils in to BALF (Hashimoto et 
al. 2003) and to AHR (Hashimoto et al. 200 I). There are also several studies showing that LP A 
can increase expression of several inflammatory cytokines that are involved in asthma 
pathogenesis, including IL-13 and IL-8, through activation of the transcription factor NFlCB 
(Cummings et al. 2004; Rubenfeld et al. 2006; Klemm et al. 2007; Kalari et al. 2009). 
Furthermore, LPA is a potent mitogen for human ASM cells (Cerutis et al. 1997; Ediger et al. 
2001) and can enhance fibronectin assembly (Olorundare et al. 2001) implicating it in airway 
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remodelling. It has previously been shown to induce a V ~ 6 6 integrin-mediated T G F - ~ ~ activation 
from airway epithelial cells via activation of RhoA and the G protein Gaq (Xu et al. 2009). 
However, a V ~ 6 6 expression is restricted to epithelial cells. The effects of LPA stimulation on 
T G F - ~ ~ activation by HASM cells have not been investigated. 
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Figure 5.1: Overview of LPA-Induced Contraction 
This is a schematic diagram illustrating how binding of LPA to its GPCR on the cell surface 
results in cell contraction. Activation of the LPA receptor causes dissociation of its associated G 
proteins, which following interaction with a guanine exchange factor activate RhoA. RhoA 
activates Rho kinase, which phosphorylates MLC and MLCP. MLC is activated upon 
phosphorylation and is able to initiate cell contraction. Phosphorylation of MLCP renders it 
unable to dephosphorylate MLC, contributing to increased intracellular levels of phosphorylated 
MLC. 
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5.2 Aims 
The aims of this chapter were to determine whether LPA can cause T G F - ~ ~ activation from 
HASM cells by inducing cytoskeletal changes. Using HASM cells isolated from asthmatic 
patients, any differences in T G F - ~ ~ activation in response to LPA stimulation by asthmatic HASM 
cells compared with non-asthmatic HASM cells will be determined. 
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5.3 Results 
5.3.1 Concentration-Response ofLPA on T G F - ~ ~ Activation 
To assess the effect of LPA stimulation on T G F - ~ ~ activation by HASM cells a co-culture of 
TMLCs with HASM cells was stimulated in duplicate with 0.1 , 1, 10 and 100JlM LPA. LPA 
caused a concentration-dependent increase in T G F - ~ ~ activation (Figure 5.2). The lowest 
concentration tested (O.lJlM) had no effect on T G F - ~ ~ activation compared with media alone. All 
other concentrations tested caused an increase in T G F - ~ ~ activation. Stimulation with 100JlM LPA 
caused the largest increase in T G F - ~ ~ activation (11S.3 ± 32.S pg/ml T G F - - , , p<O.OI). 
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Figure 5.2: Concentration-Response ofLPA on TGF-6 Activation 
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A co-culture ofHASMs and TMLCs was stimulated in duplicate with 0, 0.1, I, 10 and 100JlM 
LPA. LPA caused a concentration-dependent increase in T G F - ~ ~ activity. This figure shows the 
amalgamation of data from 3 independent experiments using 3 separate HASM cell lines. Data is 
expressed as mean T G F - ~ ~ activity ± SEM. P values less than 0.05 were accepted as significant. 
* P<0.05 **P<O.OI 
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LPA is found in varying concentrations in several bodily fluids . In serum its concentration ranges 
from around 1-51lM but local concentrations at sites of injury are likely to be higher (Eichholtz ef 
af. 1993). In light of this another concentration-response experiment was performed using 
physiologically relevant LPA concentrations. Since all 3 HASM cell lines in the previous 
experiment responded in a similar manner to one another, one cell line was selected for further 
studies. A co-culture of HASM cells and TMLCs was stimulated with 0, 5, 10 and 20IlM. In the 
absence of LPA no T G F - ~ ~ activity was detected. However as found previously a concentration-
dependent increase in T G F - ~ ~ activity following stimulation with LPA was observed. The highest 
concentration tested in this experiment was 20IlM. 
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Figure 5.3: Physiological Concentration-Response ofLPA on TGF-I} Activation 
A co-culture of HASMs and TMLCs was stimulated in duplicate with 0 5, 10 and 20llM LPA. 
LP A caused a concentration-dependent increase in TGF - ~ ~ activity. This figure shows the 
amalgamation of data from 3 independent experiments using I HASM cell line. Data is expressed 
as mean T G F - ~ ~ activity ± SEM. P values less than 0.05 were accepted as significant. 
* P<0.05 **P<O.Ol 
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5.3.2 Effect of LP A Stimulation on PAIl Expression by HASM Cells 
To further investigate whether LPA causes T G F - ~ ~ activation by HASM cells, expression of the 
T G F - ~ - i n d u c i b l e e gene PAIl was assessed following LPA stimulation using QPCR (see Methods 
section 2.4). HASM cells were stimulated in duplicate with 2 0 ~ M M LPA in the presence or 
absence of a pan T G F - ~ ~ neutralising antibody at l O ~ g l m l . . Total cell RNA was collected after 0, 
4,6 and 8 hours and reverse transcribed (see Methods section 2.3.4). Stimulation ofHASM cells 
with 2 0 ~ M M LPA caused a time-dependent increase in PAIl expression (p<O.05), which was 
almost completely abrogated by addition of a pan T G F - ~ ~ neutralising antibody (p<0.05). 
Increased expression of PAIl in response to LPA stimulation was observed at the earliest time 
point tested (4 hours). Levels of PAIl remained elevated after 6 hours of stimulation with LPA 
(3.73 ± 2.21 fold increase). A further increase in PAIl expression was detected after 8 hours of 
LPA stimulation (9.59 ± 2.53 fold increase). Addition of a p a n - T G F - ~ ~ neutralising antibody 
abrogated LP A induced increases in PAIl gene expression. 
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Figure 5.4: Effect ofLPA Stimulation on Expression of PAIl 
HASM cells were stimulated in duplicate with 20/lM LPA with or without the addition of a pan-
T G F - ~ ~ neutralising antibody and PAIl gene expression was assessed by QPCR. LPA induced a 
time-dependent increase in PAIl expression, which was abrogated by addition of a pan T G F - ~ ~
neutralising antibody. This is a representative figure from 3 separate experiments. Data is 
expressed as mean fold increase in PAIl mRNA ± SEM. P values less than 0.05 were accepted as 
significant. 
5.3.3 Effect ofLPA on Nuclear Translocation ofSmad2 and Smad3 
The first step following activation of T G F - ~ ~ is phosphorylation of Smads 2 and 3 and their 
subsequent translocation to the cell nucleus (see Introduction section 1.4.3). It was useful to 
develop an alternative method of measuring T G F - ~ ~ activation. The translocation of many 
transcription factors can be assessed by isolating cytoplasmic and nuclear fractions of cell protein 
and using western blotting to detect a specific transcription factor (Clarke et al. 2008; Clifford et 
al. 2008). It was hypothesised that by isolating nuclear and cytoplasmic fractions of protein and 
using an antibody directed against Smad2 and Smad3 it would be possible to detect the 
translocation of these Smads from the cytoplasm into the nucleus. To investigate this, HASM 
cells were stimulated with 2ng/ml recombinant T G F - ~ l l and cytoplasmic and nuclear fractions of 
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protein isolated after 0, 15, 30, 45 and 60 minutes. Following separation of the proteins by SDS-
PAGE the membrane was probed with anti-Smad2/3. As Figure 5.5 shows, Smad 2 and 3 
(Smad2/3) translocated from the cytoplasm to the nucleus following TGF-p stimulation. 
Translocation of Smad2/3 was evident after just 30 minutes of stimulation and continued up to 1 
hour. Loading controls of GAPDH for the cytoplasmic fractions and lamin AC for the nuclear 
fractions are also shown. 
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Figure 5.5: Translocation of Smad2/3 to Nucleus Following TGF-61 Stimulation 
HASM cells were stimulated with 2ng/ml TGF-pl and nuclear and cytoplasmic fractions of cell 
protein were isolated. Smad2 and Smad3 translocate from the cytoplasm to the nucleus in a time-
dependent manner. Time shown is minutes following TGF-p stimulation. This figure is 
representative of three independent experiments. Doublet Bands corresponding to Smad2/3 were 
observed at 52kD. This figure also shows the GAPDH and lamin AC loading controls for the 
cytoplasmic and nuclear fractions respectively. 
5.3.4 Effect of LPA-Stimulation on Translocation ofSmad2 and Smad3 to the Nucleus 
In order to confirm that LPA causes TGF-p activation by HASM cells, cells were stimulated with 
LPA and cytoplasmic and nuclear fractions isolated after 0, 60, 120, 180 and 240 minutes. 2 5 ~ g g
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of protein was subjected to SDS-PAGE and the resulting membrane probed with a Smad2/3 
antibody. Figure 5.6 shows that stimulation of HASM cells with LPA caused translocation of 
Smad2/3 from the cytoplasm to the nucleus. Increased levels of Smad2/3 in the nucleus were 
evident after 60 minutes of stimulation and further increases seen at 120, 180 and 240 minutes. A 
decrease in Smad2/3 levels in the cytoplasmic fraction was most evident at 240 minutes. 
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Figure 5.6: Translocation of Smad2/3 in Response to LPA Stimulation 
HASM cells were stimulated with 20 11M LPA and nuclear and cytoplasmic fractions of cell 
protein isolated after 0, 60, 120, 180 and 240 minutes. LPA caused a time-dependant 
translocation of Smad2 and Smad3 from the cytoplasm into the nucleus. This figure is 
representative of three separate experiments. Bands corresponding to Smad2/3 were observed at 
52kD. This figure also shows the GAPDH loading control for the cytoplasmic fractions and the 
lamin AC loading control for the nuclear fractions. 
5.3.5 Effect of aVB5 Neutralising Antibody on TMLC and Co-culture 
Results presented in the previous chapter suggested that HASM cells could activate TGF-p via 
the integrin aVp5 in response to mechanical wounding. The role of this integrin in LPA-induced 
TGF-p activation was therefore investigated using a neutralising antibody against aVp5 . To 
determine the effect this antibody had on the response of the TMLCs, the effect of the antibody 
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on a TGF-pl standard curve was investigated. TMLCs were stimulated in duplicate with 2S0, SOO 
and 1000pg/ml recombinant TGF -P 1 with or without 10Jlg/ml anti-a VpS. This was repeated 
stimulating HASM cells co-cultured with TMLCs. The TMLC responded in a concentration-
dependent manner to TGF-p1 (Figure S.7). The response of the TMLCs to TGF-p did not 
significantly alter in the presence of an IgG 1 isotype control antibody. In the presence of the anti-
aVpS antibody the standard curve did shift down (P<O.OS) but a concentration dependent increase 
in RLU was still evident: the highest concentration of 1000pg/ml TGF-p1 resulted in 1346.S ± 
49.S RLU in the presence of an isotype control antibody and 1089 ± 0 RLU in the presence of the 
aVpS neutralising antibody. 
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Figure 5.7: Effect of aV05 Neutralising Antibody on TMLC 
TMLC were stimulated with 0, 2S0, SOO and 1000 pg/ml TGF-p alone, with 10Jlg/ml anti-aVpS 
or with 10Jlg/ml isotype control. Anti-aVpS antibody had an inhibitory effect on the response of 
the TMLCs but the gradient of the slope remained unchanged. This figure represents 1 
e x p e ~ n t e n t . .
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To detennine whether the a n t i - a V ~ 5 5 antibody had an effect on the response of the TMLCs when 
in co-culture with HASM cells the experiment was repeated stimulating HASM cells in co-
culture with TMLCs. The co-cultured was stimulated as before with 0, 250, 500 and 1000 pg/ml 
T G F - ~ l l with or without either 101lg/ml a n t i - a V ~ 5 5 or 101lg/ml isotype control. As found 
previously the co-culture responded in a concentration dependent manner to increasing 
concentrations of recombinant T G F - ~ ~1 (Figure 5.8). Addition of an isotype control antibody did 
not significantly affect this response. Addition of the a V ~ 5 5 neutralising antibody had an 
inhibitory effect on the response of the TMLC in the co-culture (P<0.005) as found previously 
(Figure 5.7), however, there was no change in the gradient ofthe slope. In the co-culture assay, it 
is likely that basal a V ~ 5 5 mediated T G F - ~ ~ activation by the TMLCs is responsible for the shift in 
the curve. These data illustrate the importance of using more than one assay of TGF - ~ ~ activation 
in these studies. 
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Figure 5.8: Effect of aV85 Antibody on Co-culture 
1000 
HASM cells in co-culture with TMLC were stimulated with 0,250, 500 and 1000 pg/ml T G F - ~ ~
alone, with 1 0 ~ g / m l l a n t i - a V ~ 5 5 or with 1 0 ~ g / m l l isotype control. A n t i - a V ~ 5 5 antibody had an 
inhibitory effect on the response of TMLC in co-culture with HASM to increasing concentrations 
o f T G F - ~ . . This figure represents 1 experiment. 
5.3.6 Effect o f a V ~ 5 5 Neutralising Antibody on LPA-Induced Luciferase Activity 
After establishing that TMLC could still elicit a concentration-dependent response to T G F - ~ ~ in 
the presence of a n t i - a V ~ 5 , , the role of integrin a V ~ 5 5 in LPA-induced T G F - ~ ~ activation was 
investigated. A co-culture of TMLC and HASM cells was stimulated in duplicate with 2 0 ~ M M
LPA with or without 1 0 ~ g / m l l a n t i - a V ~ 5 5 or an isotype control. Confirming previous results, 
2 0 ~ M M LPA caused a statistically significant (p<O.05) increase in RLU. This increase was 
completely inhibited by addition of 1 0 ~ g / m l l a V ~ 5 5 neutralising antibody (P<O.005). Basal 
luciferase activity was also inhibited by a n t i - a V ~ 5 . .
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Figure 5.9: Effect of aV85 Neutralising Antibody on LPA-Induced RLU 
HASM cells were co-cultured with TMLCs. The co-culture was stimulated with 20flM LPA with 
or without 10flg/ml a n t i - a V ~ ~ . . Addition of a n t i - a V ~ 5 5 completely abrogated LPA-induced 
increases in RLU. This is a representative figure from 3 independent experiments. Data is 
expressed as mean RLU ± SEM. P values less than 0.05 were accepted as significant. 
5.3.7 Effect of A n t i - a V ~ 5 5 on LPA-Induced PAIl Expression 
The data presented in Figure S.9 suggests that LPA-induced TGF-p activation is mediated by the 
integrin aVpS. To confirm the role of aVpS in LPA-induced TGF-p activation by HASM cells, 
HASM cells were timulated in duplicate with 20flM LPA with or without the addition f 
I Oflg/ml a V ~ 5 5 neutrali ing antibody. RNA was collected after 0 and 6 hours and reverse 
tran cribed in to cDNA. This was subjected to QPCR analy i for the genes PAIl and ~ ~ - M . . LPA 
induced a 121 ± 0 fold increase in PAIl mRNA levels (P<O.005) that was significantly, but not 
completely, inhibited by addition of an a n t i - a V ~ S S antibody (P<O.Ol). 
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Figure 5.10: Effect of Anti-aV85 on LPA-Induced PAil Expression 
HASM cells were stimulated in duplicate with 2 0 ~ M M LPA with or without a n t i - a . V ~ S . . Addition 
of the a . V ~ S S neutralising antibody inhibited LPA-induced increase in PAll expression. This is a 
representative figure from 2 independent experiments. Data is expressed as mean ± SEM. P 
values less than O.OS were accepted as significant. 
5.3.8 Effect ofCytochalasin D on TMLC and Co-culture 
To investigate the role of the cytoskeleton in LPA-induced a . V ~ S - m e d i a t e d d T G F - ~ ~ activation an 
inhibitor of cytoskeleton reorganisation, cytochalasin D, was used. To establish whether this 
inhibitor had any effect on the response of the TMLCs its effects on a T G F - ~ l l standard curve 
were investigated. TMLCs were stimulated in duplicate with 2S0, SOO and 1000 pg/ml 
recombinant T G F - ~ l l with or without either l ~ g / m l l cytochalasin D or an equal volume of its 
vehicle DMSO. This experiment was repeated stimulating a co-culture of TMLCs with HASM 
cells. As Figure S.ll shows, addition of cytochalasin D or its vehicle DMSO had no effect on the 
response ofTMLC to increasing concentrations of recombinant T G F - ~ l . .
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Figure S.l1: Effect ofCytochalasin D on TMLC 
1000 
TMLC were stimulated in duplicate with 0, 250, 500 and 1000 pg/ml recombinant T G F - ~ 1 1 with 
or without either IIlg/ml cytochalasin D or an equal volume of its vehicle DMSO. Cytochalasin D 
had no effect on the response of TMLCs to increasing concentrations of recombinant T G F - ~ l . .
This figure shows the data from 1 experiment. 
In order to confirm that cytochalasin D does not affect the responsiveness of TMLCs to T G F - ~ ~
when co-cultured with HASMs the experiment was repeated using TMLCs in co-culture with 
HASM cells. Neither cytochalasin D nor its vehicle DMSO had any effect on the response of the 
co-culture to increasing concentrations o f T G F - ~ 1 1 (Figure 5.12). 
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Figure 5.12: Effect of Cytochalasin D on Co-culture 
1000 
A co-culture of HASM cells and TMLCs was stimulated in duplicate with 0, 250, 500 and 1000 
pglml recombinant T G F - ~ l l with or without either IJ.1g1ml cytochalasin D or an equal volume of 
its vehicle DMSO. Neither cytochalasin D nor its vehicle DMSO had any effect on the response 
of TMLCs to increasing concentrations of recombinant TGF - ~ ~ I. This figure shows the data from 
I experiment. 
5.3.9 Effect ofCytochalasin D on LPA-Induced Luciferase Activity 
To investigate the role of the cytoskeleton in LPA-induced a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation by 
HASM cells cytochalasin D was added to a co-culture of HASMs and TMLCs stimulated with 
LPA. A co-culture ofTMLCs with HASM cells was stimulated in duplicate with 20J.1M LPA with 
the addition of either 1 J.1M cytochalasin D or an equal volume of its vehicle DMSO. Confirming 
previous findings, LP A induced a statistically significant increase in RLU (see Figure 5.13). 
However, when cells were pre-treated with cytochalasin D there was no increase in LPA-induced 
T G F - ~ ~ activation. 
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Figure 5.13: Effect of Cytochalasin D on LPA-Induced Luciferase Activity 
A co-culture ofHASM cells and TMLC was stimulated with 20/lM LPA with or without l/lg/ml 
cytochalasin D. Cytochalasin D inhibited LPA-induced increases in RLU . This is a representative 
figure from 3 separate experiments. Data is expressed as mean RLU ± SEM. 
** P<O.OI Comparing 20/lM LPA with O/lM LPA 
5.3.10 Effect ofCytochalasin Don LPA-Induced PAIl Expression 
To confirm the role of the cytoskeleton in LPA-induced T G F - ~ ~ activation, the effect of 
cytochalasin D on LPA-induced PAIl expression was investigated. HASM cells were timulated 
in duplicate with 20/lM LPA with or without l/lM cytochalasin D. Cells to be treated with the 
inhib itor were pre-treated for 30 minutes prior to the addition ofLPA. RNA was collected after 0 
and 6 hours and PAll gene expression assessed . Pre-treatment with l/lg/ml cytochalasin D 
partially inhibited LPA-induced T G F - ~ ~ activation, P<0.05 (see Figure 5.14). 
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Figure 5.14: Effect of Cytochalasin D On LPA-Induced PAil Expression 
HASM cells were stimulated in duplicate with 20llM LPA with or without lllg//mi cytochalasin 
D. Cytochalasin D partially, but significantly, inhibited LPA-induced PAIl expre ion after 6 
hours of stimulation. This is a representative figure from 3 separate experiments. Data is 
expressed as mean fold increase ± SEM. 
** P<O.O I Comparing LPA treatment at 0 hours with LPA treatment at 6 hours 
P<0.05 Comparing DMSO treatment with cytochalasin treatment at 6 hours 
5.3.11 Concentration-Response of Methacholine on TGF-B Activation 
LPA is known to cause contraction of several cells types. To investigate whether cell contraction 
ofHASM cells per se can activate T G F - ~ , , the muscarinic receptor agonist methacholine, which is 
used clinically to induce HASM contraction, was used to stimulate a co-culture of HASM cells 
with TMLCs. The co-culture was stimulated in duplicate with 0, 10-1°, 10-9, 10-8 10-7 and 10-6 M 
methacholine in the presence or absence of 101lg/ml p a n - a n t i - T G F - ~ . . Methacholine appeared to 
induce T G F - ~ ~ activation in a concentration dependent manner (see Figure 5.\5). The lowest 
concentration tested only activated relatively small amounts of T G F - ~ ~ (2.4 ± 0.1 pg/ml). 
Stimulation of the co-culture with IIlM methacholine caused activation of 52.5 ± 20.9 pg/ml 
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T G F - ~ . . Interestingly, the highest concentration of methacholine tested (lOIlM) had less of an 
effect on T G F - ~ ~ activation than stimulation with IIlM methacholine (only 26.7 ± 11.3 pg/ml). 
However, there was a lot of variability between replicates and so statistical significance was not 
achieved. 
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10pM 
Figure S.lS: Concentration-Response of Methacholine on TGF-B Activation 
HASM cells co-cultured with TMLC were stimulated with 0, 10-1°, 10-9, 10-8, 10-7 and 10-6 M 
methacholine with or without IOIlg/ml anti- T G F - ~ . . Methacholine caused a concentration 
dependent increase in T G F - ~ ~ activation. This is a representative figure from 2 separate 
experiments. Data is expressed as mean ± SEM. 
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5.3.12 Effect of Methacholine on PAIl Expression 
To further investigate whether methacholine causes T G F - ~ ~ activation PAIl gene expression in 
response to methacholine was investigated . HASM cells were stimulated in duplicate with IflM 
methacholine with or without 10flglml anti- T G F - - . . RNA was collected after 0 and 6 hours PAIl 
gene expression assessed by QPCR. Methacholine induced a large increase in PAll expression 
after 6 hours (P<O.005) and this effect was completely inhibited by addition of a p a n - T G F - ~ ~
neutral ising antibody (P<O.005) . 
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Figure 5.16: Effect of Methacholine on PAIl Expression 
HASM cells were stimulated in duplicate with 1 flM methacholine with or without IOflglml anti-
T G F - - . . Stimulation of HASM cells with methacholine causes an increase in PAil expression, 
which is abrogated by a pan T G F - ~ ~ neutralising antibody. This is a representative figure from 3 
separate experiments. Data is expressed as mean ± SEM. 
*** P<O.005 comparing methacholine at 0 hours with methacholine at 6 hours. 
P<O.005 comparing methacholine at 6 hours with methacholine plus a n t i - T G F - ~ ~
at 6 hours. 
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5.3.13 Effect of62 Agonist Formoterol on LPA-Induced PAIl Expression 
The data presented here implicate cytoskeletal reorganisation in LPA-induced T G F - ~ ~ activation. 
Furthermore, the contraction agonist methacholine also stimulated T G F - ~ ~ activation by HASM 
cells. It is therefore possible that contraction of HASM cells results in TGF - ~ ~ activation. ~ 2 2
agonists are a class of asthma drug that are able to cause ASM relaxation (Nials et al. 1994; 
Delmotte et al. 2009). The effects of the ~ 2 2 agonist formoterol on LPA-induced T G F - ~ ~ activation 
were investigated. HASM cells were stimulated in duplicate with 2 0 ~ M M LPA in the presence of 
either I ~ M M formoterol or an equal volume of its vehicle. RNA was collected after 0 and 6 hours 
and PAIl gene expression assessed by QPCR. Confirming previous findings LPA caused an 
increase in PAIl expression (p<0.05). In the presence of 1 ~ M M formoterol this was abolished 
(p<0.05). Formoterol also had an inhibitory effect on the basal PAIl expression reducing it from 
1.04 ± 0.27 to 0.43 ± 0.01 fold increase PAIL 
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Figure 5.17: Effect of Formoterol on LPA-Induced PAIl Expression 
HASM cells were stimulated in duplicate with 20llM LPA in the presence of either lllM 
Formoterol or an equal volume of its vehicle DMSO. Formoterol completely inhibited LPA-
induced increases in PAIl expression. This is a representative figure from 3 separate experiments . 
Data is expressed as mean fold increase in PAIl mRNA ± SEM. 
** P<O.OI Comparing LPA stimulation at 0 and 6 hours 
P<O.Ol Comparing LPA stimulation with LPA + formoterol at 6 hours 
5.3.14 Effect of Formoterol on TMLC and Co-culture 
The data presented in Figure 5.17 shows that the ~ 2 2 agonist formoterol can inhibit LPA-induced 
PAIl expression, which suggests that formoterol can inhibit LPA-induced T G F - ~ ~ activation. To 
confirm that formoterol can abolish LPA-induced T G F - ~ ~ activation its suitability for use in a co-
culture assay was first determined by investigating its effects on the responsiveness of the 
reporter cells. TMLCs were stimulated in duplicate with 250, 500 and lOOO pg/ml recombinant 
T G F - ~ l l with or without 111M formoterol or an equal volume of its vehicle DMSO. Addition of 
formoterol to TMLCs stimulated with increasing concentrations of T G F - ~ ~1 caused an upward 
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shift in the T G F - ~ ~ standard curve (P<0.005). The luciferase activity recorded in the presence of 
formoterol was higher at each concentration of T G F - ~ I I tested than in the presence of T G F - ~ I I
alone. 
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Figure 5.18: Effect of Formoterol on TMLCs 
1000 
TMLCs were stimulated with 0, 250, 500 and 1000 pg/ml recombinant T G F - ~ ~ with or without 
IJ.lM formoterol. Formoterol increased the response TMLCs to a T G F - ~ I I standard curve. This 
figure represents I independent experiment. Data is expressed as mean RLU ± SEM. 
The effect of formoterol on a co-culture of TMLCs with HASM cells was also assessed by 
repeating the experiment on a co-culture of TMLC with HASM cells. Confirming the results of 
the previous experiment (see Figure 5.18), addition offormoterol to a co-culture ofHASM cells 
and TMLCs resulted in an exaggerated response to increasing concentrations of TGF - ~ ~ I, as 
shown by Figure 5.19 (P<0.05). The luciferase activity recorded was increased at each 
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concentration ofTGF-pl in the presence offonnoterol compared with T G F - ~ 1 1 alone. Due to its 
effects on TMLC reporter cells, fonnoterol was not used in a co-culture assay as any inhibitory 
action of fonnoterol on HASM cells might be counteracted by the stimulatory effect of 
fonnoterol on TMLCs. 
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Figure 5.19: Effect of Formoterol on Co-Culture 
1000 
A co-culture ofHASM cells with TMLC's was stimulated with 0, 250, 500 and 1000 pglml TGF-
PI with or without I/-lM fonnoterol. Fonnoterol increased the response ofa co-culture ofHASM 
cells and TMLC to a TGF-pl standard curve. This figure represents 1 independent experiment. 
Data is expressed as mean RLU ± SEM. 
5.3.15 Effect ofLPA on TGF-pActivation by Asthmatic HASM Cells 
A direct comparison of the response of asthmatic HASM cells to LP A stimulation with non-
asthmatic HASM cells was perfonned using co-culture assay. Due to differences in the 
proliferation rate of asthmatic and non-asthmatic HASM cells experiments using different HASM 
cell lines were performed on different days. Differences in HASM cell size between asthmatics 
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and non-asthmatics have been reported (Ebina et al. 1993). In order to exclude the variable of 
these differences in cell size, data was corrected for cell number. Cell number was determined by 
CellTiter Glow assay (see Methods section 2.8), which quantifies cell number by determining 
ATP concentrations following cell lysis. Non-asthmatic and asthmatic HASM cells were co-
cultured with TMLCs and stimulated with 20llM LPA with or without lDl1. All data were 
corrected for cell number. Figure S.20 shows that asthmatic HASM cells elicit an exaggerated 
response to LPA stimulation compared with non-asthmatic HASM cells (P<O.OS). There was very 
little difference in basal TGF-p activation, non-asthmatic cells activated 0.8 ± 0.2 pg/ml xl04 
cells whereas asthmatic cells activated none. However, when stimulated with SIlM LPA non-
asthmatic cells activated 1.5 ± I.S pg/ml xl04 cells compared with asthmatic cells which activated 
11.7 ± 7.6 pg/ml xl04 cells. When stimulated with 10llM LPA, non-asthmatic cells activated 2.8 
± 1.1 pg/ml xl04 cells but the asthmatic cells activated 26.8 ± 10.S pg/ml xl04 cells. Following 
stimulation with 20llM LPA, asthmatic cells activated sigDificantly more TGF-p (p<O.OS) at 30.3 
± 9.1 pglml xl04 cells compared with 7.4 ± 0.6 pglml xl04 cells by the non-asthmatic HASM 
cells. These data show asthmatic HASM cells activate more TGF-p in response to LPA than non-
asthmatic HASM cells. 
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Figure 5.20: Effect ofLPA on TGF-B Activation by Asthmatic HASM Cells 
Non-asthmatic and asthmatic HASM cells were co-cultured with TMLCs and stimulated with 0, 
5, 10 and 20 11M LPA. Asthmatic HASM cells activated more TGF-p in response to increasing 
concentrations of LPA compared with non-asthmatic HASM cells. This figure shows the 
amalgamated data from 6 separate experiments using cells isolated from 3 non-asthmatic donors 
and 3 asthmatic patients. 
5.3.16 Effect ofLPA on PAIl Expression by Asthmatic HASM Cells 
Expression of the TGF-p-inducible gene PAIl by asthmatic and non-asthmatic HASM cells in 
response to LPA was assessed using QPCR. Non-asthmatic and asthmatic HASM cells were 
stimulated in duplicate with 20llM LPA for 0, 4, 6 and 8 hours. Expression of PAIl and P2-M 
mRNA was assessed by QPCR. LPA-induced increases in PAIl have been shown to be mediated 
by TGF-p (Figure 5.4). Confirming earlier findings LPA induced a time-dependent increase in 
PAil expression by both non-asthmatic and asthmatic HASM cells (see Figure 5.21). Expression 
of PAIl by asthmatic HASM cells was greater than expression by non-asthmatic cells at each 
time point tested following LPA stimulation (P<0.05), although basally there was very little 
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difference in PAIl expression between non-asthmatic and asthmatic cells (1.02 ± 0.01 fold 
increase and 1.48 ± 0.31 fold increase respectively). However after 4 hours a 6.75 ± 4.08 fold 
increase in PAIl by asthmatic HASM cells was observed compared with 3.13 ± 0.56 by non-
asthmatic HASM cells. At 6 hours a 16.4 ± 3.39 fold increase by asthmatic HASM cells 
compared with 3.32 ± 0.26 fold increase by non-asthmatic HASM cells was observed. After 8 
hours of LPA stimulation the difference in PAIl expression between the two cell types was less 
pronounced but expression still appeared marginally higher in the asthmatic cells (6.64 ± 3.84 
fold increase in asthmatic cells compared with 6.35 ± 2 fold increase in non-asthmatic cells). 
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Figure 5.21: Effect ofLPA on PAIl Expression by Asthmatic HASM Cells 
Non-asthmatic and asthmatic HASM cells were stimulated in duplicate with 20JlM LA and PAll 
gene expression assessed after 0, 4, 6 and 8 hours. LP A induced PAIl expression in both non-
asthmatic and asthmatic HASM cells, however, larger increasing in PAIl were observed in 
asthmatic HASM cells. N=3 each group. 
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5.3.17 Levels of Total TGF -B Released from Non-asthmatic and Asthmatic HASM Cells 
To investigate whether asthmatic HASM cells sequester more latent TGF-p than non-asthmatic 
HASM cells the levels of total TGF-p released from non-asthmatic and asthmatic HASM cells 
were compared. Unstimulated non-asthmatic and asthmatic HASM cells cultured in 24 well 
plates were treated with 2SIlI IN HCl for 10 minutes to activate all TGF-p present (Brown et al. 
1990). Following neutralisation by addition of2SIlI 1.2N NaOH, TMLCs were plated directly on 
top of the HASM cells and co-cultured for 16 hours. Asthmatic HASM cells released more total 
TGF-p (147.S ± 11.1 pg/ml per 104 cells) than HASM cells from non-asthmatic individuals (8S.9 
± 12.4 pg/ml per 104 cells, P<O.OOS). 
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Figure 5.22: Expression of Total TGF-8 by Non-asthmatic and Asthmatic HASM Cells 
Unstimulated non-asthmatic and asthmatic HASM cells were acid-treated to activate all TGF-p 
present and levels of TGF-p determined by co-culture assay. Asthmatic HASM cells expressed 
higher levels of total TGF-p than non-asthmatic HASM cells. N=3 each group .. Data is expressed 
as mean ± SEM. 
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5.3.18 Effect ofLPA on Fibronectin Expression by HASM Cells 
To investigate whether the increased activation of TGF-p in response to LPA by asthmatic cells 
contributes to airway remodelling, expression of fibronectin was assessed using QPCR. 
Fibronectin is a component of the extracellular matrix that is up-regulated in asthma (Roche et al. 
1989; Araujo et al. 2008). Non-asthmatic, and asthmatic, HASM cells were stimulated in 
duplicate with 20,.,IM LPA, mRNA was collected after 0, 4, 6 and 8 hours and expression of 
fibronectin assessed by QPCR (see section 2.4). LPA had no effect on fibronectin expression in 
non-asthmatic HASM cells. However, expression of fibronectin by asthmatic HASM cells in 
response to LP A stimulation was increased at all time points tested and was a statistically 
significant increase compared with non-asthmatic cells (P<0.005). After 4 hours of stimulation a 
5.46 ± 1.53 fold increase in fibronectin was recorded. At 6 hours, an 11.13 ± 1.93 fold increase 
was detected. The asthmatic HASM cells continued to express more fibronectin than the non-
asthmatic HASM cells after 8 hours of stimulation (5.59 ± 3.91 fold increase and 0.98 ± 0.43 fold 
increase respectively). 
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Figure 5.23: Effect of LP A on Fibronectin Expression by HASM 
Non-asthmatic and asthmatic HASM cells were stimulated in duplicate with 20)lM LPA and 
expression of fibronectin mRNA assessed. Expression of fibronectin mRNA increased in a time-
dependent manner in response to LPA stimulation. N=3 each group. 
5.3.19 Effect of Anti-aVB5 on Increased Activation of T G F - ~ ~ by Asthmatic HASM 
To determine whether an aVpS-independent mechanism is responsible for the increased 
activation ofTGF-p in response to LPA stimulation an anti-aVpS neutralising antibody was used. 
A co-culture of asthmatic HASM cells with TMLCs was stimulated in duplicate with 20)lM LPA 
in the presence or absence of lO)lg/ml of an aVpS neutralising antibody (clone P1f6). Asthmatic 
HASM cells activated TGF-p in response to LPA stimulation as shown by an increase in RLU 
from 8583 ± 1946 to 18221 ± 1146. Addition of this antibody completely inhibited the LPA-
induced increase in RLU, reducing it to 5392 ± 1511 (P<O.OI). Anti-aVpS also reduced the basal 
RLU to 6911 ± 1577. 
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Figure 5.24: Effect of Anti-aV85 on LPA-Induced RLU by Asthmatic HASM 
A co-culture of asthmatic HASM cells with TMLCs was stimulated in duplicate with 20IJ.M with 
or without 101J.g/ml anti-aVpS. Addition of anti-aVpS antibody completely inhibited LPA-
induced increases in RLU when asthmatic HASM cells were co-cultured with TMLC reporter 
cells. This is a representative figure from 3 separate experiments using HASM cells from 3 
asthmatic donors. Data is expressed as mean fold increase in RLU over basal ± SEM. 
** P<O.OI 
5.3.20 Cell Surface Expression of aVp5 Integrin on HASM Cells 
To determine whether the enhanced activation of TGF-p of asthmatic cells in response to LPA is 
caused by increased cell surface expression of aVpS, flow cytometry was performed using an 
anti-aVpS antibody (clone ALULA). Unstimulated non-asthmatic and asthmatic HASM cells 
were stained with 20 lJ.g/m I anti-aVpS followed by a phycoerythrin (PE)-labelled anti-mouse 
secondary antibody (1 :200 dilution). Some cells were stained with secondary antibody alone as a 
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negative control. The fluorescence intensity of the cells was determined using a flow cytometer. 
Data was expressed as fold increase in mean fluorescence intensity (MFI) over cells stained with 
secondary antibody alone. A representative figure from a non-asthmatic HASM cell line is 
shown as Figure 5.25 and a representative figure from a asthmatic HASM cell line is shown as 
Figure 5.26. The mean fold increase in mean fluorescence intensity (MFI) from HASM cells from 
3 non-asthmatic and 3 asthmatic donors was compared. There was no significant difference in 
cell surface expression of a V ~ 5 5 between non-asthmatic and asthmatic donors (Figure 5.27). 
Figure 5.25: Expression of aVB5 Integrin by Non-asthmatic HASM Cells 
This is a representative figure from 3 experiments using HASM cells from 3 separate non-
asthmatic donors. 
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Figure 5.26: Expression of aV65 Integrin by Asthmatic HASM Cells 
This is a representative figure from 3 separate experiments using HASM cells from 3 separate 
asthmatic donors . 
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Figure 5.27: CeU Surface Expression on aV65 Integrin on HASM Cells 
Expression of ( l V ~ 5 5 by both non-asthmatic and asthmatic HASM cells was assessed by flow 
cytometry. There was no difference in the cell surface expression of ( l V ~ 5 5 between non-asthmatic 
and asthmatic HASM cells. Figure shows the data from HASM cells isolated from 3 non-
asthmatic and 3 asthmatic donors. Data is expressed as mean fold increase in MFJ ± SEM. 
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5.3.21 Expression ofLPA Receptor by HASM Cells 
At present 4 distinct LPA receptors have been identified termed LPARl , LPAR2, LPAR3, 
LPAR4. To establish which receptors are expressed by the HASM cells used in this study the 
expression of each of the four receptors at the mRNA level was investigated using RT-PCR (see 
Methods section 2.3). RNA was isolated from unstimulated non-asthmatic HASM cells and 
reverse transcribed into cDNA. The cDNA was subjected to PCR analysis to determine which of 
the four LPA receptors are expressed at the mRNA level. The HASM cells used in the current 
study expressed mRNA for LPARl , LPAR2 and LPAR4 (see Figure 5.28). 
LPAR1 LPAR2 LPAR3 LPAR4 
Figure 5.28: Expression of LPA Receptors 
RNA was collected from unstimulated non-asthmatic HASM cells. Expression of LPAR 1, 
LPAR2, LPAR3 and LPAR4 was assessed by RT-PCR. The HASM cells used in this study 
expressed mRNA for LPARl , LPAR2 and LPAR4. This figure is representative of 3 separate 
experiments using HASM cells from I non-asthmatic donor. 
As Figure 5.28 shows, HASM cells express mRNA for LPARI, LPAR2 and LPAR4. To 
investigate whether there was any difference in expression of these three LPA receptors between 
non-asthmatic and asthmatic HASM cells QPCR was utilised (Methods section 2.4). RNA from 
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unstimulated non-asthmatic and asthmatic HASM cells was collected and reverse transcribed into 
cDNA (see Methods section 2.3.4). Expression of LPARI mRNA by both non-asthmatic and 
asthmatic HASM cells was assessed by QPCR. The basal expression of both LPARl (Figure 
5.29) and LPAR2 (Figure 5.30) did not differ between non-asthmatic and asthmatic HASM cells. 
Unlike LPARI and LPAR2, basal expression of LPAR4 was higher in asthmatic HASM cells 
than in non-asthmatic HASM cells (Figure 5.31). However, this was not statistically significant. 
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Figure 5.29: Expression of LP ARt by HASM Cells 
RNA was collected from unstimulated non-asthmatic and asthmatic HASM cells and expression 
of LPARI was assessed by QPCR. There was no difference in expression of LPARI mRNA 
between non-asthmatic and asthmatic HASM cells. This figure shows the amalgamation of data 
from HASM cells isolated from 10 non-asthmatic and 8 asthmatic donors. Data is expressed as 
mean relative expression ± SEM. 
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Figure 5.30: Expression ofLPAR2 By Asthmatic and Non-asthmatic HASM Cells 
RNA was collected from unstimulated non-asthmatic and asthmatic HASM cells and expression 
of LPAR2 was assessed by QPCR. There was no difference in expression of LPARI mRNA 
between non-asthmatic and asthmatic HASM cells. This figure shows the amalgamation of data 
from HASM cells isolated from lOnon-asthmatic and 8 asthmatic donors . Data is expressed as 
mean relative expression ± SEM. 
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Figure 5.31: Expression of LPAR4 by Asthmatic and Non-asthmatic HASM Cells 
RNA was collected from unstimulated non-asthmatic and asthmatic HASM cells and expression 
of LPAR4 was assessed by QPCR. Non-asthmatic HASM cells expressed more LPAR4 mRNA 
than asthmatic HASM cells. This figure shows the amalgamation of data from HASM cells 
isolated from 8 non-asthmatic and 7 asthmatic donors. Data is expressed as mean relative 
expression ± SEM. 
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5.4 Discussion 
The aim of these studies was to investigate whether LPA induces TGF-p activation in HASM 
cells and explore the mechanism of activation. Using three methods of measuring TGF-p 
activation we have identified a novel mechanism of TGF-p activation in HASM cells involving 
the cytoskeleton and the aVpS integrin. Furthermore, these data show that HASM cells isolated 
from asthmatic patients activate more TGF-p via this pathway than cells isolated from non-
asthmatic individuals. This is the first time that a mechanism of TGF-p activation in response to 
cell activation has been described in asthma. 
During this study a previously unpublished method of measuring TGF-p activation has been used. 
Detection of phosphorylated Smad2 or Smad3 is a commonly used method of assessing TGF-p 
activity (Jenkins et al. 2006; Xu et al. 2009). However, phosphorylated Smad2 and Smad3 were 
very difficult to detect in HASM cells by conventional western blot of whole cell protein extracts. 
Therefore I isolated nuclear and cytoplasmic fractions of cell protein from HASM cells to detect 
the translocation of Smad2 and Smad3 from the cytoplasm to the nucleus, as has been shown for 
other transcription factors (Clarke et al. 2008; Clifford et al. 2008; John et al. 2009). This is the 
first time that TGF-p activity has been measured in this way. 
Previous studies have shown that the aVpS integrin can activate TGF-p in myofibroblasts (Wipff 
et al. 2007) and fibroblasts (Asano et al. 200Sb; Scotton et a/. 2009). However, this is the first 
description of aVpS integrin-mediated TGF-p activation in airway smooth muscle cells. Smooth 
muscle cells are contractile cells, and Wipff and colleagues demonstrated that contraction of 
myofibroblasts causes aVpS-mediated TGF-p activation via a mechanism involving the 
cytoskeleton and requires mechanical tension from the ECM (Wipff et al. 2007). LP A is known 
to induce reorganisation of the cytoskeleton and the formation of stress fibers in several cell types 
(Chrzanowska-Wodnicka et al. 1996; Hirakawa et al. 2007; Xu et al. 2009), suggesting that 
contraction of smooth muscle cells may promote TGF-p activation. The P2 agonist formoterol, 
which induces relaxation of ASM cells (Nials et al. 1994; Delmotte et al. 2009) and is a 
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commonly used asthma therapy (Price et al. 2007), completely inhibited LPA-induced PAIl 
expression, which was previously shown to be mediated by T G F - ~ . . Furthermore, inhibiting 
cytoskeletal reorganisation with cytochalasin D had an inhibitory effect on LPA-induced T G F - ~ ~
activation in HASM cells supporting this hypothesis. However, inhibition o f T G F - ~ ~ activation by 
cytochalasin D was not complete, failing to reduce TGF - ~ ~ activation to basal levels. This may 
suggest that a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation is not entirely mediated via the cytoskeleton and 
other, as yet undiscovered, pathways are involved. It is also possible that cytochalasin D does not 
completely depolymerise microfilaments and thus they could still function in inducing 
cytoskeletal changes. Certainly, incomplete inhibition of integrin-mediated T G F - ~ ~ activation by 
cytochalasin D has been observed in several other studies (Munger et al. 1999; Wipff et al. 2007) 
suggesting that it is not unique to a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation in HASM cells. 
To help corroborate the hypothesis that HASM cell contraction results in T G F - ~ ~ activation we 
used the muscarinic receptor agonist methacholine, which induces ASM contraction and is used 
clinically to induce bronchoconstriction (Boulet et al. 1997; Anderson et al. 2009), to stimulate 
HASM cells and assessed T G F - ~ ~ activation in response. Similar to the effects of LPA, 
methacholine induced a concentration dependent increase in T G F - ~ ~ activation and a T G F - ~ ~
dependent increase in PAIl expression by HASM cells. Although there have been no reports of 
methacholine inducing T G F - ~ ~ activation in HASM cells, activation of T G F - ~ ~ in epithelial and 
subepithelial cells has been observed following allergen challenge in mild asthmatics (Torrego et 
al. 2007). The number of nuclei that stained positively for Smad2, Smad3 and Smad4 increased 
significantly. These patients elicited both EAR and LAR associated with significant decreases in 
FEVI indicating that bronchoconstriction had occurred. Together these data suggest that 
bronchoconstriction could indeed lead to activation o f T G F - ~ ~ in the airway wall. 
D ~ t a a presented here show that HASM cells from asthmatic patients activate more T G F - ~ ~ via the 
a V ~ 5 5 integrin in response to LP A stimulation than cells from non-asthmatic individuals. 
Increased T G F - ~ ~ activation by the a V ~ 5 5 integrin in diseased cells has previously been 
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demonstrated in sclerodenna fibroblasts when compared with control fibroblasts (Asano et al. 
2006). This enhanced T G F - ~ ~ activation was also detected in unstimulated cells, which was not 
seen in asthmatic HASM cells in the present study. Increased activation o f T G F - ~ ~ by sclerodenna 
fibroblasts was attributed to increased cell surface expression of C l V ~ 5 5 (Asano et al. 2006), 
however, no difference in cell surface expression of Cl V ~ 5 5 was found between asthmatic and non-
asthmatic HASM cells in this study. This may reflect a difference in the nature of defect in the 
C l V ~ 5 - m e d i a t e d d T G F - ~ ~ activation pathway between the two diseases. Increased duration of 
exposure of sclerodenna fibroblasts to active T G F - ~ ~ due to their enhanced T G F - ~ ~ activation 
basally, could induce ITGB5 gene expression (Lai et al. 2000), promoting a positive feedback 
loop that ultimately leads to increased activation of T G F - ~ . . However, this does not seem to be 
involved in the enhanced activation o f T G F - ~ ~ by asthmatic HASM cells. 
Our data show for the first time that HASM cells from asthmatic patients activate more T G F - ~ ~
than cells from non-asthmatic individuals in response to LP A stimulation. It is possible that the 
enhanced T G F - ~ ~ activity is merely due to the enhanced total T G F - ~ ~ secreted by HASMs from 
asthmatic patients. However, this possibility is not favoured because the level of total T G F - ~ ~ in 
HASMs from both control and asthmatics was in considerable excess of levels of active T G F - ~ ~
following stimulation with LPA, as we have found in other cell systems (Xu et al. 2009). This 
means that the amount of latent T G F - ~ ~ available was not a rate limiting factor in LPA-induced 
T G F - ~ ~ activation. Furthennore, the enhanced T G F - ~ ~ activity observed in asthmatic HASM cells 
was completely inhibited by blocking the function of the Cl V ~ 5 5 integrin. These data show that 
there was no difference in C l V ~ 5 5 integrin expression between diseased and control cells. This 
suggests that changes in the interaction between the C l V ~ 5 5 integrin and its ligand, latent T G F - ~ , ,
control the activation status of T G F - ~ ~ rather than increased expression of either latent T G F - ~ ~ or 
the C l V ~ 5 5 integrin. Such interaction changes have previously been described for T G F - ~ ~ activation 
mediated by the epithelially restricted integrin C l V ~ 6 6 (Munger et al. 1999). Further study is 
required to investigate the role of such interaction changes in C l V ~ 5 - m e d i a t e d d T G F - ~ ~ activation. 
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Although the data presented in this chapter show that asthmatic HASM cells activate more T G F - ~ ~
in response to LP A stimulation than non-asthmatic cells, the mechanism of this enhanced 
response has not been fully elucidated. It has been shown that it is not mediated by increased 
expression of the ( l V ~ 5 5 integrin, and it is unlikely to be caused by the increased levels of total 
T G F - ~ ~ released from asthmatic HASM cells. Furthermore, these data suggest that LPA-induced 
( l V ~ 5 - m e d i a t e d d T G F - ~ ~ activation is caused by contraction of the HASM cells. Enhanced 
bronchoconstriction is a significant feature of asthma and is responsible for the variable airway 
obstruction observed in asthmatic patients. Published data suggests that this may be caused by a 
fundamental difference in HASM cells, since primary HASM cells from asthmatic patients are 
more contractile in in vitro models (Ma et al. 2002; Matsumoto et al. 2007). Increased 
contractility could be caused by many different factors including increased expression of 
contractile proteins such as MLCK, RhoA and myosin (Ammit et al. 2000; Sakai et al. 2001; 
Leguillette et al. 2009). The difference in contractility between non-asthmatic and asthmatic 
HASM cells could account for the enhanced activation o f T G F - ~ ~ in response to LPA stimulation, 
which is known to cause contraction and stress fibre formation (Chrzanowska-Wodnicka et al. 
1996; Toews et al. 2002; Ainslie et al. 2004; Hirakawa et al. 2007; Xu et al. 2009). Future studies 
will address this possibility using in vitro, ex vivo and in vivo models. 
As has been discussed in Introduction section 1.4, T G F - ~ ~ plays a fundamental role in 
orchestrating structural changes in the airways that are associated with airway remodelling. These 
data show that asthmatic HASM cells activate more TGF - ~ ~ in response to LPA stimulation than 
non-asthmatic HASM cells. This lead us to the hypothesis that expression of T G F - ~ - i n d u c i b l e e
genes that are involved in airway remodelling would also be increased in asthmatic cells 
compared with non-asthmatic cells in response to LP A stimulation. Expression of fibronectin was 
assessed. Fibronectin expression by asthmatic HASM cells increased over time in response to 
LPA, however, in non-asthmatic cells no increase was observed. Despite evidence that LPA 
enhances assembly offibronectin matrix extracellularly (Checovich et al. 1993; Olorundare et al. 
2001) there is currently no evidence to suggest that LP A can increase expression of fibronectin 
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transcriptionally. It is possible that the increased expression of fibronectin by asthmatic HASM 
cells in response to LP A stimulation is mediated by activation of TGF - ~ , , which acts in an 
autocrine fashion to increase fibronectin transcription (Kucich et al. 2000). This could be 
confirmed by repeating the experiment with the addition of a T G F - ~ ~ neutral ising antibody. It is 
possible that the lack of increase in fibronectin expression observed in non-asthmatic cells is 
caused by insufficient activation o f T G F - ~ . .
This is the first time that enhanced TGF - ~ ~ activation by asthmatic HASM cells has been 
described in response to any stimulus, and is the first description of a V ~ 5 - m e d i a t e d d T G F - ~ ~ in this 
cell type. Furthermore, we have found that the contraction agonist methacholine, which is used 
clinically to induce bronchoconstriction (Anderson et al. 2009), can also induce T G F - ~ ~ activation 
by HASM cells suggesting that contraction of HASM cells results in T G F - ~ ~ activation. This 
hypothesis was corroborated by the finding that inhibiting cytoskeletal reorganisation with 
cytochalasin D and inducing HASM cell relaxation with the ~ 2 2 agonist formoterol both inhibit 
LPA-induced T G F - ~ ~ activation. These findings could have important implications for asthma 
pathogenesis. AHR and bronchoconstriction are fundamental features of asthma and involve the 
ASM layer. These data suggest that contraction of the ASM layer during an asthma exacerbation 
could result in T G F - ~ ~ activation, which would potentiate the development of structural changes 
associated with airway remodelling such as subepithelial fibrosis, mucous gland hyperplasia and 
epithelial cell apoptosis. There is currently little information about how airway remodelling is 
initiated in the asthmatic airway and so these findings could shed some light on the link between 
asthma symptoms and pathogenesis, and the development of airway remodelling, which 
ultimately is detrimental to lung function over time and contributes to worsening disease (Lange 
et al. 1998; Mascia et al. 2005). 
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6 Role of the ~ 5 5 Cytoplasmic Domain In a V ~ 5 - M e d i a t e d d T G F - ~ ~
Activation 
6.1 Rationale 
Integrins are unique in that they are capable of bi-directional signalling. Ligand binding to the 
extracellular domain initiates intracellular signalling pathways via what is known as outside-in 
signalling. In addition, the affinity of an integrin for its ligand, or its activation state, can be 
influenced by intracellular signalling pathways via a process known as inside-out signalling. 
Inside-out signalling results in a conformational change in the extracellular domain of the 
integrin, which increases its ligand binding affinity (Zhu et al. 2008). The cytoplasmic domains 
of integrin subunits are fundamental for this purpose (O'Toole et al. 1994). Several cytoplasmic 
proteins have been shown to interact with integrin cytoplasmic domains to initiate inside-out 
activation of integrins (Liu et al. 2000) the most important of which is thought to be talin. Talin 
promotes inside-out signalling by binding to both actin filaments and the cytoplasmic domain of 
~ ~ integrin subunits (Calderwood et al. 1999; Vinogradova et al. 2002) creating a link between the 
actin cytoskeleton and the integrin on the cell surface. 
The data described in the previous chapter shows that stimulation of HASM cells with LP A 
results in a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation via a mechanism that involves the cytoskeleton 
similar to that described for a V ~ 6 - m e d i a t e d d T G F - ~ ~ activation in epithelial cells (Munger et al. 
1999; Jenkins et al. 2006; Xu et al. 2009). Structural interactions of the ~ 5 5 subunit with latent 
T G F - ~ ~ and cytoskeletal proteins are therefore likely to be crucial for a V ~ 5 - m e d i a t e d d T G F - ~ . .
Munger and colleagues (1999) used truncation mutants of the ~ 6 6 subunit cytoplasmic domain to 
show that regions within this domain are essential for the ability of a V ~ 6 6 to mediate T G F - ~ ~
activation. The role of the cytoplasmic domain in a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation has not been 
investigated. 
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A polymorphism in the ~ 5 5 cytoplasmic domain has been previously described (Kawahara et al. 
2005) (see Figure 6.1). This polymorphism occurs within an NxxY talin binding motif and results 
in the loss of 3 amino acids (FNK767-769) from the cytoplasmic tail. Although a talin binding 
domain is still present in the polymorphic ~ 5 5 cytoplasmic tail it is possible that the deletion may 
affect the ability of talin to bind. A role for talin in integrin-mediated T G F - ~ ~ activation has not 
been described for any of the integrins known to mediate this process, although it is expected due 
to evidence that deletion of a talin binding domain from the cytoplasmic domain of ~ 6 6 results in 
an a V ~ 6 6 integrin that is unable to activate T G F - ~ ~ (Munger et aI, 1999). 
Full Length §5 Subunit (FNKFNK) 
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Figure 6.1: Sequence of Cytoplasmic Domains of Full Length and Polymorphic 85 
6.2 Aims 
The aim of these experiments was to investigate the role of the talin binding domain at amino 
acids 768-771 of the ~ 5 5 cytoplasmic domain in a V ~ 5 - m e d i a t e d d T G G - ~ ~ activation . DNA 
constructs corresponding to the full length ~ 5 5 subunit and the polymorphic ~ 5 5 subunit were over-
expressed in CS-I cells that express no endogenous ~ ~ . . Activation of T G F - ~ ~ by these cells was 
investigated using a co-culture assay. The ability of the two variants of ~ 5 5 to interact with talin 
was investigated using co-immunoprecipitation. 
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6.3 Results 
6.3.1 Kill Curve ofG418 on Untransfected CS-l Cells 
The two DNA constructs to be used (FNKFNK and FNK) contain a neomycin resistance gene 
which gives cells expressing the construct resistance against the antibiotic G418. In order to 
determine the concentration of G418 sufficient to kill cells not expressing the construct lxl06 
untransfected CS-l cells were cultured in serum plus media containing 0, 31.25, 65, 125, 250, 
500 and IOOOIlg/ml of the antibiotic G418. After three days the cells were harvested and counted. 
The antibiotic G418 killed untransfected CS-l cells in a concentration-dependent manner. The 
two highest concentrations tested, 500 and IOOOIlg/ml, killed all cells after 3 days of culture. 
G418 at 5001lg/ml was therefore used in future experiments to select CS-l cells that express the 
~ 5 5 DNA constructs. 
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Figure 6.2: KiD Curve ofG418 on Untransfected CS-l Cells 
Untransfected CS-l cells (lxl06 cells) were cultured in the presence of 0, 31.25, 65, 125,250,500 
and IOOOIlg/ml of the antibiotic G418. After three days the cells were harvested and counted. 
G418 killed CS-l cells in a concentration-dependent manner. This figure represents a single 
experiment. 
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6.3.2 Generation of Stable CS-IIFNK and CS-IIFNKFNK Cell Lines 
CS-l cells at 1.5xl06 were transfected with the two ~ 5 5 DNA constructs using Transfast 
transfection reagent (see Methods section 2.12). A variety of DNA concentrations and DNA: 
Transfast ratios were used, these are outlined in Table 6.1. Expression of the constructs by the 
CS-l cells resulted in their adhesion to plastic. Since all ratios and all DNA concentrations 
resulted in successful transfections and subsequent expression of ~ 5 5 by the CS-l cells, the result 
was several CS-l cell lines expressing varying levels of ~ 5 . .
CS-l Cell Line Created DNA Concentration Used DNA: Transfast Ratio 
CS-IIFNKFNK-l IJlg 1:2 
CS-IIFNKFNK-2 2Jlg 1:2 
CS-l/FNKFNK-3 3Jlg 1 :2 
CS-l/FNKFNK-4 IJlg 1:3 
CS-IIFNKFNK-5 2Jlg 1 :3 
CS-IIFNKFNK-6 3Jlg 1:3 
CS-IIFNK-l IJlg 1:2 
CS-IIFNK-2 2Jlg 1:2 
CS-IIFNK-3 3Jlg 1:2 
CS-IIFNK-4 IJlg 1 :3 
CS-IIFNK-5 2Jlg 1 :3 
CS-IIFNK-6 3Jlg 1:3 
Table 6.1: Generation ofCS-IIFNKFNK and CS-IIFNK Cell Lines 
This table outlines the DNA concentrations and DNA: Transfast ratios used in the generation of 
stable CS-l cell lines that express either the full length ~ 5 5 construct (FNKFNK) or the 
polymorphic ~ 5 5 construct. 
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6.3.3 Expression of aVf35 by CS-IIFNKFNK and CS-I /FNK Cell Lines 
Following transfection and clonal expansion of CS-IIFNKFNK and CS-lIFNK cells cell surface 
expression of a V ~ 5 5 was confirmed by flow cytometry (see Methods section 2.14). Cel1s were 
stained with 20Ilg/ml a n t i - a V ~ 5 5 and a PE-Iabelled secondary antibody. The fluorescence intensity 
of the cells was determined using a flow cytometer. These data show that a V ~ 5 5 integrin was 
expressed on the surface of both CS-I /FNKFNK and CS-lIFNK (Figure 6.3). 
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Figure 6.3: Expression of aV85 by CS-IIFNKFNK and CS-IIFNK Cell Lines 
Cell surface expression of a V ~ 5 5 by unstimulated CS-I /FNKFNK and CS-I /FNK was assessed by 
flow cytometry. Both CS-l cell lines expressed a V ~ 5 5 on their cell surface as shown by flow 
cytometry. This figure shows representative data from one CS-I /FNKFNK cell line and one CS-
lIFNK cell line. Data is expressed as fold increase in MFI over negative control (secondary 
antibody only). 
6.3.4 T G F - ~ ~ Activation by CS-I/FNKFNK and CS-IIFNK Cells 
CS-I /FNKFNK and CS-lIFNK cells were co-cultured with TMLC reporter cells to investigate 
both basal and LPA-induced T G F - ~ ~ activation. The co-cultures were either left unstimulated with 
or without lOIlg/ml a n t i - T G F - - , , or stimulated with 20llM LPA with or without lOIlg/ml anti-
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TGF-p. All stimulations were performed in duplicate. CS-IIFNKFNK cells were able to activate 
TGF-p basally (Figure 6.4) as shown by the decrease in luciferase activity from 1074 ± 65 to 869 
± 27 in the presence of a pan-TGF-p neutralising antibody (P<0.05). However, CS-IIFNK cells 
could not activate TGF-p basally (Figure 6.5) as there was no decrease in RLU upon addition of 
the pan-TGF-p neutralising antibody. 
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Figure 6.4: Basal Activation ofTGF-B by CS-lfFNKFNK Cells 
CS-J/FNKFNK cells were co-cultured with TMLCs with or without 10J.lg/ml anti-TGF-p. CS-
lIFNKFNK cells activate TGF-p basally. This is a representative figure from 4 experiments using 
4 separate CS-lIFNKFNK cell lines. The cell line used in this experiment was the same cell line 
for which the expression of aVp5 is shown in Figure 6.3. Data is expressed as mean ± SEM. P 
values < 0.05 were accepted as significant. 
* P<0.05 
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Figure 6.5: Basal Activation ofTGF-B by CS-IIFNK Cells 
CS-I!FNKFNK cells were co-cultured with TMLCs with or without l O ~ g / m l l a n t i - T G F - ~ . . CS-
I1FNK cells do not activate T G F - ~ ~ basally. This is a representative figure from 4 experiments 
using 4 separate CS-lIFNK cell lines. The cell line used in this experiment was the same cell line 
for which the expression of a V ~ 5 5 is shown in 
Figure 6.3 Data is expressed as mean ± SEM. 
The effect of LPA stimulation on T G F - ~ ~ activation by CS-lfFNKFNK and CS-I fFNK cells was 
also investigated by stimulating co-cultures of each cell line and TMLCs with 0 and 2 0 ~ M M LPA. 
Activation of T G F - ~ ~ in response to LPA stimulation did not occur in either CS-lfFNKFNK 
(Figure 6.6) or CS-lfFNK cells (Figure 6.7), as shown by no difference in luciferase activity 
between 0 and 2 0 ~ M M LPA stimulation. 
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Figure 6.6: Effect ofLPA Stimulation on TGF-6 Activation by CS-IIFNKFNK Cells 
A co-culture of CS-I/FNKFNK cells and TMLCs was stimulated with 0 and 20llM LPA in 
duplicate. LPA had no effect on TGF-p activation by CS-IIFNKFNK cells. This is a 
representative figure from 4 experiments using 4 eparate CS-l/FNKFNK cell lines. The cell line 
used in this figure was the same as the one shown in Figure 6.3 . Data is expressed as mean ± 
SEM. 
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Figure 6.7: Effect ofLPA Stimulation on TGF-6 Activation by CS-IIFNK Cells 
A co-culture of CS-lIFNK cells and TMLCs was stimulated with 0 and 2 0 ~ M M LPA in duplicate. 
LPA had no effect on T G F - ~ ~ activation by CS-I/FNK cells. This is a representative figure from 4 
experiments using 4 separate CS-lIFNK cell lines. The cell line used in this figure was the same 
as the one shown in Figure 6.3. Data is expressed as mean ± SEM. 
6.3.5 Co-immunoprecipitation (Co-Ip) of Talin with ~ 5 5
To assess whether the deletion of FNK767-769 affects the ability of talin to interact with the ~ 5 5
cytoplasmic domain, unstimulated protein from CS-IIFNKFNK and CS-I/FNK cells was 
subjected to a co-immunoprecipitation assay. Three CS-IIFNKFNK and three CS-lIFNK cells 
lines were cultured and unstimulated cell protein collected according to the manufacturer's 
protocol (Active Motif, see chapter 2.13). Talin was immunoprecipitated from 500flg of total cell 
protein using magnetic protein G beads and 5 ~ g g of antibody directed against both talinl and 
talin2. The immunoprecipitated protein was separated by SDS-PAGE and immunoblotted for ~ 5 . .
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Talin associates with the pS subunit in both CS-I/FNKFNK cells (lanes 1-3) and CS-IIFNK cells 
(lanes 4-6), as shown by bands at approximately 9SkDa. The bands in lanes loaded with CS-
I/FNK protein are not as pronounced as those in lanes loaded with CS-IIFNKFNK protein, 
however, loading was not equal between lanes (see Input protein bands). pS protein was present 
in protein samples prior to immunoprecipitation as seen by bands in all 6 lanes loaded with input 
protein. 
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Figure 6.8: Co-immunoprecipitation of Talin and 85 in CS-IIFNKFNK and CS-IIFNK Cells 
Co-immunoprecipitation assay was used to determine whether talin and pS are associated with 
one another intracellularly by immunoprecipitating talin and western blotting the resulting protein 
for the pS subunit. Lanes 1-3 were loaded with protein from unsitmulated CS-IIFNKFNK cell 
lines and lanes 4-6 were loaded with protein from unstimulated CS-IIFNK cell lines. I O ~ g g of 
total cell protein prior to immunoprecipitation was loaded and used as an loading control. An 
anti-talin antibody was used to immunoprecipitate talin from the total protein mixture. The 
immunoprecipitated protein was then subjected to western blot analysis for the pS integrin 
subunit. Talin associates with pS in both CS-IIFNKFNK cells and CS-IIFNK cells. This is a 
representative figure from 1 experiment using N=3 CS-lIFNKFNK cell lines and N=3 CS-I /FNK 
cell lines. 
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To confirm that talin associates with pS in both CS-IIFNKFNK and CS-IIFNK cells, the co-
immunoprecipitation was repeated in reverse i.e. cell protein was immunoprecipitated with an 
anti-pS antibody and then immunoblotted for talin. The reverse Co-Ip confirmed that talin and pS 
associate with one another in both CS-IIFNKFNK and CS-lIFNK cells. Bands at the expected 
molecular weight for talin (22SkDa) were observed in lanes loaded with both CS-IIFNKFNK and 
CS-IIFNK immunoprecipitated protein (Figure 6.9). 
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Figure 6.9: Reverse Co-Ip of 85 and Talin in CS-IIFNKFNK and CS-IIFNK Cells 
Co-immunoprecipitation assay was used to confmn that talin and pS are associated with one 
another by immunoprecipitating the pS subunit and western blotting the reSUlting protein for talin. 
Lane 1 was loaded with protein from an unsitmulated CS-IIFNK cell line and lane 2 was loaded 
with protein from an unstimulated CS-IIFNKFNK cell line. 1 O ~ g g of total cell protein prior to 
immunoprecipitation was loaded and used as an loading control. An anti-pS antibody was used to 
immunoprecipitate pS from the total protein mixture. The immunoprecipitated protein was then 
subjected to western blot analysis for talin. Talin associates with pS in both CS-IIFNKFNK cells 
and CS-IIFNK cells. This is a representative figure from I experiment usingN=1 CS-lIFNKFNK 
cell line and N= l CS-IIFNK cell line. 
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6.4 Discussion 
The results presented in Results Chapter 5 show that HASM cells are capable of activating T G F - ~ ~
via the integrin a V ~ 5 . . Structural interactions of the ~ 5 5 subunit with both latent T G F - ~ ~ and 
cytoskeletal proteins are likely to be crucial for a V ~ 5 - m e d i a t e d d T G F - ~ ~ as has been shown for the 
a V ~ 6 6 integrin (Munger et al. 1999). A polymorphism in the ~ 5 5 cytoplasmic domain involving a 
9 base pair deletion has been previously described (Kawahara et al. 2005). This polymorphism 
occurs within an NxxY talin binding region and results in the loss of three amino acids (FNK767-
769) from the cytoplasmic tail. Here, I show that this polymorphism results in a ~ 5 5 subunit that is 
unable to mediate T G F - ~ ~ activation. Cells expressing this polymorphic ~ 5 5 are unable to activate 
T G F - ~ , , however, cells that expressed the full length ~ 5 5 subunit activated T G F - ~ . . This is the first 
description of a biologically relevant integrin mutant that can't activate TGFf3. 
Previous work studying the role of the ~ 6 6 cytoplasmic domain in a V ~ 6 - m e d i a t e d d T G F - ~ ~
activation has highlighted the importance of the ~ ~ subunit cytoplasmic domain in this process. By 
studying ~ 6 6 mutants that have truncated cytoplasmic domains it was shown that distinct regions 
of integrin ~ ~ subunits are responsible for T G F - ~ ~ activation (Munger et al. 1999). These data 
suggest that this is also true of a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation since a polymorphism that 
results in the deletion of just three amino acids from the cytoplasmic domain of ~ 5 5 results in an 
inability to activate T G F - ~ . . However, this polymorphism doesn't abrogate all biological functions 
of ~ 5 5 as adhesiveness of a V ~ 5 5 to extracellular ligands is not affected (Kawahara et al. 2005). 
The frequency of individuals heterozygous for this polymorphism in ~ 5 5 was determined to be 
11 % (Kawahara et al. 2005). The results described here suggest that individuals that express this 
polymorphism in ITGB5 would not be able to activate T G F - ~ ~ via this integrin. The relevance of 
this polymorphism in disease is not yet clear. It would be predicted that this mutation would 
" 
protect against fibrotic conditions, although it is possible that compensation through the avf33 
integrin may occur (Asano et al. 2005a; Wipff et al. 2007). It may also be relevant in diseases 
such as cancer where a failure to activate TGFf3 may mitigate against TGFf3's known effect 
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inhibiting epithelial cell proliferation (Guasch et al. 2007). Although it is unlikely that this 
specific mutation has any relationship with fibrotic disease, there are 720 currently described 
polymorphisms in the ~ 5 5 gene, 3 of which lead to coding changes in the latent TGFI3 binding 
domain and it is quite possible that a mutation in this region could lead to enhanced TGFI3 
activation and fibrogenesis. However, this hypothesis remains to be tested. 
CS-l cells were utilised in these studies because they express endogenous aV integrin subunits 
but no ~ ~ subunits (Thomas et al. 1993), making them an excellent model for investigating 
structural differences in the ~ 5 5 cytoplasmic domain. Cells that over-expressed the full length ~ 5 5
subunit (CS-IIFNKFNK) were capable of activating T G F - ~ ~ basally but cells over-expressing the 
~ 5 5 subunit that lacks amino acids 767-769 (CS-IIFNK) were not, despite these cells actually 
expressing more a V ~ 5 5 on their cell surface. U n f o r t u ~ a t e l y , , these cells did not respond to 
stimulation with LPA and so the effect of the two different forms of ~ 5 5 on LPA-induced a V ~ 5 5
mediated T G F - ~ ~ activation could not be investigated. There are several possible reasons for this. 
Expression of LPA receptors by CS-l cells was not assessed and it may be that they are unable to 
respond to LPA stimulation due to a lack of LPA receptors. It is also possible that for some 
reason these cells are unable to contract, and if our hypothesis that LP A induces TGF - ~ ~ activation 
via induction of cell contraction is correct this would result in no increased T G F - ~ ~ activation in 
response to LP A. 
These data show that the deletion of amino acids FNK767-769 from the ~ 5 5 cytoplasmic tail did not 
completely abrogate the interaction of ~ 5 5 with the cytoskeletal protein talin, despite it abrogating 
T G F - ~ ~ activation. Although the deletion occurs within an NxxY talin binding domain, two talin 
binding domains are still present within the polymorphic ~ 5 5 cytoplasmic domain (see Figure 6.1). 
This suggests that the inability of the polymorphic ~ 5 5 subunit to activate T G F - ~ ~ is not the result 
of an inability of talin to interact with the ~ 5 5 cytoplasmic tail. a V ~ 6 - m e d i a t e d d TGF - ~ ~ activation is 
associated with the formation of stress fibers and reorganisation of the a V ~ 6 6 integrin into focal 
adhesions (Munger et al. 1999; Xu et al. 2009). However, it is not known at present whether the 
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polymorphic ~ 5 5 subunit can still organise into focal adhesions. Further investigation is required to 
establish how the deletion ofFNK767-769 affects the ability of the integrin to activate T G F - ~ . .
The data presented in this chapter show that a deletion of just three amino acids from the 
cytoplasmic domain of the ~ 5 5 subunit results in an a V ~ 5 5 integrin that is unable to activate T G F - ~ . .
This is the first description of a biologically relevant integrin that is unable to activate T G F - ~ . .
The data suggests that talin is still is still able to interact with the polymorphic ~ 5 5 subunit, 
however, it is not currently clear whether this interaction is impaired by the deletion. Further 
investigation is therefore required to elucidate the mechanism that results in the inability of the 
polymorphic ~ 5 5 to activate T G F - ~ . .
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7 Conclusions and Future Directions 
Asthma is an extremely common inflammatory disease of the airways. Airway remodelling is the 
term given to the structural changes that occur within the airways of asthmatic patients, including 
subepithelial fibrosis and increased ASM mass, and is more common in individuals suffering 
from severe forms of the disease. The causes responsible for the development of airway 
remodelling are currently unknown, however, the pro-fibrotic cytokine T G F - ~ ~ has been 
implicated. T G F - ~ ~ is released from cells as a latent complex that requires activation for 
functionality. Activation of TGF - ~ ~ by airway epithelial cells has been well documented. 
However, activation of T G F - ~ ~ by ASM cells has never been investigated, despite these cells 
being implicated in asthma pathogenesis. 
The results presented in this thesis highlight two biologically-relevant mechanisms of T G F - ~ ~
activation employed by HASM cells in vitro. The first is proteolytic activation by the serine 
protease mast cell tryptase. Mast cell infiltration of the ASM layer is a defining characteristic of 
asthma compared with other inflammatory airway diseases (Brightling et al. 2002). This means 
that ASM cells in vivo are influenced by mast cell mediators following mast cell degranulation in 
response to inhaled asthmatic stimuli. Tryptase is the most abundant protease secreted by mast 
cells and these data suggest that release of tryptase could cause TGF - ~ ~ activation in vivo. This 
would provide a direct link between inflammation of the airways and the development of airway 
remodelling. It has been shown that an inhaled tryptase inhibitor, APC366, can inhibit tryptase-
induced airway hyper-responsiveness and bronchoconstriction (Molinari et al. 1996). Clinical 
trials using this inhibitor have been promising. Administration of APC366 abrogates decreases in 
FEV 1 associated with the late asthmatic response (LAR) following allergen challenge (Krishna et 
al. 2001). The data presented in this thesis suggest that using this treatment might help reduce 
airway remodelling in asthma. 
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The second mechanism o f T G F - ~ ~ activation described here was mediated by the integrin ( l V ~ 5 5 in 
response to LP A stimulation via the cytoskeleton. LP A is present in the serum and levels of LPA 
in BALF are increased following allergen challenge (Eichholtz et al. 1993; Georas et al. 2007). It 
has multiple effects on ASM cells but this is the first description of LPA-induced T G F - ~ ~
activation by HASM cells. During an asthma exacerbation serum is exudated into the airways 
(BeIda et al. 2005) and levels of LP A in the airways are likely to increase. Furthermore, data 
presented in this thesis using a wounding model suggest that HASM cells might be able to 
activate T G F - ~ ~ via ( l V ~ 5 5 independently of LPA. These data suggest that HASM cells may 
activate T G F - ~ ~ locally in asthmatic airways, which could lead to airway remodelling. This is the 
first description of ( l V ~ 5 - 1 i 1 e d i a t e d d T G F - ~ ~ activation in this cell type and these findings provide 
evidence that ( l V ~ 5 5 is a potential target for treatment or prevention' of airway remodelling in 
asthma. 
Angiogenesis is a key feature of asthmatic airway remodelling (see Introduction section 1.2.4), as 
well as many other pathologies including cancer and ischemic diseases. The integrin ( l V ~ 5 , , in 
addition to several other integrins including ( l V ~ 3 3 and ( l V ~ 8 , , is thought to be involved in 
angiogenesis. (l V ~ 5 5 does not appear to affect developmental angiogenesis since mice null for 
either ~ 5 5 or (lV exhibit extensive angiogenesis during development (Bader et al. 1998; Huang et 
al. 2000). However, published data indicates a role for ( l V ~ 5 5 in pathological angiogenesis. A dual 
inhibitor of ( l V ~ 5 5 and the closely related integrin ( l V ~ 3 3 inhibits angiogenesis in vitro and in a 
murine xenograft tumour model (Kumar et al. 2001), and an ( l V ~ 5 5 neutral ising antibody inhibits 
angiogenesis in vitro (Friedlander et al. 1995). However, the precise role of ( l V ~ 5 5 in mediating 
angiogenesis is still very unclear as some studies have shown that inhibition of ( l V ~ 5 5 can promote 
angiogenesis and tumourigenesis. Mice null for both ~ 5 5 and ~ 3 3 exhibit enhanced tumour-
associated angiogenesis in vivo (Reynolds et al. 2002). Moreover, RGD-mimetic inhibitors of 
( l V ~ 5 5 and ( l V ~ 3 3 enhance angiogenesis within tumours when used at low concentrations 
(Reynolds et al. 2009). Further work is needed to fully elucidate how ( l V ~ 5 5 affects pathological 
angiogenesis in asthma These studies and the data presented in this thesis raise the possibility 
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that a . V ~ 5 5 might promote angiogenesis in asthmatic airway remodelling in two separate ways. 
The ftrst involves direct stimulation of angiogenesis via an as yet unclear, direct a . V ~ 5 - m e d i a t e d d
mechanism, and the second by activating the pro-angiogenic mediator TGF - ~ . . The data presented 
here suggest that distinct regions of the ~ 5 5 cytoplasmic domain are responsible for mediating 
T G F - ~ ~ activation, as has been shown for a . V ~ 6 - m e d i a t e d d T G F - ~ ~ activation (Munger et al. 1999). 
It is possible that distinct regions of ~ 5 5 are responsible for promoting angiogenesis in disease. 
Such regions might prove to be a more effective target for combating pathological angiogenesis 
than completely abrogating all a . V ~ 5 5 functions. 
The ftnding that LPA causes T G F - ~ ~ activation by HASM cells may have wider implications for 
asthma pathogenesis. It is well known that LP A induces cytoskeletal changes via activation of 
RhoA and Rho kinase (Hashimoto et al. 2003; Xu et al. 2009). The observation that the 
contraction agonist methacholine can also induce TGF - ~ ~ activation and the bronchodilator 
formoterol can inhibit LPA-induced T G F - ~ ~ activation has led us to hypothesise that contraction 
of ASM cells causes T G F - ~ ~ activation (see Figure 7.1). If correct, this could be fundamental to 
our understanding of the development of airway remodelling in asthma. Furthermore, we have 
found that asthmatic cells activate more T G F - ~ ~ in response to LPA stimulation than non-
asthmatic cells. There have been several descriptions of asthmatic HASM cells being more 
contractile than non-asthmatic HASM cells. Our hypothesis suggests that this may be a reason 
that asthmatic cells activate more T G F - ~ ~ and develop airway remodelling. However, further work 
is needed to conftrm this. Ultimately, it is hoped that these data and future work will identify a 
therapeutic target for the development of novel treatments for airway remodelling and asthma. 
Following the discovery that HASM cells can activate T G F - ~ ~ via the integrin a . V ~ 5 5 we 
investigated the role of the ~ 5 5 cytoplasmic domain in mediating T G F - ~ ~ activation. We found that 
a melanoma cell line over-expressing a polymorphic ~ 5 5 subunit that lacks three amino acids (767-
769) in its cytoplasmic domain, were unable to activate T G F - ~ ~ compared with cells over-
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expressing full length ~ 5 , , which were able to activate T G F - ~ . . This suggests an essential role for 
specific regions of the ~ 5 5 cytoplasmic domain ( ' L V ~ 5 - m e d i a t e d d T G F - ~ ~ activation and is also the 
first description of a biologically-relevant integrin-variant that is unable to activate T G F - - . .
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Figure 7.1 : Overview of Proposed Mechanism of Contraction-Induced aVB5-Mediated 
TGF -B Activation by HASM Cells 
The results presented in this thesis have led us to hypothesise that ASM contraction during an 
asthma exacerbation results in T G F - ~ ~ activation via the cytoskeletal changes and the integrin 
a . V ~ 5 . . This schematic shows an overview of the proposed hypothesis. Allergen-induced 
bronchoconstriction would cause T G F - ~ ~ activation but treatment with a bronchodilator such as a 
p2-agonist would inhibit this activation by inhibiting ASM contraction. 
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7.1 Future Directions 
This thesis has highlighted two biological relevant mechanisms o f T G F - ~ ~ activation employed by 
HASM cells in vitro. I have found that mast cell tryptase proteolytically activates T G F - ~ ~
independently of its receptor PAR2. However, difficulties obtaining tryptase with consistent 
proteolytic activity made further investigation complicated. These data also suggest that 
mechanically wounding HASM cells causes T G F - ~ ~ activation, possibly via the integrin a . V ~ 5 . .
However, the wounding model was very inconsistent and further investigation was not 
performed. Finally, I have shown that stimulation of HASM cells with LPA causes T G F - ~ ~
activation via the cytoskeleton and the integrin a . V ~ 5 . . Further experiments are required to 
investigate the relevance of a . V ~ 5 - m e d i a t e d d T G F - ~ ~ activation in asthma pathogenesis in vivo. An 
outline of future studies is provided here. 
To further explore the role of a . V ~ 5 - m e d i a t e d d T G F - ~ ~ activation in airway remodelling and asthma 
and the hypothesis that enhanced contractility of asthmatic HASM cells leads to increased a. V ~ 5 5
mediated T G F - ~ ~ activation, in vitro, ex vivo and in vivo techniques could be used. To confirm the 
hypothesis that ASM contraction causes T G F - ~ ~ activation, the effects of several contraction 
agonists, including methacholine, histamine and 5-hydroxytryptamine (5-HT), on 
phosphorylation of MLCK, T G F - ~ ~ activation and collagen synthesis will be determined. Con-
focal microscopy will be used to assess whether integrins and cytoskeletal proteins redistribute in 
response to these agonists as previously described (Xu et al. 2009). Furthermore, the effects of a 
variety of relaxation agents, including the ~ 2 - a g o n i s t s s formoterol, the anti-muscarinic atropine 
and the potassium-channel opener chromokalin, will be investigated. Together, the results of 
these experiments should confirm the role of HASM cell contraction in T G F - ~ ~ activation and 
airway remodelling. 
T h ~ ' ' results presented in this thesis have shown that asthmatic HASM cells activate more T G F - ~ ~
via a. V ~ 5 5 in response to LP A stimulation than non-asthmatic HASM cells and this was not the 
result of increased expression of a . V ~ 5 5 by the asthmatic cells. However, the mechanism of this 
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enhanced response was not investigated. Future studies will therefore focus on investigating the 
mechanism responsible for this observation. Several studies have suggested that asthmatic ASM 
cells are more contractile than non-asthmatic cells (Ma et al. 2002; Matsumoto et al. 2007), 
which may explain the enhanced response of asthmatic cells. To investigate this, levels of MLCK 
between asthmatic and non-asthmatic cells will be compared. Furthermore, the inhibitor H-1152, 
which inhibits Rho Kinase and therefore the Rho signalling pathway and Rho dependent cell 
contraction, will be used to determine whether inhibition of this pathway reduces activation of 
T G F - ~ ~ and ECM protein synthesis by asthmatic cells. In addition to these in vitro studies, the role 
of cell contraction on T G F - ~ ~ activation by ASM cells will be investigated using an ex vivo lung 
slice model. Intact bronchial lung slices from ovalbumin sensitised mice will be stimulated with 
the contraction agonists previously mentioned and TGF - ~ ~ activity and ECM gene synthesis by the 
lung slices will be determined over 24 hours using immunohistochemistry and western blotting. 
The role of a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation in airway remodelling and asthma in vivo will be 
investigated using a V ~ 5 - n u l l l mice and an Aspergillus fumigates (Asp.j) model of allergic asthma. 
This model will be used over the more commonly used ovalbumin model of asthma because the 
background strain of the a V ~ 5 - n u l l l mice is not compatible with the ovalbumin model. Following 
the repeated challenges of wild-type and a V ~ 5 - n u l l l mice with the Asp.f antigen, lung histology, 
collagen content and markers of T G F - ~ ~ activity such as phosphorylated Smad2 or Smad3 will be 
compared between the two types of mice. 
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7.2 Concluding Remarks 
Airway remodelling is associated with severe asthma and leads to a progressive decline in lung 
function over time. T G F - ~ ~ has been implicated in the development of airway remodelling as it is 
both mitogenic and pro-fibrotic. However, activation of extracellular stores oflatent T G F - ~ ~ is the 
rate limiting step in T G F - ~ ~ bioavailability. The findings outlined in this thesis have provided 
evidence that HASM cells are capable of activating T G F - ~ ~ in vitro, which could contribute to the 
development of airway remodelling in vivo. Two mechanisms of T G F - ~ ~ activation employed by 
HASM cells have been identified, both of which may be relevant for asthma pathogenesis and 
airway remodelling in vivo. Future studies will concentrate on assessing the role of these 
mechanisms of T G F - ~ ~ activation in vivo. Data concerning a V ~ 5 - m e d i a t e d d T G F - ~ ~ activation in 
HASM cells has led us to hypothesise that contraction of HASM cells leads to T G F - ~ ~ activation 
in vivo. If correct this could be vital to our understanding.of how airway remodelling is initiated 
in asthma and could lead to the development of new treatments aimed at inhibiting contraction-
induced T G F - ~ ~ activation. This would hopefully improve symptoms in asthmatics and help to 
inhibit the decline in lung function over time that is commonly observed. 
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9 Appendix 
9.1 Materials 
Hyperfilm ECLTM ...................................................................... Amersham Biosciences 
Pure nitrocellulose membrane ............................................................. Gelman Sciences 
9.2 Reagents 
Ammonium persulphate ...................................................................... Sigma-Aldrich 
Dissolved in distilled water 
Amphotericin B ........................................................................................ Sigma-Aldrich 
Bisacrylamide ................................................................................. Sigma-Aldrich 
~ - m e r c a p t o e t h a n o l l .................................................. : ........................... Sigma-Aldrich 
Bradford protein reagent .............................................................................. BioRad 
Bovine serum albumin (BSA) ...................................................................... Sigma-Aldrich 
Bromophenol blue ............................................................................... Sigma-Aldrich 
Bronchial epithelial cell medium and supplements .............................. Cambrex BioSciences 
Cycloheximide ................................................................................ Sigma-Aldrich 
Dissolved in water 
Cytochalasin .................................................................................... Sigma-Aldrich 
Dissolved in dimethyl sulphoxide 
DEPC treated water (RNase free) ..................................................................... Sigma-Aldrich 
Dulbecco's modified Eagle's medium (DMEM) ........................................... Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) .................................................................... Sigma-Aldrich 
Deoxynucleosides (dNTPs) ........................................................................... Promega 
Dithiothreitol (DTT) ......................................................................... Sigma-Aldrich 
ECLTM detection reagents ......................................................... Amersham Biosciences 
E t h y l ~ n e d i a m i n e e tetraacetic acid (EDT A) ................................................. Sigma-Aldrich 
Ethanol ...................................................................................................... BDH 
Ethidium bromide .............................................................................. Sigma-Aldrich 
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Foetal calf serum (FCS) ........................................................................... Harlan UK 
Goat serum ................................................................................................................ Sigma-Aldrich 
Glycerol ......................................................................................... Sigma-Aldrich 
B-glycerophosphate ............................................................................ Sigma-Aldrich 
Glycine .......................................................................................... Sigma-Aldrich 
GoTaq® DNA polymerase ............................................................................... Promega 
GoTaq® 5x green buffer ............................................................................. Promega 
G418 antibiotic ........................................................................................ Sigma-Aldrich 
Leupeptin ...................................................................................... Sigma-Aldrich 
L-glutamine .................................................................................... Sigma-Aldrich 
Lysophosphatidic acid (LPA) ............................................................... Sigma-Aldrich 
Dissolved in 0.1 % BSA in PBS 
Methanol ............................................................ : ...................................... BDH 
MgCl2 ................................................................................................ Promega 
Moloney murine leukaemia virus (M-MLV) ...................................................... Promega 
reverse transcriptase 
N ,N ,N ,N -Tetramethylethylenediamine (Temed) .......................................... Sigma-Aldrich 
Nafamostat mesilate (FUT175) .................................................. Biomol International LP 
Non-fat dry milk ..................................................................... Santa Cruz Technology 
Oligo(DT) primer ..................................................................................... Promega 
PAR2 activating peptide (PAR2-AP) ............................................................... Bachem 
SLlGKV-NH2 
PCR DNA ladders ............................................................................. Sigma-Aldrich 
Phosphate buffered saline (PBS) tablets ................................................... Sigma-Aldrich 
Penicillin/streptomycin ....................................................................... Sigma-Aldrich 
Phenylmethanesulphonylfluoride (PM SF) ................................................. Sigma-Aldrich 
Ponceau S solution ............................................................................ Sigma-Aldrich 
Protein inhibitor cocktail ................................................... '" ............... Sigma-Aldrich 
Rainbow™ molecular weight marker ................................................. Amersham Biosciences 
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RPMI .......................................................................................................................... Sigma-Aldrich 
RNase free DNase ...................................................................................... Qiagen 
RNasin RNase inhibitor .............................................................................. Promega 
RT buffer (S x) ........................................................................................ Promega 
Sodium azide (NaN3) .................................................................... Sigma-Aldrich 
Sodium chloride (NaCl) ...................................................................... Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) ............................................................ Sigma-Aldrich 
Sodium orthovanadate (Na3V04) ......................................................... Sigma-Aldrich 
Sulphuric acid (H2S04) .............................................................................. BDH 
Takara SYBR Premix Ex Taq .......................................................................... Lonza 
Transfast transfection reagent ..................................................................... Promega 
Tryptase, purified human lung ......................................................... Europa Bioproducts 
Supplied in SOmM NaOAc, 1M NaCl, O.OSmM heparin. 
Specific activity 63.3 U/mg using n-benzyl-Phe-Arg-pNA as substrate. 
Tris buffered saline (TBS) ................................................................... Sigma-Aldrich 
Trizma® base (Tris-base) .................................................................. Sigma-Aldrich 
Trizma® hydrochloride (Tris-HCI) ......................................................... Sigma-Aldrich 
Triton X 100 .................................................................................... Sigma-Aldrich 
TrypsinlEDTA ................................................................................. Sigma-Aldrich 
Tween-20 ....................................................................................... Sigma-Aldrich 
9.3 Antibodies 
Integrin aVpS antibody (clone PIF6) .............................................................. Tebu-bio 
Raised in mouse 
Integrin aVpS antibody (ALULA) ................................................ Professor Dean Sheppard, UCSF 
Raised in mouse 
Integrin pS polyclonal antibody ..................................................................... Abcam 
Raised in rabbit. 
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GAPDH monoclonal antibody ................................................................ ABD Serotec 
Raised in mouse 
Pan T G F - ~ ~ monoclonal antibody (clone IDII) ............................................ R & D Systems 
Raised in mouse. 
T G F - ~ I I monoclonal antibody ................................................................. R & D Systems 
Raised in mouse 
T G F - ~ 2 2 monoclonal antibody ................................................................ R & D Systems 
Raised in mouse 
PAR2 monoclonal antibody (clone SAM I I) ................................. Santa Cruz Biotechnology 
Raised in mouse. 
Talin I and 2 monoclonal antibody (clone 8D4) ................................................... Abcam 
Raised in mouse 
Lamin AC monoclonal antibody (clone) ................................. Santa Cruz Biotechnology 
Raised in mouse 
Anti-mouse polyclonal antibody ........................................................... Dakocytomation 
Raised in rabbit 
Anti-rabbit polyclonal antibody ........................................................... Dakocytomation 
Raised in goat 
9.4 Kits 
QIAEX II Gel purification kit ........................................................................ Qiagen 
Luciferase reporter assay kit ........................................................................ Promega 
NucleoSpin RNA II RNA Extraction kit. .............................................. Macherey Nagel 
Universal CoIp Kit .............................................................................. Active Motif 
NXtract CellLytic nuclear extraction kit ..................................................... Sigma-Aldrich 
Cell Titer Glow kit ................................................................................... Promega 
BCA Protein Assay ..................................................................................... Pierce 
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9.5 Buffer Recipes 
9.5.1 RT-PCR Buffers 
0.5xTris-borate-EDT A Buffer 89mM Tris borate, 2mM EDT A, pH 8.3 
9.5.2 Western Blotting Buffer Recipes 
Lysis Buffer: 50mM Tris-HCI pH 6.8, 150mM NaCI, 1 % TritonX 100, 0.1 % SDS, 0.5% 
deoxycholic acid and O.OIM EDTA 
Prior to use, the buffer was diluted 1:2 and the following protease inhibitors 
added: 
IJlVmlleupeptin, 20JlVml PMSF, 40JlVml protease inhibitor cocktail and 10JlVml 
NaV04 
4x Lamellae Buffer: 
62.5mM Tris-HCI pH 6.8, 10% v/v glycerol, 1% w/v SDS and 0.01% 
bromophenol blue. 
Just before use 1 % v/v ~ - m e r c a p t o e t h a n o l l was added. 
lOx Transfer Buffer: 
50mM Tris base pH 8.3, 192mM glycine and 20% v/v methanol 
Buffer 1: 1.5M Tris-HCI, 0.4% SDS, pH 8.8 
Buffer ,2: 0.5M Tris-HCI, 0.4% SDS, pH 6.8 
Tris Buffered Saline plus Tween 20 (TBST): 
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24.2g Tris base, 87.6g NaCl, I L dH20, pH 7.4-7.6, 10mls Tween 20 in 1 L 
10% Resolving Gel: 
6.66mI30% Bis/acrylamide, 5.2ml buffer 1, 7,92ml distilled water 
Then add 200J.ll 10% ammonium persulphate and 20J.ll 
tetramethylethylenediamine (temed) just prior to use 
Stacking Gel: 1.3m130% bis/acrylamide, 2.5ml buffer 2, 6.lml distilled water, 
Then add 50J.ll 10% ammonium persulphate and I OJ.ll temed just prior to use 
9.6 Media Recipes 
Serum plus DMEM: DMEM plus 10% FCS, 4mM L-glutamine, 100U/ml penicillin, 
100J.lg/ml streptomycin and 2.5 J.lg/mr amphotercin B 
Serum free DMEM: DMEM plus 4mM L-glutamine, 100U/ml penicillin, 100J.lg/ml 
streptomycin and 2.5J.lg/ml amphotercin B 
Serum plus TMLC media: 
DMEM plus 10% FCS, 4mM L-glutamine, 100U/ml penicillin, 
100J.lglml streptomycin, 2.5J.lglml amphotercin Band 25J.lglml G418. 
Serum free TMLC media: 
Serum plus RPMI: 
DMEM plus 4mM L-glutamine, 100U/ml penicillin, 100J.lglml 
streptomycin, 2.5J.lglml amphotercin B and 25J.lglml G418 
RPMI plus 10% FCS, 4mM L-glutamine, 100U/ml penicillin, 100J.lglml 
streptomycin and 2.5J.lg/ml amphotercin B 
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Serum free RPM!: RPM! plus 4mM L-glutamine, 100Vlmi penicillin, 100J.1g/ml 
streptomycin and 2.5J.1g/ml amphotercin B 
Transfection media: RPM! plus 10% FCS and 4mM L-glutamine. 
CS-I media: RPM! plus 4mM L-glutamine, 100U/mi penicillin, 100J.1g/ml 
streptomycin, 2.5J.1g/ml amphotercin B and 500J.1g/ml G418. 
9.7 PCR Primers and Cycling Conditions 
Gene Primer Sequences QPCR Cycling RT -PCR Cycling 
. 
Conditions Conditions 
PAIl 95°C for 30s 
TCTGCAGACCTGGTTCCCAC 40 cycles: 95°C N/A 
AGCCCCGTAGTTCCATCCTG for 5s, 60°C for 
30s, 72°C for 
15s. 
P2- 95°C for 30s 
microglobulin AATCCAAATGCG GCATCT 40 cycles: 95°C N/A 
GAGTATGCCTGCCGTGTG for 5s, 60°C for 
30s, 72°C for 
15s. 
Protease 95°C for 7min 
Activated TGTGAACTGATCATGTTTATG N/A 35 cycles: 94°C for 
Receptor-I TTCGTAAGATAAGAGATATGT 1 min, 60°C for 
(PARI) Imin, 72°C for 
Imin, 
72°C for 5 min 
Protease 95°C for 2min 
Activated CCTTTGTATGTCGTGAAGCAGAC N/A 35 cycles: 94°C for 
Receptor-2 TTCCTGGAGTGTTTCTTTGAGGTG 30s, 55°C for 30s, 
(PAR2) 68°C for I min, 
68°C for 5 min 
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Protease 95°C for 2min 
Activated CTGATACCTGCCATCTACCTCC N/A 35 cycles: 94°C for 
Receptor-3 AGAAAACTGTTGCCCACACC 30s, 55°C for 30s, 
(PAR3) 68°C for 1 min, 
68°C for 5 min 
Protease 95°C for 2min 
Activated ATTACTCGGACCCGAGCC N/A 35 cycles: 94°C for 
Receptor-4 TGTAAGGCCCACCCTTCTC 30s, 55°C for 30s, 
(PAR4) 68°C for 1 min, 
68°C for 5 min 
95°C for 30s 95°C for 2min 
LP A receptor GGTGATTGGGACTTGGAAT 40 cycles: 95°C 35 cycles: 95°C for 
1 (LPAR1) AAACCGTAATGTGCCTCT for 5s, 60°C for 1 min, 58°C for 
30s, noc for 1 min, noc for 
15s. 1min, 
noc for 5 min 
95°C for 30s 95°C for 2m in 
LP A receptor CCCAACCAACAGGACTGACT 40 cycles: 95°C 35 cycles: 95°C for 
2 GAAGAGCCAGATTCCTG for 5s, 60°C for 1min, 60°C for 
(LPAR2) 30s, noc for 1min, noc for 
15s. 1 min, 
noc for 5 min 
95°C for 2m in 
LP A receptor CCGCAGGTACACCACAAC 35 cycles: 95°C for 
3 TGCTTCCCTCACCAACTT N/A 1min, 58°C for 
(LPAR3) 1min, noc for 
1min, 
noc for 5 min 
95°C for 30s 95°C for 2min 
LP A receptor TGCGCTCCCAAGCTATTACA 40 cycles: 95°C 35 cycles: 95°C for 
4 (LPAR4) GGCTTTGTGGTCAAAGGT for 5s, 60°C for 1min, 58°C for 
30s, noc for 1min, noc for 
15s. 1min, 
noc for 5 min 
95°C for 30s 
Integrin aV ACTCAAGCAAAAGGGACGAA 40 cycles: 95°C N/A 
TGCAAGCCTGTTGTATCAGC for 5s, 60°C for 
30s, noc for 
15s. 
95°C for 30s 95°C for Imin 
Integrin p3 GCAAAGGGCTCTGGAGACAG 40 cycles: 95°C 30 cycles: 95°C 
CTTGGTACCCAGGTTCTGGA for 5s, 62°C for I min, 62°C I min, 
30s, noc for noc Imin 
15s, noc for 5 min 
40 cycles: 95°C 95°C for Imin 
Integrin p5 GGAACGTCACCAGCAACTTC for 5s, 60°C for 30 cycles: 95°C for 
CTGTCTGTGAGAGGCAGCAG 30s, noc for Imin, 60°C for 
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ISs. Imin, 72°C for 
Imin 
72°C for 5 min 
95°C for Imin 
Integrin ~ 6 6 GCAAGCTGCTGTGTGTAAGGA N/A 30 cycles: 95°C for 
CTTGGGTTACAGCGAAGATCA Imin, 60°C for 
Imin, 72°C for 
Imin 
72°C for 5 min 
CATTAAGTGTTTAAAAATCTTTTT 95°C for Imin 
Integrin ~ 8 8 TTCATCATTTTCATAGTTACATTC N/A 30 cycles: 95°C for 
Imin, 60°C for 
Imin, 72°C for 
Imin 
72°C for 5 min 
95°C for 30s 
Fibronectin CAGGATCACTTACGGAGAAACAG 40 cycles: 95°C N/A 
GCCAGTGACAGCATACACAGTG for 5s, 60°C for 
30s, 72°C for 
ISs. 
Vascular 95°C for 30s 
endothelial ATCTGCATGGTGATGTTGGA 40 cycles: 95°C N/A 
growth factor GGGCAGAATCATCACGAAGT for 5s, 59°C for 
(VEGF) 30s, 72°C for 
ISs. 
Table 9.1: PCR Primers and Cycling Conditions 
This table shows the primer sequences and thermal PCR profile for all of the primers used 
throughout this thesis. 
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